Appendix 17a: Forest plots for clinical evidence reviews on psychological interventions

Psychological vs. Control (OCD)
BT vs. BT (OCD)
Psychological vs. Psychological (OCD)
Psychological vs. Control (BDD)
Psychological vs. Psychological (BDD)
Treatment Intensity Review

Psychological vs. Control (OCD)

Review: OCD: psychological interventions
Comparison: 01 Behaviour therapy v Control
Outcome: 01 Leaving the study early



Review: OCD: psychological interventions
Comparison: 01 Behaviour therapy v Control
Outcome: 02 Non-responders (CGI)



Review: OCD: psychological interventions
Comparison: 01 Behaviour therapy v Control
Outcome: 03 Y-BOCS




Review: OCD: psychological interventions
Comparison: 01 Behaviour therapy v Control
Outcome: 04 Padua Inventory
Study or sub-category
Behaviour therapy N Mean (SD)
Control N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 ERP v Anxiety management
Lindsay 1997 9 41.44(22.54) 9 81.22(35.15) -1.28 [-2.32, -0.24]
Subtotal (95% CI) 9 9 -1.28 [-2.32, -0.24]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.02)
Total (95% CI) 9 9 -1.28 [-2.32, -0.24]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.02)
-10 -5 0 5 10
Favours BT Favours control


Review: OCD: psychological interventions
Comparison: 01 Behaviour therapy v Control
Outcome: 05 Depression: BDI or HAM-D
Study or sub-category
Behaviour therapy N Mean (SD)
Control N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 ERP v Anxiety management
Lindsay 1997 9 13.11(8.30) 9 18.33(9.66) -0.55 [-1.50, 0.39]
Subtotal (95% CI) 9 9 -0.55 [-1.50, 0.39]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
03 Clinician-guided BT v Systematic relaxation
Greist 2002 55 -2.00(9.40) 66 0.30(7.00) -0.28 [-0.64, 0.08]
Subtotal (95% CI) 55 66 -0.28 [-0.64, 0.08]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
04 Computer-guided BT v Systematic relaxation
Greist 2002 55 0.00(6.80) 66 0.30(7.00) -0.04 [-0.40, 0.31]
Subtotal (95% CI) 55 66 -0.04 [-0.40, 0.31]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
-10 -5 0 5 10
Favours BT Favours control


Review: OCD: psychological interventions
Comparison: 01 Behaviour therapy v Control
Outcome: 06 Maudsley Obsessive-Compulsive Inventory
Study or sub-category
Behaviour therapy N Mean (SD)
Control N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 ERP v Anxiety management
Lindsay 1997 9 9.56(4.59) 9 17.89(4.23) -1.80 [-2.94, -0.66]
Subtotal (95% CI) 9 9 -1.80 [-2.94, -0.66]
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.10 (P = 0.002)
-10 -5 0 5 10
Favours BT Favours control


Review: OCD: psychological interventions
Comparison: 01 Behaviour therapy v Control
Outcome: 07 STAI: Trait
Study or sub-category
Behaviour therapy N Mean (SD)
Control N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 ERP v Anxiety management
Lindsay 1997 9 49.89(8.71) 9 55.89(12.89) -0.52 [-1.46, 0.42]
Subtotal (95% CI) 9 9 -0.52 [-1.46, 0.42]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
-10 -5 0 5 10
Favours BT Favours control


Review: OCD: psychological interventions
Comparison: 01 Behaviour therapy v Control
Outcome: 08 STAI: State
Study or sub-category
Behaviour therapy N Mean (SD)
Control N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 ERP v Anxiety management
Lindsay 1997 9 44.33(8.97) 9 52.11(13.77) -0.64 [-1.59, 0.32]
Subtotal (95% CI) 9 9 -0.64 [-1.59, 0.32]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
-10 -5 0 5 10
Favours BT Favours control


Review: OCD: psychological interventions
Comparison: 01 Behaviour therapy v Control
Outcome: 12 Work and Social Adjustment Scale
Study or sub-category
Behaviour therapy N Mean (SD)
Control N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clinician-guided BT v Systematic relaxation
Greist 2002 55 -6.80(8.30) 66 -2.00(7.70) -0.60 [-0.96, -0.23]
Subtotal (95% CI) 55 66 -0.60 [-0.96, -0.23]
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.20 (P = 0.001)
02 Computer-guided BT v Systematic relaxation
Greist 2002 55 -5.00(7.20) 66 -2.00(7.70) -0.40 [-0.76, -0.04]
Subtotal (95% CI) 55 66 -0.40 [-0.76, -0.04]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.03)
-1 -0.5 0 0.5 1
Favours BT Favours control


Review: OCD: psychological interventions
Comparison: 01 Behaviour therapy v Control
Outcome: 13 Interference
Study or sub-category
Behaviour therapy N Mean (SD)
Control N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 ERP v Anxiety management
Lindsay 1997 9 3.40(0.88) 9 6.30(0.87) -3.16 [-4.64, -1.67]
Subtotal (95% CI) 9 9 -3.16 [-4.64, -1.67]
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.16 (P < 0.0001)
-10 -5 0 5 10
Favours BT Favours control


Review: OCD: psychological interventions
Comparison: 02 CBT v Control
Outcome: 01 Y-BOCS
Study or sub-category
CBT N Mean (SD)
Control N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 CBT v Wait-list control (patients with obsessions only)
Freeston 1997 15 12.20(9.60) 14 22.00(6.00) -1.18 [-1.98, -0.38]
Subtotal (95% CI) 15 14 -1.18 [-1.98, -0.38]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.90 (P = 0.004)
03 CBT vs Wait-list control (Group format)
Cordioli 2003 23 15.10(7.80) 24 23.20(5.50) -1.18 [-1.81, -0.56]
Subtotal (95% CI) 23 24 -1.18 [-1.81, -0.56]
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.72 (P = 0.0002)
-10 -5 0 5 10
Favours CBT Favours control


Review: OCD: psychological interventions
Comparison: 02 CBT v Control
Outcome: 02 Padua Inventory
Study or sub-category
CBT N Mean (SD)
Control N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 CBT v Wait-list control
Freeston 1997 15 54.70(32.90) 14 83.90(35.60) -0.83 [-1.59, -0.07]
Subtotal (95% CI) 15 14 -0.83 [-1.59, -0.07]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.03)
-10 -5 0 5 10
Favours CBT Favours control


Review: OCD: psychological interventions
Comparison: 02 CBT v Control
Outcome: 03 Current Functioning Assessment
Study or sub-category
CBT N Mean (SD)
Control N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 CBT v Wait-list control
Freeston 1997 15 -4.70(2.50) 14 -5.70(1.60) 0.46 [-0.28, 1.20]
Subtotal (95% CI) 15 14 0.46 [-0.28, 1.20]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
-10 -5 0 5 10
Favours CBT Favours control

Review: OCD: psychological interventions
Comparison: 02 CBT v Control
Outcome: 04 Beck Anxiety Inventory



Review: OCD: psychological interventions
Comparison: 02 CBT v Control
Outcome: 05 Beck Depression Inventory



Review: OCD: psychological interventions
Comparison: 02 CBT v Control
Outcome: 06 NIMH-OC



Review: OCD: psychological interventions
Comparison: 02 CBT v Control
Outcome: 10 Overvalued Ideas Scale



Review: OCD: psychological interventions
Comparison: 02 CBT v Control
Outcome: 11 WHOQOL-BREF: physical



Review: OCD: psychological interventions
Comparison: 02 CBT v Control
Outcome: 12 WHOQOL-BREF: psychological




Review: OCD: psychological interventions
Comparison: 02 CBT v Control
Outcome: 13 WHOQOL-BREF: social
Study or sub-category
N
CBT Mean (SD)
N
Control Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 CBGT vs Wait-list control
Cordioli 2003 23 -61.60(18.40) 24 -57.60(20.40) -0.20 [-0.78, 0.37]
Subtotal (95% CI) 23 24 -0.20 [-0.78, 0.37]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
-10 -5 0 5 10
Favours CBT
Favours control


Review: OCD: psychological interventions
Comparison: 02 CBT v Control
Outcome: 14 WHOQOL-BREF: environmental
Study or sub-category
N
CBT Mean (SD)
N
Control Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 CBGT vs Wait-list control
Cordioli 2003 23 -69.60(13.50) 24 -54.70(14.40) -1.05 [-1.66, -0.44]
Subtotal (95% CI) 23 24 -1.05 [-1.66, -0.44]
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.35 (P = 0.0008)
-10 -5 0 5 10
Favours CBT
Favours control


Review: OCD: psychological interventions
Comparison: 02 CBT v Control
Outcome: 15 Non-responders (35% Y-BOCS)
Study or sub-category
CBT n/N
Control n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 CBGT vs Wait-list control
Cordioli 2003 7/23 23/24 0.32 [0.17, 0.59]
Subtotal (95% CI) 7/23 23/24 0.32 [0.17, 0.59]
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.61 (P = 0.0003)
0.1 0.2 0.5 1 2 5 10
Favours CBT
Favours control


Review: OCD: psychological interventions
Comparison: 02 CBT v Control
Outcome: 16 Leaving the study early
Study or sub-category
CBT n/N
Control n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 CBT v Wait-list control
Freeston 1997 3/15 4/14 0.70 [0.19, 2.59]
Subtotal (95% CI) 3/15 4/14 0.70 [0.19, 2.59]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
02 CBGT vs Wait-list control
Cordioli 2003 1/23 1/24 1.04 [0.07, 15.72]
Subtotal (95% CI) 1/23 1/24 1.04 [0.07, 15.72]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
0.01 0.1 1 10 100
Favours CBT
Favours control


Review: OCD: psychological interventions
Comparison: 12 Anxiogenic exposure v Neutral thoughts
Outcome: 01 Non-responders (multiple outcomes "much improved")
Study or sub-category
Anxiogenic exposure n/N
Neutral thoughts n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Lovell 1994 2/7 0/9 6.25 [0.35, 112.52]
Total (95% CI) 7 9 6.25 [0.35, 112.52]
Total events: 2 (Anxiogenic exposure), 0 (Neutral thoughts)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.21)
0.001 0.01 0.1 1 10 100 1000
Favours Exposure
Favours Neutral

Review: OCD: psychological interventions
Comparison: 12 Anxiogenic exposure v Neutral thoughts
Outcome: 02 Leaving the study early



Review: OCD: psychological interventions
Comparison: 12 Anxiogenic exposure v Neutral thoughts
Outcome: 03 Compulsions checklist



Review: OCD: psychological interventions
Comparison: 12 Anxiogenic exposure v Neutral thoughts
Outcome: 04 Obsessions - time



Review: OCD: psychological interventions
Comparison: 12 Anxiogenic exposure v Neutral thoughts
Outcome: 05 Obsessions - discomfort



Review: OCD: psychological interventions
Comparison: 12 Anxiogenic exposure v Neutral thoughts
Outcome: 06 Main target




Review: OCD: psychological interventions
Comparison: 12 Anxiogenic exposure v Neutral thoughts
Outcome: 07 Beck Depression Inventory
Study or sub-category
Anxiogenic exposure N Mean (SD)
Neutral thoughts N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Lovell 1994 6 14.80(7.50) 6 14.00(7.80) 0.10 [-1.04, 1.23]
Total (95% CI) 6 6 0.10 [-1.04, 1.23]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
-10 -5 0 5 10
Favours treatment Favours control


Review: OCD: psychological interventions
Comparison: 12 Anxiogenic exposure v Neutral thoughts
Outcome: 08 Work adjustment
Study or sub-category
Anxiogenic exposure N Mean (SD)
Neutral thoughts N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Lovell 1994 6 3.50(2.30) 6 3.20(1.80) 0.13 [-1.00, 1.27]
Total (95% CI) 6 6 0.13 [-1.00, 1.27]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
-10 -5 0 5 10
Favours treatment Favours control


Review: OCD: psychological interventions
Comparison: 12 Anxiogenic exposure v Neutral thoughts
Outcome: 09 Home adjustment
Study or sub-category
Anxiogenic exposure N Mean (SD)
Neutral thoughts N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Lovell 1994 6 2.20(2.00) 6 3.50(2.10) -0.59 [-1.75, 0.58]
Total (95% CI) 6 6 -0.59 [-1.75, 0.58]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
-10 -5 0 5 10
Favours treatment Favours control


Review: OCD: psychological interventions
Comparison: 12 Anxiogenic exposure v Neutral thoughts
Outcome: 10 Social adjustment
Study or sub-category
Anxiogenic exposure N Mean (SD)
Neutral thoughts N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Lovell 1994 6 3.50(1.40) 6 3.00(2.20) 0.25 [-0.89, 1.39]
Total (95% CI) 6 6 0.25 [-0.89, 1.39]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
-10 -5 0 5 10
Favours treatment Favours control


Review: OCD: psychological interventions
Comparison: 12 Anxiogenic exposure v Neutral thoughts
Outcome: 11 Private adjustment
Study or sub-category
Anxiogenic exposure N Mean (SD)
Neutral thoughts N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Lovell 1994 6 2.50(1.50) 6 2.50(0.80) 0.00 [-1.13, 1.13]
Total (95% CI) 6 6 0.00 [-1.13, 1.13]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
-10 -5 0 5 10
Favours treatment Favours control


Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 01 CY-BOCS
Study or sub-category
Individual CBFT N Mean (SD)
Wait-list control N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Barrett 2004 22 8.36(6.93) 24 24.02(4.14) -2.73 [-3.55, -1.90]
Total (95% CI) 22 24 -2.73 [-3.55, -1.90]
Test for heterogeneity: not applicable
Test for overall effect: Z = 6.51 (P < 0.00001)
-10 -5 0 5 10
Favours Ind-CBFT Favours WLC

Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 02 NIMH-GOCS



Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 03 Multidimensional Anxiety Scale for Children



Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 04 Children's Depression Inventory



Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 05 McMaster Family Assessment Device - Mother's rating



Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 06 McMaster Family Assessment Device - Father's rating



Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 07 Depression Anxiety Stress Scale: Mother depression



Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 08 Depression Anxiety Stress Scale: Mother anxiety



Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 09 Depression Anxiety Stress Scale: Mother stress



Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 10 Depression Anxiety Stress Scale: Father depression



Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 11 Depression Anxiety Stress Scale: Father anxiety



Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 12 Depression Anxiety Stress Scale: Father stress



Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 13 Children's Depression Inventory: sibling's rating



Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 14 Multidimensional Anxiety Scale for Children - sibling's ratings



Review: OCD: psychological interventions
Comparison: 15 Children: Individual CBFT v Wait-list control
Outcome: 15 Sibling Accomodation Scale



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 01 CY-BOCS



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 02 NIMH-GOCS



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 03 Multidimensional Anxiety Scale for Children



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 04 Children's Depression Inventory



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 05 McMaster Family Assessment Device - Mother's rating



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 06 McMaster Family Assessment Device - Father's rating



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 07 Depression Anxiety Stress Scale: Mother depression



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 08 Depression Anxiety Stress Scale: Mother anxiety



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 09 Depression Anxiety Stress Scale: Mother stress



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 10 Depression Anxiety Stress Scale: Father depression



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 11 Depression Anxiety Stress Scale: Father anxiety



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 12 Depression Anxiety Stress Scale: Father stress



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 13 Children's Depression Inventory: sibling's rating



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 14 Multidimensional Anxiety Scale for Children - sibling's ratings



Review: OCD: psychological interventions
Comparison: 16 Children: Group CBFT v Wait-list control
Outcome: 15 Sibling Accomodation Scale



BT vs. BT (OCD)

Review: OCD: psychological interventions
Comparison: 13 Self-exposure v Partner-assisted exposure
Outcome: 01 Anxiety/discomfort - Main compulsion (assessor rated)



Review: OCD: psychological interventions
Comparison: 13 Self-exposure v Partner-assisted exposure
Outcome: 02 Anxiety/discomfort - Other compulsions (assessor rated)



Review: OCD: psychological interventions
Comparison: 13 Self-exposure v Partner-assisted exposure
Outcome: 03 Maudsley Obsessive-compulsive inventory



Review: OCD: psychological interventions
Comparison: 13 Self-exposure v Partner-assisted exposure
Outcome: 04 Social and Marital Adjustment: Marital



Review: OCD: psychological interventions
Comparison: 13 Self-exposure v Partner-assisted exposure
Outcome: 05 Social and Marital Adjustment: Sexual



Review: OCD: psychological interventions
Comparison: 13 Self-exposure v Partner-assisted exposure
Outcome: 06 Social and Marital Adjustment: Social




Review: OCD: psychological interventions
Comparison: 13 Self-exposure v Partner-assisted exposure
Outcome: 07 Anxious mood (assessor-rated)
Study or sub-category
Self-controlled exp N Mean (SD)
Partner-assisted exp N Mean (SD)
WMD (random) 95% CI
WMD (random) 95% CI
Emmelkamp 1983 6 2.30(1.93) 6 3.30(0.87) -1.00 [-2.69, 0.69]
Total (95% CI) 6 6 -1.00 [-2.69, 0.69]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
-10 -5 0 5 10
Favours Self-exp Favours Couple-exp


Review: OCD: psychological interventions
Comparison: 13 Self-exposure v Partner-assisted exposure
Outcome: 08 Self-rating Depression scale
Study or sub-category
Self-controlled exp N Mean (SD)
Partner-assisted exp N Mean (SD)
WMD (random) 95% CI
WMD (random) 95% CI
Emmelkamp 1983 6 49.00(9.69) 6 43.30(7.50) 5.70 [-4.10, 15.50]
Total (95% CI) 6 6 5.70 [-4.10, 15.50]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
-100 -50 0 50 100
Favours Self-exp Favours Couple-exp


Review: OCD: psychological interventions
Comparison: 14 Imaginal + live ERP v Live ERP
Outcome: 01 Leaving the study early
Study or sub-category
Imagined + live ERP n/N
Live ERP n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
De Araujo1995 5/28 5/28 1.00 [0.33, 3.08]
Total (95% CI) 5/28 5/28 1.00 [0.33, 3.08]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
0.1 0.2 0.5 1 2 5 10
Favours Img/Live ERP Favours Live ERP


Review: OCD: psychological interventions
Comparison: 14 Imaginal + live ERP v Live ERP
Outcome: 02 Relapse (multiple outcomes)
Study or sub-category
Imagined + live ERP n/N
Live ERP n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 At 20 weeks follow-up
De Araujo1995 8/28 5/28 1.60 [0.60, 4.29]
Subtotal (95% CI) 8/28 5/28 1.60 [0.60, 4.29]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
02 At 32 weeks follow-up
De Araujo1995 2/28 4/28 0.50 [0.10, 2.51]
Subtotal (95% CI) 2/28 4/28 0.50 [0.10, 2.51]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
0.1 0.2 0.5 1 2 5 10
Favours Img/Live ERP Favours Live ERP

Review: OCD: psychological interventions
Comparison: 14 Imaginal + live ERP v Live ERP
Outcome: 03 Y-BOCS obsessions



Review: OCD: psychological interventions
Comparison: 14 Imaginal + live ERP v Live ERP
Outcome: 04 Y-BOCS rituals



Review: OCD: psychological interventions
Comparison: 14 Imaginal + live ERP v Live ERP
Outcome: 05 Compulsions checklist




Review: OCD: psychological interventions
Comparison: 14 Imaginal + live ERP v Live ERP
Outcome: 06 Beck Depression Inventory
Study or sub-category
Imagined + live ERP N Mean (SD)
Live ERP N Mean (SD)
WMD (random) 95% CI
WMD (random) 95% CI
01 At 9 weeks (post treatment)
De Araujo1995 23 15.00(13.10) 23 19.00(13.20) -4.00 [-11.60, 3.60]
Subtotal (95% CI) 23 23 -4.00 [-11.60, 3.60]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
02 At 20 weeks (post treatment)
De Araujo1995 20 14.00(15.20) 21 22.00(19.10) -8.00 [-18.54, 2.54]
Subtotal (95% CI) 20 21 -8.00 [-18.54, 2.54]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
03 At 32 weeks (post treatment)
De Araujo1995 20 12.00(14.00) 21 17.00(17.60) -5.00 [-14.71, 4.71]
Subtotal (95% CI) 20 21 -5.00 [-14.71, 4.71]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
-100 -50 0 50 100
Favours Img/live ERP
Favours Live ERP


Review: OCD: psychological interventions
Comparison: 15 ERP + response prevention v ERP + associative therapy
Outcome: 01 Non-responders (Y-BOCS 50%)
Study or sub-category
ERP + resp. prevent n/N
ERP + assn. therapy n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Post treatment
Hiss 1994 4/10 3/10 1.33 [0.40, 4.49]
Subtotal (95% CI) 4/10 3/10 1.33 [0.40, 4.49]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
02 At 6 months follow-up
Hiss 1994 4/10 7/10 0.57 [0.24, 1.35]
Subtotal (95% CI) 4/10 7/10 0.57 [0.24, 1.35]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
0.1 0.2 0.5 1 2 5 10
Favours ERP+RP
Favours ERP+assn.the


Review: OCD: psychological interventions
Comparison: 15 ERP + response prevention v ERP + associative therapy
Outcome: 02 Leaving the study early
Study or sub-category
ERP + resp. prevent n/N
ERP + assn. therapy n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Hiss 1994 2/10 0/10 5.00 [0.27, 92.63]
Total (95% CI) 2/10 0/10 5.00 [0.27, 92.63]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
0.01 0.1 1 10 100
Favours ERP+RP
Favours ERP+assn.the


Review: OCD: psychological interventions
Comparison: 15 ERP + response prevention v ERP + associative therapy
Outcome: 03 Y-BOCS
Study or sub-category
ERP + resp. prevent N Mean (SD)
ERP + assn. therapy N Mean (SD)
WMD (random) 95% CI
WMD (random) 95% CI
01 Post treatment
Hiss 1994 8 8.75(4.53) 10 9.80(7.24) -1.05 [-6.53, 4.43]
Subtotal (95% CI) 8 10 -1.05 [-6.53, 4.43]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
02 At 6-month follow-up
Hiss 1994 8 8.13(7.10) 10 13.44(8.78) -5.31 [-12.65, 2.03]
Subtotal (95% CI) 8 10 -5.31 [-12.65, 2.03]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
-100 -50 0 50 100
Favours ERP+RP
Favours ERP+assn.the


Review: OCD: psychological interventions
Comparison: 15 ERP + response prevention v ERP + associative therapy
Outcome: 04 Obsessive-compulsive symptoms (assessor-rated)
Study or sub-category
ERP + resp. prevent N Mean (SD)
ERP + assn. therapy N Mean (SD)
WMD (random) 95% CI
WMD (random) 95% CI
01 Post treatment
Hiss 1994 8 2.75(2.25) 10 5.00(4.57) -2.25 [-5.48, 0.98]
Subtotal (95% CI) 8 10 -2.25 [-5.48, 0.98]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
02 At 6-month follow-up
Hiss 1994 8 4.50(4.66) 10 11.80(7.55) -7.30 [-12.99, -1.61]
Subtotal (95% CI) 8 10 -7.30 [-12.99, -1.61]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.01)
-100 -50 0 50 100
Favours ERP+RP
Favours ERP+assn.the


Review: OCD: psychological interventions
Comparison: 15 ERP + response prevention v ERP + associative therapy
Outcome: 05 Hamilton Depression Scale
Study or sub-category
ERP + resp. prevent N Mean (SD)
ERP + assn. therapy N Mean (SD)
WMD (random) 95% CI
WMD (random) 95% CI
01 Post treatment
Hiss 1994 8 7.71(4.92) 10 5.70(3.74) 2.01 [-2.11, 6.13]
Subtotal (95% CI) 8 10 2.01 [-2.11, 6.13]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
02 At 6-month follow-up
Hiss 1994 8 3.75(2.38) 10 7.89(7.64) -4.14 [-9.15, 0.87]
Subtotal (95% CI) 8 10 -4.14 [-9.15, 0.87]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
-10 -5 0 5 10
Favours ERP+RP
Favours ERP+assn.the


Review: OCD: psychological interventions
Comparison: 15 ERP + response prevention v ERP + associative therapy
Outcome: 06 Beck Depression Inventory
Study or sub-category
ERP + resp. prevent N Mean (SD)
ERP + assn. therapy N Mean (SD)
WMD (random) 95% CI
WMD (random) 95% CI
01 Post treatment
Hiss 1994 8 6.13(5.84) 10 5.56(8.63) 0.57 [-6.14, 7.28]
Subtotal (95% CI) 8 10 0.57 [-6.14, 7.28]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
02 At 6-month follow-up
Hiss 1994 8 6.33(8.26) 10 10.00(16.10) -3.67 [-15.17, 7.83]
Subtotal (95% CI) 8 10 -3.67 [-15.17, 7.83]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
-100 -50 0 50 100
Favours ERP+RP
Favours ERP+assn.the


Review: OCD: psychological interventions
Comparison: 15 ERP + response prevention v ERP + associative therapy
Outcome: 07 State-Trait Anxiety Inventory - State
Study or sub-category
ERP + resp. prevent N Mean (SD)
ERP + assn. therapy N Mean (SD)
WMD (random) 95% CI
WMD (random) 95% CI
01 Post treatment
Hiss 1994 8 42.00(9.78) 10 36.00(13.79) 6.00 [-4.91, 16.91]
Subtotal (95% CI) 8 10 6.00 [-4.91, 16.91]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
02 At 6-month follow-up
Hiss 1994 8 34.67(10.23) 10 37.38(10.39) -2.71 [-12.29, 6.87]
Subtotal (95% CI) 8 10 -2.71 [-12.29, 6.87]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
-100 -50 0 50 100
Favours ERP+RP
Favours ERP+assn.the


Review: OCD: psychological interventions
Comparison: 16 Anxiogenic exposure v Neutral thoughts
Outcome: 01 Non-responders (multiple outcomes "much improved")
Study or sub-category
Anxiogenic exposure n/N
Neutral thoughts n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Lovell 1994 2/7 0/9 6.25 [0.35, 112.52]
Total (95% CI) 2/7 0/9 6.25 [0.35, 112.52]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.21)
0.001 0.01 0.1 1 10 100 1000
Favours Exposure
Favours Neutral


Review: OCD: psychological interventions
Comparison: 16 Anxiogenic exposure v Neutral thoughts
Outcome: 02 Leaving the study early
Study or sub-category
Anxiogenic exposure n/N
Neutral thoughts n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Lovell 1994 1/7 3/9 0.43 [0.06, 3.28]
Total (95% CI) 1/7 3/9 0.43 [0.06, 3.28]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
0.01 0.1 1 10 100
Favours Exposure
Favours Neutral


Review: OCD: psychological interventions
Comparison: 16 Anxiogenic exposure v Neutral thoughts
Outcome: 03 Compulsions checklist
Study or sub-category
Anxiogenic exposure N Mean (SD)
Neutral thoughts N Mean (SD)
WMD (random) 95% CI
WMD (random) 95% CI
Lovell 1994 6 16.60(16.00) 6 9.50(6.70) 7.10 [-6.78, 20.98]
Total (95% CI) 6 6 7.10 [-6.78, 20.98]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
-100 -50 0 50 100
Favours treatment
Favours control


Review: OCD: psychological interventions
Comparison: 16 Anxiogenic exposure v Neutral thoughts
Outcome: 04 Obsessions - time
Study or sub-category
Anxiogenic exposure N Mean (SD)
Neutral thoughts N Mean (SD)
WMD (random) 95% CI
WMD (random) 95% CI
Lovell 1994 6 2.50(2.50) 6 3.70(1.90) -1.20 [-3.71, 1.31]
Total (95% CI) 6 6 -1.20 [-3.71, 1.31]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
-10 -5 0 5 10
Favours treatment
Favours control

Review: OCD: psychological interventions
Comparison: 16 Anxiogenic exposure v Neutral thoughts
Outcome: 05 Obsessions - discomfort



Review: OCD: psychological interventions
Comparison: 16 Anxiogenic exposure v Neutral thoughts
Outcome: 06 Main target



Review: OCD: psychological interventions
Comparison: 16 Anxiogenic exposure v Neutral thoughts
Outcome: 07 Beck Depression Inventory



Review: OCD: psychological interventions
Comparison: 16 Anxiogenic exposure v Neutral thoughts
Outcome: 08 Work adjustment



Review: OCD: psychological interventions
Comparison: 16 Anxiogenic exposure v Neutral thoughts
Outcome: 09 Home adjustment



Review: OCD: psychological interventions
Comparison: 16 Anxiogenic exposure v Neutral thoughts
Outcome: 10 Social adjustment



Review: OCD: psychological interventions
Comparison: 16 Anxiogenic exposure v Neutral thoughts
Outcome: 11 Private adjustment



Psychological vs. Psychological (OCD)

Review: OCD: psychological interventions
Comparison: 03 Behaviour therapy: Computer-guided v Clinician-guided
Outcome: 01 Non-responders (CGI)



Review: OCD: psychological interventions
Comparison: 03 Behaviour therapy: Computer-guided v Clinician-guided
Outcome: 02 Y-BOCS



Review: OCD: psychological interventions
Comparison: 03 Behaviour therapy: Computer-guided v Clinician-guided
Outcome: 03 Hamilton Depression Rating Scale



Review: OCD: psychological interventions
Comparison: 03 Behaviour therapy: Computer-guided v Clinician-guided
Outcome: 04 Work and Social Adjustment Scale




Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 01 Leaving the study early
Study or sub-category
Behaviour therapy n/N
Cognitive therapy n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Individual format
Cottraux 2001 3/33 2/32 1.45 [0.26, 8.14]
Van Oppen 1995 7/36 7/35 0.97 [0.38, 2.49]
Whittal(under review 10/39 7/37 1.36 [0.58, 3.19]
Subtotal (95% CI) 108 104 1.20 [0.66, 2.17]
Total events: 20 (Behaviour therapy), 16 (Cognitive therapy)
Test for heterogeneity: Chi² = 0.32, df = 2 (P = 0.85), I² = 0%
Test for overall effect: Z = 0.61 (P = 0.54)
02 Group format
McLean 2001 12/44 18/49 0.74 [0.40, 1.36]
Subtotal (95% CI) 44 49 0.74 [0.40, 1.36]
Total events: 12 (Behaviour therapy), 18 (Cognitive therapy)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 152 153 0.97 [0.63, 1.47]
Total events: 32 (Behaviour therapy), 34 (Cognitive therapy)
Test for heterogeneity: Chi² = 1.54, df = 3 (P = 0.67), I² = 0%
Test for overall effect: Z = 0.16 (P = 0.88)
0.001 0.01 0.1 1 10 100 1000
Favours BT Favours CT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 02 Leaving the study early at 26 weeks follow-up
Study or sub-category
Behaviour therapy n/N
Cognitive therapy n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 At 26 weeks follow-up
Cottraux 2001 8/33 4/32 1.94 [0.65, 5.81]
Subtotal (95% CI) 33 32 1.94 [0.65, 5.81]
Total events: 8 (Behaviour therapy), 4 (Cognitive therapy)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
0.001 0.01 0.1 1 10 100 1000
Favours BT Favours CT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 03 Leaving the study early at 52 weeks follow-up
Study or sub-category
Behaviour therapy n/N
Cognitive therapy n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 At 52 weeks follow-up
Cottraux 2001 10/33 7/32 1.39 [0.60, 3.19]
Subtotal (95% CI) 33 32 1.39 [0.60, 3.19]
Total events: 10 (Behaviour therapy), 7 (Cognitive therapy)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
0.001 0.01 0.1 1 10 100 1000
Favours BT Favours CT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 04 Not recovered (Y-BOCS) post treatment
Study or sub-category
Behaviour therapy n/N
Cognitive therapy n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Individual format
Van Oppen 1995 24/36 21/35 1.11 [0.78, 1.59]
Subtotal (95% CI) 36 35 1.11 [0.78, 1.59]
Total events: 24 (Behaviour therapy), 21 (Cognitive therapy)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
02 Group format
McLean 2001 32/44 44/49 0.81 [0.66, 0.99]
Subtotal (95% CI) 44 49 0.81 [0.66, 0.99]
Total events: 32 (Behaviour therapy), 44 (Cognitive therapy)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.04)
Total (95% CI) 80 84 0.91 [0.76, 1.10]
Total events: 56 (Behaviour therapy), 65 (Cognitive therapy)
Test for heterogeneity: Chi² = 2.48, df = 1 (P = 0.12), I² = 59.7%
Test for overall effect: Z = 0.98 (P = 0.33)
0.5 0.7 1 1.5 2
Favours BT Favours CT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 05 Not reliable change (Y-BOCS) post treatment
Study or sub-category
Behaviour therapy n/N
Cognitive therapy n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Individual format
Van Oppen 1995 17/36 14/35 1.18 [0.69, 2.01]
Subtotal (95% CI) 36 35 1.18 [0.69, 2.01]
Total events: 17 (Behaviour therapy), 14 (Cognitive therapy)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
02 Group format
McLean 2001 7/19 6/16 0.98 [0.41, 2.33]
Subtotal (95% CI) 19 16 0.98 [0.41, 2.33]
Total events: 7 (Behaviour therapy), 6 (Cognitive therapy)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 55 51 1.12 [0.71, 1.76]
Total events: 24 (Behaviour therapy), 20 (Cognitive therapy)
Test for heterogeneity: Chi² = 0.13, df = 1 (P = 0.72), I² = 0%
Test for overall effect: Z = 0.48 (P = 0.63)
0.2 0.5 1 2 5
Favours BT Favours CT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 06 Not recovered (Y-BOCS) at 12 weeks follow-up
Study or sub-category
Behaviour therapy n/N
Cognitive therapy n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Group format
McLean 2001 30/44 45/49 0.74 [0.60, 0.92]
Subtotal (95% CI) 44 49 0.74 [0.60, 0.92]
Total events: 30 (Behaviour therapy), 45 (Cognitive therapy)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.67 (P = 0.008)
0.5 0.7 1 1.5 2
Favours BT Favours CT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 07 Non-responder (Y-BOCS 25%)
Study or sub-category
Behaviour therapy n/N
Cognitive therapy n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Individual format post-treatment
Cottraux 2001 12/33 9/32 1.29 [0.63, 2.64]
Subtotal (95% CI) 33 32 1.29 [0.63, 2.64]
Total events: 12 (Behaviour therapy), 9 (Cognitive therapy)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
02 Individual format at 26 weeks follow-up
Cottraux 2001 13/33 10/32 1.26 [0.65, 2.45]
Subtotal (95% CI) 33 32 1.26 [0.65, 2.45]
Total events: 13 (Behaviour therapy), 10 (Cognitive therapy)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
03 Individual format at 52 weeks follow-up
Cottraux 2001 13/33 13/32 0.97 [0.53, 1.76]
Subtotal (95% CI) 33 32 0.97 [0.53, 1.76]
Total events: 13 (Behaviour therapy), 13 (Cognitive therapy)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
0.2 0.5 1 2 5
Favours BT Favours CT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 08 Y-BOCS post treatment
Study or sub-category
Behaviour therapy N Mean (SD)
Cognitive therapy N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Individual format
Cottraux 2001 30 -12.10(7.80) 30 -12.50(8.20) 0.05 [-0.46, 0.56]
Van Oppen 1995 29 17.30(8.30) 28 13.30(8.50) 0.47 [-0.06, 1.00]
Whittal(under review 37 13.57(9.27) 34 11.94(8.21) 0.18 [-0.28, 0.65]
Subtotal (95% CI) 96 92 0.23 [-0.06, 0.51]
Test for heterogeneity: Chi² = 1.32, df = 2 (P = 0.52), I² = 0%
Test for overall effect: Z = 1.54 (P = 0.12)
02 Group format
McLean 2001 40 16.40(9.28) 33 16.52(6.93) -0.01 [-0.48, 0.45]
Subtotal (95% CI) 40 33 -0.01 [-0.48, 0.45]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Total (95% CI) 136 125 0.16 [-0.09, 0.40]
Test for heterogeneity: Chi² = 2.07, df = 3 (P = 0.56), I² = 0%
Test for overall effect: Z = 1.27 (P = 0.20)
-4 -2 0 2 4
Favours BT Favours CT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 09 Y-BOCS at 12 weeks follow-up
Study or sub-category
Behaviour therapy N Mean (SD)
CBT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Individual
Whittal(under review 37 14.43(9.41) 34 11.59(7.80) 0.32 [-0.15, 0.79]
Subtotal (95% CI) 37 34 0.32 [-0.15, 0.79]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
02 Group format
McLean 2001 40 16.35(9.34) 33 17.91(8.43) -0.17 [-0.63, 0.29]
Subtotal (95% CI) 40 33 -0.17 [-0.63, 0.29]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
Total (95% CI) 77 67 0.07 [-0.26, 0.40]
Test for heterogeneity: Chi² = 2.19, df = 1 (P = 0.14), I² = 54.2%
Test for overall effect: Z = 0.43 (P = 0.67)
-4 -2 0 2 4
Favours BT Favours CBT

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 10 Y-BOCS at 26 weeks follow-up

Study or sub-category	N	Behaviour therapy Mean (SD)	N	Cognitive therapy Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
02 Individual format						
Cottraux 2001	25	-15.30(10.20)	28	-13.90(8.00)		-0.15 [-0.69, 0.39]
Subtotal (95% CI)	25		28			-0.15 [-0.69, 0.39]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.55 (P = 0.58)						



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 11 Y-BOCS at 52 weeks follow-up

Study or sub-category	N	Behaviour therapy Mean (SD)	N	Cognitive therapy Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
03 Individual format						
Cottraux 2001	23	-17.40(8.50)	25	-13.60(8.80)		-0.43 [-1.01, 0.14]
Subtotal (95% CI)	23		25			-0.43 [-1.01, 0.14]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.48 (P = 0.14)						



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 12 Y-BOCS at 2 years follow-up

Study or sub-category	N	Behaviour therapy Mean (SD)	N	Cognitive therapy Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Individual format						
Whittal(under review	37	13.92(9.51)	34	11.68(7.68)		0.26 [-0.21, 0.72]
Subtotal (95% CI)	37		34			0.26 [-0.21, 0.72]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.07 (P = 0.28)						
02 Group format						
McLean 2001	40	17.00(9.91)	33	15.64(8.80)		0.14 [-0.32, 0.60]
Subtotal (95% CI)	40		33			0.14 [-0.32, 0.60]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.61 (P = 0.54)						
Total (95% CI)	77		67			0.20 [-0.13, 0.53]
Test for heterogeneity: Chi² = 0.11, df = 1 (P = 0.74), I² = 0%						
Test for overall effect: Z = 1.18 (P = 0.24)						



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 13 Beck Depression Inventory post treatment

Study or sub-category	N	Behaviour therapy Mean (SD)	N	Cognitive therapy Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Individual format						
Cottraux 2001	30	-3.40(5.50)	30	-8.40(7.20)		0.77 [0.24, 1.30]
Van Oppen 1995	29	12.90(8.50)	27	11.30(8.70)		0.18 [-0.34, 0.71]
Whittal(under review	37	12.32(11.33)	34	13.47(9.00)		-0.11 [-0.58, 0.36]
Subtotal (95% CI)	96		91			0.25 [-0.04, 0.54]
Test for heterogeneity: Chi² = 6.12, df = 2 (P = 0.05), I² = 67.3%						
Test for overall effect: Z = 1.68 (P = 0.09)						
02 Group format						
McLean 2001	40	15.38(13.21)	33	16.15(13.44)		-0.06 [-0.52, 0.40]
Subtotal (95% CI)	40		33			-0.06 [-0.52, 0.40]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.24 (P = 0.81)						
Total (95% CI)	136		124			0.16 [-0.08, 0.41]
Test for heterogeneity: Chi² = 7.33, df = 3 (P = 0.06), I² = 59.1%						
Test for overall effect: Z = 1.29 (P = 0.20)						




Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 14 Beck Depression Inventory at 12 weeks follow-up
Study or sub-category
Behaviour therapy N Mean (SD)
Cognitive therapy N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Individual format
Whittal(under review 37 12.16(11.25) 34 12.82(9.15) -0.06 [-0.53, 0.40]
Subtotal (95% CI) 37 34 -0.06 [-0.53, 0.40]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
03 Group format
McLean 2001 40 15.40(13.86) 33 17.46(15.08) -0.14 [-0.60, 0.32]
Subtotal (95% CI) 40 33 -0.14 [-0.60, 0.32]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 77 67 -0.10 [-0.43, 0.23]
Test for heterogeneity: Chi² = 0.05, df = 1 (P = 0.82), I² = 0%
Test for overall effect: Z = 0.61 (P = 0.54)
-4 -2 0 2 4
Favours BT Favours CT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 15 Beck Depression Inventory at 26 weeks follow-up
Study or sub-category
Behaviour therapy N Mean (SD)
Cognitive therapy N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Individual format
Cottraux 2001 25 -5.40(8.50) 28 -8.00(6.40) 0.34 [-0.20, 0.89]
Subtotal (95% CI) 25 28 0.34 [-0.20, 0.89]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
-4 -2 0 2 4
Favours BT Favours CT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 16 Beck Depression Inventory at 52 weeks follow-up
Study or sub-category
Behaviour therapy N Mean (SD)
Cognitive therapy N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
02 Individual format
Cottraux 2001 23 -5.20(5.50) 25 -7.10(7.40) 0.28 [-0.28, 0.85]
Subtotal (95% CI) 23 25 0.28 [-0.28, 0.85]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
-4 -2 0 2 4
Favours BT Favours CT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 17 Beck Depression Inventory at 2 years follow-up
Study or sub-category
Behaviour therapy N Mean (SD)
Cognitive therapy N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Individual format
Whittal(under review 37 11.21(10.32) 34 13.73(9.79) -0.25 [-0.72, 0.22]
Subtotal (95% CI) 37 34 -0.25 [-0.72, 0.22]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
02 Group format
McLean 2001 40 15.33(13.65) 33 14.94(14.22) 0.03 [-0.43, 0.49]
Subtotal (95% CI) 40 33 0.03 [-0.43, 0.49]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
Total (95% CI) 77 67 -0.11 [-0.44, 0.22]
Test for heterogeneity: Chi² = 0.68, df = 1 (P = 0.41), I² = 0%
Test for overall effect: Z = 0.64 (P = 0.52)
-4 -2 0 2 4
Favours BT Favours CT

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 18 NIMH-OCS



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 19 Padua Inventory post treatment



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 20 Padua Inventory at 12 weeks follow-up



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 21 Padua Inventory at 2 years follow-up



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 22 Beck Anixety Inventory post treatment



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 23 Beck Anxiety Inventory at 12 weeks follow-up



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 24 Beck Anxiety Inventory at 2 years follow-up



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 25 Symptom Checklist-90



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 26 Anxiety Discomfort Scale: mean of patient, therapist and assessor ratings



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 27 Irrational Belief Inventory



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 28 Behavioural Avoidance Test: Avoidance



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 29 Behavioural Avoidance Test: Discomfort



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 30 Obsessive Thoughts Checklist: total




Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 31 ITIQ - intrusive thoughts
Study or sub-category
N
Behaviour therapy Mean (SD)
N
Cognitive therapy Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Cottraux 2001 30 -7.10(8.50) 30 -9.50(7.90) 0.29 [-0.22, 0.80]
Subtotal (95% CI) 30 30 0.29 [-0.22, 0.80]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
02 At 26 weeks follow-up
Cottraux 2001 25 -9.30(8.60) 28 -9.70(8.50) 0.05 [-0.49, 0.59]
Subtotal (95% CI) 25 28 0.05 [-0.49, 0.59]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
03 At 52 weeks follow-up
Cottraux 2001 23 -8.30(8.60) 25 -10.60(8.90) 0.26 [-0.31, 0.83]
Subtotal (95% CI) 23 25 0.26 [-0.31, 0.83]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
-1 -0.5 0 0.5 1
Favours BT Favours CT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 32 ITIQ - interpretation/intrusion
Study or sub-category
N
Behaviour therapy Mean (SD)
N
Cognitive therapy Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Cottraux 2001 30 -24.40(33.20) 30 -25.10(28.30) 0.02 [-0.48, 0.53]
Subtotal (95% CI) 30 30 0.02 [-0.48, 0.53]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
02 At 26 weeks follow-up
Cottraux 2001 25 -40.00(30.80) 28 -29.20(27.10) -0.37 [-0.91, 0.18]
Subtotal (95% CI) 25 28 -0.37 [-0.91, 0.18]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
03 At 52 weeks follow-up
Cottraux 2001 23 -32.30(30.70) 25 -28.70(26.50) -0.12 [-0.69, 0.44]
Subtotal (95% CI) 23 25 -0.12 [-0.69, 0.44]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
-1 -0.5 0 0.5 1
Favours BT Favours CT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 33 ITIQ - responsibility
Study or sub-category
N
Behaviour therapy Mean (SD)
N
Cognitive therapy Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Cottraux 2001 30 -8.10(11.90) 30 -9.30(10.40) 0.11 [-0.40, 0.61]
Subtotal (95% CI) 30 30 0.11 [-0.40, 0.61]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
02 At 26 weeks follow-up
Cottraux 2001 25 -14.30(11.00) 28 -10.30(10.50) -0.37 [-0.91, 0.18]
Subtotal (95% CI) 25 28 -0.37 [-0.91, 0.18]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
03 At 52 weeks follow-up
Cottraux 2001 23 -11.00(10.50) 25 -10.80(8.90) -0.02 [-0.59, 0.55]
Subtotal (95% CI) 23 25 -0.02 [-0.59, 0.55]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
-1 -0.5 0 0.5 1
Favours BT Favours CT

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 34 ITIQ - guilt



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 35 ITIQ - inferiority



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 36 Salkovskis Responsibility Scale




Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 37 Quality of life
Study or sub-category
Behaviour therapy N Mean (SD)
Cognitive therapy N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Cottraux 2001 30 -7.20(9.70) 30 -10.30(9.00) 0.33 [-0.18, 0.84]
Subtotal (95% CI) 30 30 0.33 [-0.18, 0.84]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
02 At 26 weeks follow-up
Cottraux 2001 25 -11.10(10.60) 28 -11.50(9.00) 0.04 [-0.50, 0.58]
Subtotal (95% CI) 25 28 0.04 [-0.50, 0.58]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
03 At 52 weeks follow-up
Cottraux 2001 23 -10.50(10.90) 25 -12.00(9.20) 0.15 [-0.42, 0.71]
Subtotal (95% CI) 23 25 0.15 [-0.42, 0.71]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
-1 -0.5 0 0.5 1
Favours BT Favours CT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 38 Thought Action Fusion Scale: Moral
Study or sub-category
Behaviour therapy N Mean (SD)
CBT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
McLean 2001 32 15.10(11.70) 31 15.20(14.50) -0.01 [-0.50, 0.49]
Subtotal (95% CI) 32 31 -0.01 [-0.50, 0.49]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
02 At 3-months follow-up
McLean 2001 31 17.00(14.20) 30 14.20(15.10) 0.19 [-0.31, 0.69]
Subtotal (95% CI) 31 30 0.19 [-0.31, 0.69]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
-1 -0.5 0 0.5 1
Favours BT Favours CBT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 39 Thought Action Fusion Scale: Likelihood for Others
Study or sub-category
BT N Mean (SD)
CBT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
McLean 2001 32 2.40(3.20) 31 3.00(4.60) -0.15 [-0.64, 0.34]
Subtotal (95% CI) 32 31 -0.15 [-0.64, 0.34]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
02 At 3-months follow-up
McLean 2001 31 3.00(3.70) 30 3.00(4.90) 0.00 [-0.50, 0.50]
Subtotal (95% CI) 31 30 0.00 [-0.50, 0.50]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
-10 -5 0 5 10
Favours BT Favours CBT


Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 40 Thought Action Fusion Scale: Likelihood for Self
Study or sub-category
BT N Mean (SD)
CBT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
McLean 2001 32 2.90(2.90) 31 3.00(4.10) -0.03 [-0.52, 0.47]
Subtotal (95% CI) 32 31 -0.03 [-0.52, 0.47]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
02 At 3-months follow-up
McLean 2001 31 2.90(2.80) 30 3.20(4.10) -0.08 [-0.59, 0.42]
Subtotal (95% CI) 31 30 -0.08 [-0.59, 0.42]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
-10 -5 0 5 10
Favours BT Favours CBT

Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 41 IBRO: inflated responsibility



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 42 IBRO: overestimation of threat



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 43 IBRO: intolerance of uncertainty



Review: OCD: psychological interventions
Comparison: 04 Behaviour therapy v Cognitive therapy
Outcome: 44 Responsibility Attitude Scale




Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 01 Non-responders (ADS 70%)
Study or sub-category
Behaviour therapy n/N
RET n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Post treatment
Emmelkamp 1988 7/9 9/9 0.78 [0.55, 1.10]
Subtotal (95% CI) 9 9 0.78 [0.55, 1.10]
Total events: 7 (Behaviour therapy), 9 (RET)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
02 At 1-month follow-up
Emmelkamp 1988 7/9 7/9 1.00 [0.61, 1.64]
Subtotal (95% CI) 9 9 1.00 [0.61, 1.64]
Total events: 7 (Behaviour therapy), 7 (RET)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
0.5
0.7
1
1.5
2
Favours BT
Favours RET


Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 02 Maudsley Obsessive-Compulsive Inventory
Study or sub-category
N
Behaviour therapy Mean (SD)
N
RET Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1988 9 12.60(5.40) 9 11.30(1.70) 0.31 [-0.62, 1.24]
Emmelkamp 1991 11 13.70(6.10) 10 12.30(7.30) 0.20 [-0.66, 1.06]
Subtotal (95% CI) 20 19 0.25 [-0.38, 0.88]
Test for heterogeneity: Chi² = 0.03, df = 1 (P = 0.87), I² = 0%
Test for overall effect: Z = 0.78 (P = 0.44)
02 At 1-month follow-up
Emmelkamp 1988 9 11.40(4.70) 9 9.80(5.40) 0.30 [-0.63, 1.23]
Subtotal (95% CI) 9 9 0.30 [-0.63, 1.23]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
-4
-2
0
2
4
Favours BT
Favours RET


Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 03 Anxiety Discomfort Scale
Study or sub-category
N
Behaviour therapy Mean (SD)
N
RET Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1988 9 26.00(15.70) 9 29.10(10.00) -0.22 [-1.15, 0.70]
Subtotal (95% CI) 9 9 -0.22 [-1.15, 0.70]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
02 At 1-month follow-up
Emmelkamp 1988 9 23.30(10.20) 9 25.70(14.70) -0.18 [-1.11, 0.75]
Subtotal (95% CI) 9 9 -0.18 [-1.11, 0.75]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
-4
-2
0
2
4
Favours BT
Favours RET


Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 04 Irrational Beliefs Test
Study or sub-category
N
Behaviour therapy Mean (SD)
N
RET Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1988 9 164.30(16.90) 9 164.00(12.50) 0.02 [-0.90, 0.94]
Emmelkamp 1991 11 104.60(11.00) 10 97.50(16.60) 0.49 [-0.38, 1.36]
Subtotal (95% CI) 20 19 0.27 [-0.37, 0.90]
Test for heterogeneity: Chi² = 0.53, df = 1 (P = 0.47), I² = 0%
Test for overall effect: Z = 0.83 (P = 0.41)
02 At 1-month follow-up
Emmelkamp 1988 9 163.90(16.90) 9 155.80(17.10) 0.45 [-0.49, 1.39]
Subtotal (95% CI) 9 9 0.45 [-0.49, 1.39]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
-4
-2
0
2
4
Favours BT
Favours RET


Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 05 Self-rating Depression Scale
Study or sub-category
Behaviour therapy N Mean (SD)
RET N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1988 9 47.90(6.20) 9 45.60(7.30) 0.32 [-0.61, 1.26]
Emmelkamp 1991 11 52.10(8.10) 10 47.80(9.40) 0.47 [-0.40, 1.34]
Subtotal (95% CI) 20 19 0.40 [-0.23, 1.04]
Test for heterogeneity: Chi² = 0.05, df = 1 (P = 0.82), I² = 0%
Test for overall effect: Z = 1.24 (P = 0.21)
02 At 1-month follow-up
Emmelkamp 1988 9 48.70(10.40) 9 43.40(9.50) 0.51 [-0.44, 1.45]
Subtotal (95% CI) 9 9 0.51 [-0.44, 1.45]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
-4 -2 0 2 4
Favours BT Favours RET


Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 06 Social Anxiety scale
Study or sub-category
Behaviour therapy N Mean (SD)
RET N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1988 9 48.30(18.80) 9 48.10(14.20) 0.01 [-0.91, 0.94]
Subtotal (95% CI) 9 9 0.01 [-0.91, 0.94]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
02 At 1-month follow-up
Emmelkamp 1988 9 44.30(23.30) 9 44.30(17.20) 0.00 [-0.92, 0.92]
Subtotal (95% CI) 9 9 0.00 [-0.92, 0.92]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
-1 -0.5 0 0.5 1
Favours BT Favours RET


Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 07 Hostility and Direction of Hostility Questionnaire: Intrapunitivity
Study or sub-category
Behaviour therapy N Mean (SD)
RET N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1988 9 17.10(7.70) 9 17.30(7.20) -0.03 [-0.95, 0.90]
Subtotal (95% CI) 9 9 -0.03 [-0.95, 0.90]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
02 At 1-month follow-up
Emmelkamp 1988 9 17.10(10.00) 9 16.10(8.20) 0.10 [-0.82, 1.03]
Subtotal (95% CI) 9 9 0.10 [-0.82, 1.03]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
-4 -2 0 2 4
Favours BT Favours RET


Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 08 Hostility and Direction of Hostility Questionnaire: Extrapunitivity
Study or sub-category
Behaviour therapy N Mean (SD)
RET N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1988 9 16.80(6.00) 9 16.30(7.20) 0.07 [-0.85, 1.00]
Subtotal (95% CI) 9 9 0.07 [-0.85, 1.00]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
02 At 1-month follow-up
Emmelkamp 1988 9 14.80(5.90) 9 15.80(9.50) -0.12 [-1.05, 0.80]
Subtotal (95% CI) 9 9 -0.12 [-1.05, 0.80]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
-4 -2 0 2 4
Favours BT Favours RET


Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 09 Dutch Obsessive-Compulsive Questionnaire
Study or sub-category
Behaviour therapy N Mean (SD)
RET N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1991 11 84.80(24.40) 10 80.50(23.20) 0.17 [-0.69, 1.03]
Subtotal (95% CI) 11 10 0.17 [-0.69, 1.03]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
-1 -0.5 0 0.5 1
Favours BT Favours RET


Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 10 Anxiety Discomfort Scale: main OC symptoms (Assessor)
Study or sub-category
Behaviour therapy N Mean (SD)
RET N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1991 11 4.30(2.10) 10 4.10(2.90) 0.08 [-0.78, 0.93]
Subtotal (95% CI) 11 10 0.08 [-0.78, 0.93]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
-1 -0.5 0 0.5 1
Favours BT Favours RET


Review: OCD: psychological interventions
Comparison: 06 BT v RET + exposure in vivo (post RET alone)
Outcome: 01 Maudsley Obsessive-Compulsive Inventory
Study or sub-category
Behaviour therapy N Mean (SD)
RET + exposure N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1991 11 11.70(6.10) 10 9.60(6.90) 0.31 [-0.55, 1.17]
Subtotal (95% CI) 11 10 0.31 [-0.55, 1.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
02 At follow-up
Emmelkamp 1991 11 12.20(5.90) 10 9.60(7.20) 0.38 [-0.48, 1.25]
Subtotal (95% CI) 11 10 0.38 [-0.48, 1.25]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
-4 -2 0 2 4
Favours BT Favours RET + exp


Review: OCD: psychological interventions
Comparison: 06 BT v RET + exposure in vivo (post RET alone)
Outcome: 02 Dutch Obsessive-Compulsive Questionnaire
Study or sub-category
Behaviour therapy N Mean (SD)
RET + exposure N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1991 11 80.80(25.90) 10 73.80(15.90) 0.31 [-0.55, 1.17]
Subtotal (95% CI) 11 10 0.31 [-0.55, 1.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
02 At follow-up
Emmelkamp 1991 11 83.40(26.60) 10 76.60(20.20) 0.27 [-0.59, 1.14]
Subtotal (95% CI) 11 10 0.27 [-0.59, 1.14]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
-4 -2 0 2 4
Favours BT Favours RET + exp


Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 03 Anxiety Discomfort Scale
Study or sub-category
Behaviour therapy N Mean (SD)
RET N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1988 9 26.00(15.70) 9 29.10(10.00) -0.22 [-1.15, 0.70]
Subtotal (95% CI) 9 9 -0.22 [-1.15, 0.70]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
02 At 1-month follow-up
Emmelkamp 1988 9 23.30(10.20) 9 25.70(14.70) -0.18 [-1.11, 0.75]
Subtotal (95% CI) 9 9 -0.18 [-1.11, 0.75]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
-4 -2 0 2 4
Favours BT Favours RET


Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 04 Irrational Beliefs Test
Study or sub-category
Behaviour therapy N Mean (SD)
RET N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1988 9 164.30(16.90) 9 164.00(12.50) 0.02 [-0.90, 0.94]
Emmelkamp 1991 11 104.60(11.00) 10 97.50(16.60) 0.49 [-0.38, 1.36]
Subtotal (95% CI) 20 19 0.27 [-0.37, 0.90]
Test for heterogeneity: Chi² = 0.53, df = 1 (P = 0.47), I² = 0%
Test for overall effect: Z = 0.83 (P = 0.41)
02 At 1-month follow-up
Emmelkamp 1988 9 163.90(16.90) 9 155.80(17.10) 0.45 [-0.49, 1.39]
Subtotal (95% CI) 9 9 0.45 [-0.49, 1.39]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
-4 -2 0 2 4
Favours BT Favours RET


Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 05 Self-rating Depression Scale
Study or sub-category
Behaviour therapy N Mean (SD)
RET N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1988 9 47.90(6.20) 9 45.60(7.30) 0.32 [-0.61, 1.26]
Emmelkamp 1991 11 52.10(8.10) 10 47.80(9.40) 0.47 [-0.40, 1.34]
Subtotal (95% CI) 20 19 0.40 [-0.23, 1.04]
Test for heterogeneity: Chi² = 0.05, df = 1 (P = 0.82), I² = 0%
Test for overall effect: Z = 1.24 (P = 0.21)
02 At 1-month follow-up
Emmelkamp 1988 9 48.70(10.40) 9 43.40(9.50) 0.51 [-0.44, 1.45]
Subtotal (95% CI) 9 9 0.51 [-0.44, 1.45]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
-4 -2 0 2 4
Favours BT Favours RET


Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 06 Social Anxiety scale
Study or sub-category
Behaviour therapy N Mean (SD)
RET N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1988 9 48.30(18.80) 9 48.10(14.20) 0.01 [-0.91, 0.94]
Subtotal (95% CI) 9 9 0.01 [-0.91, 0.94]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
02 At 1-month follow-up
Emmelkamp 1988 9 44.30(23.30) 9 44.30(17.20) 0.00 [-0.92, 0.92]
Subtotal (95% CI) 9 9 0.00 [-0.92, 0.92]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
-1 -0.5 0 0.5 1
Favours BT Favours RET

Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 07 Hostility and Direction of Hostility Questionnaire: Intrapunitivity



Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 08 Hostility and Direction of Hostility Questionnaire: Extrapunitivity



Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 09 Dutch Obsessive-Compulsive Questionnaire



Review: OCD: psychological interventions
Comparison: 05 Behaviour therapy v Rational emotive therapy
Outcome: 10 Anxiety Discomfort Scale: main OC symptoms (Assessor)




Review: OCD: psychological interventions
Comparison: 06 BT v RET + exposure in vivo (post RET alone)
Outcome: 01 Maudsley Obsessive-Compulsive Inventory
Study or sub-category
Behaviour therapy N Mean (SD)
RET + exposure N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1991 11 11.70(6.10) 10 9.60(6.90) 0.31 [-0.55, 1.17]
Subtotal (95% CI) 11 10 0.31 [-0.55, 1.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
02 At follow-up
Emmelkamp 1991 11 12.20(5.90) 10 9.60(7.20) 0.38 [-0.48, 1.25]
Subtotal (95% CI) 11 10 0.38 [-0.48, 1.25]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
-4 -2 0 2 4
Favours BT
Favours RET + exp


Review: OCD: psychological interventions
Comparison: 06 BT v RET + exposure in vivo (post RET alone)
Outcome: 02 Dutch Obsessive-Compulsive Questionnaire
Study or sub-category
Behaviour therapy N Mean (SD)
RET + exposure N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1991 11 80.80(25.90) 10 73.80(15.90) 0.31 [-0.55, 1.17]
Subtotal (95% CI) 11 10 0.31 [-0.55, 1.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
02 At follow-up
Emmelkamp 1991 11 83.40(26.60) 10 76.60(20.20) 0.27 [-0.59, 1.14]
Subtotal (95% CI) 11 10 0.27 [-0.59, 1.14]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
-4 -2 0 2 4
Favours BT
Favours RET + exp


Review: OCD: psychological interventions
Comparison: 06 BT v RET + exposure in vivo (post RET alone)
Outcome: 03 Anxiety Discomfort Scale: main OC symptoms (assessor)
Study or sub-category
Behaviour therapy N Mean (SD)
RET + exposure N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1991 11 2.30(1.70) 10 3.50(3.00) -0.48 [-1.35, 0.39]
Subtotal (95% CI) 11 10 -0.48 [-1.35, 0.39]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
-4 -2 0 2 4
Favours BT
Favours RET + exp


Review: OCD: psychological interventions
Comparison: 06 BT v RET + exposure in vivo (post RET alone)
Outcome: 04 Irrational Beliefs Test
Study or sub-category
Behaviour therapy N Mean (SD)
RET + exposure N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1991 11 100.80(21.10) 10 88.80(18.30) 0.58 [-0.30, 1.46]
Subtotal (95% CI) 11 10 0.58 [-0.30, 1.46]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
02 At follow-up
Emmelkamp 1991 11 103.50(17.80) 10 88.90(24.70) 0.66 [-0.23, 1.54]
Subtotal (95% CI) 11 10 0.66 [-0.23, 1.54]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.15)
-4 -2 0 2 4
Favours BT
Favours RET + exp


Review: OCD: psychological interventions
Comparison: 06 BT v RET + exposure in vivo (post RET alone)
Outcome: 05 Self-rating Depression Scale
Study or sub-category
Behaviour therapy N Mean (SD)
RET + exposure N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Emmelkamp 1991 11 49.50(10.80) 10 43.70(10.40) 0.52 [-0.35, 1.40]
Subtotal (95% CI) 11 10 0.52 [-0.35, 1.40]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
02 At follow-up
Emmelkamp 1991 11 49.90(11.80) 10 49.60(16.40) 0.02 [-0.84, 0.88]
Subtotal (95% CI) 11 10 0.02 [-0.84, 0.88]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
-4 -2 0 2 4
Favours BT
Favours RET + exp


Review: OCD: psychological interventions
Comparison: 07 BT v CBT
Outcome: 01 Leaving the study early
Study or sub-category
Behaviour therapy n/N
CBT n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Vogel 2004 8/19 1/16 6.74 [0.94, 48.29]
Total (95% CI) 19 16 6.74 [0.94, 48.29]
Total events: 8 (Behaviour therapy), 1 (CBT)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.06)
0.01 0.1 1 10 100
Favours BT
Favours CBT


Review: OCD: psychological interventions
Comparison: 07 BT v CBT
Outcome: 02 Non-remission (Y-BOCS)
Study or sub-category
Behaviour therapy n/N
CBT n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Post treatment
Vogel 2004 9/19 10/16 0.76 [0.41, 1.39]
Subtotal (95% CI) 19 16 0.76 [0.41, 1.39]
Total events: 9 (Behaviour therapy), 10 (CBT)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
02 At 3 months follow-up
Vogel 2004 9/19 10/16 0.76 [0.41, 1.39]
Subtotal (95% CI) 19 16 0.76 [0.41, 1.39]
Total events: 9 (Behaviour therapy), 10 (CBT)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
Total (95% CI) 38 32 0.76 [0.49, 1.16]
Total events: 18 (Behaviour therapy), 20 (CBT)
Test for heterogeneity: Chi² = 0.00, df = 1 (P = 1.00), I² = 0%
Test for overall effect: Z = 1.27 (P = 0.21)
0.2 0.5 1 2 5
Favours BT
Favours CBT


Review: OCD: psychological interventions
Comparison: 07 BT v CBT
Outcome: 03 Y-BOCS
Study or sub-category
Behaviour therapy N Mean (SD)
CBT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Vogel 2004 19 16.10(7.30) 16 16.70(7.20) -0.08 [-0.75, 0.58]
Subtotal (95% CI) 19 16 -0.08 [-0.75, 0.58]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
02 At 3 months follow-up
Vogel 2004 19 17.30(7.10) 16 14.40(7.00) 0.40 [-0.27, 1.07]
Subtotal (95% CI) 19 16 0.40 [-0.27, 1.07]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
03 At 6 months follow-up
Vogel 2004 19 17.80(5.70) 16 12.70(5.90) 0.86 [0.16, 1.56]
Subtotal (95% CI) 19 16 0.86 [0.16, 1.56]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.02)
04 At 12 months follow-up
Vogel 2004 19 15.40(8.10) 16 14.80(8.30) 0.07 [-0.59, 0.74]
Subtotal (95% CI) 19 16 0.07 [-0.59, 0.74]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
Total (95% CI) 76 64 0.30 [-0.04, 0.64]
Test for heterogeneity: Chi² = 4.27, df = 3 (P = 0.23), I² = 29.8%
Test for overall effect: Z = 1.74 (P = 0.08)
-4 -2 0 2 4
Favours BT Favours CBT


Review: OCD: psychological interventions
Comparison: 07 BT v CBT
Outcome: 08 BDI
Study or sub-category
Behaviour therapy N Mean (SD)
CBT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Vogel 2004 18 9.70(8.30) 16 10.60(9.20) -0.10 [-0.77, 0.57]
Subtotal (95% CI) 18 16 -0.10 [-0.77, 0.57]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
02 At 3 months follow-up
Vogel 2004 18 10.80(6.00) 16 9.40(9.30) 0.18 [-0.50, 0.85]
Subtotal (95% CI) 18 16 0.18 [-0.50, 0.85]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
03 At 6 months follow-up
Vogel 2004 18 10.70(8.10) 16 10.40(10.40) 0.03 [-0.64, 0.71]
Subtotal (95% CI) 18 16 0.03 [-0.64, 0.71]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
04 At 12 months follow-up
Vogel 2004 18 9.20(8.80) 16 11.20(9.70) -0.21 [-0.89, 0.46]
Subtotal (95% CI) 18 16 -0.21 [-0.89, 0.46]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 72 64 -0.03 [-0.36, 0.31]
Test for heterogeneity: Chi² = 0.71, df = 3 (P = 0.87), I² = 0%
Test for overall effect: Z = 0.15 (P = 0.88)
-1 -0.5 0 0.5 1
Favours BT Favours CBT


Review: OCD: psychological interventions
Comparison: 08 Kundalini yoga v Relaxation response + mindfulness meditation
Outcome: 01 Leaving the study early
Study or sub-category
Kundalini yoga n/N
RR+MM n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Shannahoff-Khalsa99 5/12 3/10 1.39 [0.44, 4.43]
Total (95% CI) 12 10 1.39 [0.44, 4.43]
Total events: 5 (Kundalini yoga), 3 (RR+MM)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
0.1 0.2 0.5 1 2 5 10
Favours K-yoga Favours RR+MM

Review: OCD: psychological interventions
Comparison: 08 Kundalini yoga v Relaxation response + mindfulness meditation
Outcome: 02 Y-BOCS (ITT)



Review: OCD: psychological interventions
Comparison: 08 Kundalini yoga v Relaxation response + mindfulness meditation
Outcome: 03 Profile of Moods scale



Review: OCD: psychological interventions
Comparison: 08 Kundalini yoga v Relaxation response + mindfulness meditation
Outcome: 04 Perceived Stress scale



Review: OCD: psychological interventions
Comparison: 08 Kundalini yoga v Relaxation response + mindfulness meditation
Outcome: 05 Purpose in Life scale



Review: OCD: psychological interventions
Comparison: 08 Kundalini yoga v Relaxation response + mindfulness meditation
Outcome: 06 Y-BOCS (PP)



Review: OCD: psychological interventions
Comparison: 09 Self-exposure v Partner-assisted exposure
Outcome: 01 Anxiety/discomfort - Main compulsion (assessor rated)



Review: OCD: psychological interventions
Comparison: 09 Self-exposure v Partner-assisted exposure
Outcome: 02 Anxiety/discomfort - Other compulsions (assessor rated)



Review: OCD: psychological interventions
Comparison: 09 Self-exposure v Partner-assisted exposure
Outcome: 03 Maudsley Obsessive-compulsive inventory



Review: OCD: psychological interventions
Comparison: 09 Self-exposure v Partner-assisted exposure
Outcome: 04 Social and Marital Adjustment: Marital



Review: OCD: psychological interventions
Comparison: 09 Self-exposure v Partner-assisted exposure
Outcome: 05 Social and Marital Adjustment: Sexual



Review: OCD: psychological interventions
Comparison: 09 Self-exposure v Partner-assisted exposure
Outcome: 06 Social and Marital Adjustment: Social



Review: OCD: psychological interventions
Comparison: 09 Self-exposure v Partner-assisted exposure
Outcome: 07 Anxious mood (assessor-rated)




Review: OCD: psychological interventions
Comparison: 09 Self-exposure v Partner-assisted exposure
Outcome: 08 Self-rating Depression scale
Study or sub-category
Self-controlled exp N Mean (SD)
Partner-assisted exp N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Emmelkamp 1983 6 49.00(9.69) 6 43.30(7.50) 0.61 [-0.56, 1.78]
Total (95% CI) 6 6 0.61 [-0.56, 1.78]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
-100 -50 0 50 100
Favours Self-exp
Favours Couple-exp


Review: OCD: psychological interventions
Comparison: 10 Imaginal + live ERP v Live ERP
Outcome: 01 Leaving the study early
Study or sub-category
Imagined + live ERP n/N
Live ERP n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
De Araujo1995 5/28 5/28 1.00 [0.33, 3.08]
Total (95% CI) 28 28 1.00 [0.33, 3.08]
Total events: 5 (Imagined + live ERP), 5 (Live ERP)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
0.1 0.2 0.5 1 2 5 10
Favours Img/Live ERP
Favours Live ERP


Review: OCD: psychological interventions
Comparison: 10 Imaginal + live ERP v Live ERP
Outcome: 02 Relapse (multiple outcomes)
Study or sub-category
Imagined + live ERP n/N
Live ERP n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 At 20 weeks follow-up
De Araujo1995 8/28 5/28 1.60 [0.60, 4.29]
Subtotal (95% CI) 28 28 1.60 [0.60, 4.29]
Total events: 8 (Imagined + live ERP), 5 (Live ERP)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
02 At 32 weeks follow-up
De Araujo1995 2/28 4/28 0.50 [0.10, 2.51]
Subtotal (95% CI) 28 28 0.50 [0.10, 2.51]
Total events: 2 (Imagined + live ERP), 4 (Live ERP)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
0.1 0.2 0.5 1 2 5 10
Favours Img/Live ERP
Favours Live ERP


Review: OCD: psychological interventions
Comparison: 10 Imaginal + live ERP v Live ERP
Outcome: 03 Y-BOCS obsessions
Study or sub-category
Imagined + live ERP N Mean (SD)
Live ERP N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 At 9 weeks (post treatment)
De Araujo1995 23 7.50(3.20) 23 7.90(3.90) -0.11 [-0.69, 0.47]
Subtotal (95% CI) 23 23 -0.11 [-0.69, 0.47]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
02 At 20 weeks (post treatment)
De Araujo1995 23 8.00(4.00) 23 8.80(5.40) -0.17 [-0.74, 0.41]
Subtotal (95% CI) 23 23 -0.17 [-0.74, 0.41]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
03 At 32 weeks (post treatment)
De Araujo1995 20 7.00(2.90) 21 8.00(5.90) -0.21 [-0.82, 0.40]
Subtotal (95% CI) 20 21 -0.21 [-0.82, 0.40]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
-10 -5 0 5 10
Favours Img/live ERP
Favours Live ERP

Review: OCD: psychological interventions
Comparison: 10 Imaginal + live ERP v Live ERP
Outcome: 04 Y-BOCS rituals



Review: OCD: psychological interventions
Comparison: 10 Imaginal + live ERP v Live ERP
Outcome: 05 Compulsions checklist



Review: OCD: psychological interventions
Comparison: 10 Imaginal + live ERP v Live ERP
Outcome: 06 Beck Depression Inventory




Review: OCD: psychological interventions
Comparison: 11 ERP + relapse prevention v ERP + associative therapy
Outcome: 01 Non-responders (Y-BOCS 50%)
Study or sub-category
ERP + resp. prevent n/N
ERP + assn. therapy n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Post treatment
Hiss 1994 4/10 3/10 1.33 [0.40, 4.49]
Subtotal (95% CI) 10 10 1.33 [0.40, 4.49]
Total events: 4 (ERP + resp. prevent), 3 (ERP + assn. therapy)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
02 At 6 months follow-up
Hiss 1994 4/10 7/10 0.57 [0.24, 1.35]
Subtotal (95% CI) 10 10 0.57 [0.24, 1.35]
Total events: 4 (ERP + resp. prevent), 7 (ERP + assn. therapy)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
0.1 0.2 0.5 1 2 5 10
Favours ERP+RP
Favours ERP+assn.the


Review: OCD: psychological interventions
Comparison: 11 ERP + relapse prevention v ERP + associative therapy
Outcome: 02 Leaving the study early
Study or sub-category
ERP + resp. prevent n/N
ERP + assn. therapy n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Hiss 1994 2/10 0/10 5.00 [0.27, 92.62]
Total (95% CI) 10 10 5.00 [0.27, 92.62]
Total events: 2 (ERP + resp. prevent), 0 (ERP + assn. therapy)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
0.01 0.1 1 10 100
Favours ERP+RP
Favours ERP+assn.the


Review: OCD: psychological interventions
Comparison: 11 ERP + relapse prevention v ERP + associative therapy
Outcome: 03 Y-BOCS
Study or sub-category
ERP + resp. prevent N Mean (SD)
ERP + assn. therapy N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Hiss 1994 8 8.75(4.53) 10 9.80(7.24) -0.16 [-1.09, 0.77]
Subtotal (95% CI) 8 10 -0.16 [-1.09, 0.77]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
02 At 6-month follow-up
Hiss 1994 8 8.13(7.10) 10 13.44(8.78) -0.63 [-1.58, 0.33]
Subtotal (95% CI) 8 10 -0.63 [-1.58, 0.33]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
-100 -50 0 50 100
Favours ERP+RP
Favours ERP+assn.the


Review: OCD: psychological interventions
Comparison: 11 ERP + relapse prevention v ERP + associative therapy
Outcome: 04 Obsessive-compulsive symptoms (assessor-rated)
Study or sub-category
ERP + resp. prevent N Mean (SD)
ERP + assn. therapy N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Hiss 1994 8 2.75(2.25) 10 5.00(4.57) -0.57 [-1.53, 0.38]
Subtotal (95% CI) 8 10 -0.57 [-1.53, 0.38]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
02 At 6-month follow-up
Hiss 1994 8 4.50(4.66) 10 11.80(7.55) -1.08 [-2.09, -0.07]
Subtotal (95% CI) 8 10 -1.08 [-2.09, -0.07]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.04)
-100 -50 0 50 100
Favours ERP+RP
Favours ERP+assn.the

Review: OCD: psychological interventions
Comparison: 11 ERP + relapse prevention v ERP + associative therapy
Outcome: 05 Hamilton Depression Scale



Review: OCD: psychological interventions
Comparison: 11 ERP + relapse prevention v ERP + associative therapy
Outcome: 06 Beck Depression Inventory



Review: OCD: psychological interventions
Comparison: 13 BTSTEPS + scheduled support v BTSTEPS + requested support
Outcome: 04 Leaving the study early



Review: OCD: psychological interventions
Comparison: 13 BTSTEPS + scheduled support v BTSTEPS + requested support
Outcome: 01 Y-BOCS



Review: OCD: psychological interventions
Comparison: 13 BTSTEPS + scheduled support v BTSTEPS + requested support
Outcome: 02 Target triggers discomfort



Review: OCD: psychological interventions
Comparison: 13 BTSTEPS + scheduled support v BTSTEPS + requested support
Outcome: 03 Work and Social Adjustment Scale



Review: OCD: psychological interventions
Comparison: 11 ERP + relapse prevention v ERP + associative therapy
Outcome: 07 State-Trait Anxiety Inventory - State



Review: OCD: psychological interventions
Comparison: 14 Family-based BT v Patient-based BT
Outcome: 01 MOCI



Review: OCD: psychological interventions
Comparison: 14 Family-based BT v Patient-based BT
Outcome: 02 Zung Self-rating Depression Scale



Review: OCD: psychological interventions
Comparison: 14 Family-based BT v Patient-based BT
Outcome: 03 Social adjustment: Occupation



Review: OCD: psychological interventions
Comparison: 14 Family-based BT v Patient-based BT
Outcome: 04 Social adjustment: family



Review: OCD: psychological interventions
Comparison: 14 Family-based BT v Patient-based BT
Outcome: 05 Social adjustment: household responsibilities



Review: OCD: psychological interventions
Comparison: 14 Family-based BT v Patient-based BT
Outcome: 06 Social adjustment: leisure-time activities




Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 01 CY-BOCS
Study or sub-category
Individual CBFT N Mean (SD)
Group CBFT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Barrett 2004 22 8.36(6.93) 29 8.28(7.33) 0.01 [-0.54, 0.57]
Total (95% CI) 22 29 0.01 [-0.54, 0.57]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
-10 -5 0 5 10
Favours Ind-CBFT Favours Group-CBFT


Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 02 NIMH-GOCS
Study or sub-category
Individual CBFT N Mean (SD)
Group CBFT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Barrett 2004 24 3.50(2.30) 29 3.31(2.16) 0.08 [-0.46, 0.63]
Total (95% CI) 24 29 0.08 [-0.46, 0.63]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
-10 -5 0 5 10
Favours Ind-CBFT Favours Group-CBFT


Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 03 Multidimensional Anxiety Scale for Children
Study or sub-category
Individual CBFT N Mean (SD)
Group CBFT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Barrett 2004 19 50.37(15.31) 23 39.09(18.00) 0.66 [0.03, 1.28]
Total (95% CI) 19 23 0.66 [0.03, 1.28]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.04)
-10 -5 0 5 10
Favours Ind-CBFT Favours Group-CBFT


Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 04 Children's Depression Inventory
Study or sub-category
Individual CBFT N Mean (SD)
Group CBFT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Barrett 2004 19 6.26(6.59) 23 3.35(4.82) 0.50 [-0.12, 1.12]
Total (95% CI) 19 23 0.50 [-0.12, 1.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
-10 -5 0 5 10
Favours Ind-CBFT Favours Group-CBFT


Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 05 McMaster Family Assessment Device - Mother's rating
Study or sub-category
Individual CBFT N Mean (SD)
Group CBFT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Barrett 2004 18 2.16(0.30) 26 2.16(0.39) 0.00 [-0.60, 0.60]
Total (95% CI) 18 26 0.00 [-0.60, 0.60]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
-10 -5 0 5 10
Favours Ind-CBFT Favours Group-CBFT


Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 06 McMaster Family Assessment Device - Father's rating
Study or sub-category
Individual CBFT N Mean (SD)
Group CBFT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Barrett 2004 9 2.12(0.37) 13 2.13(0.45) -0.02 [-0.87, 0.83]
Total (95% CI) 9 13 -0.02 [-0.87, 0.83]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
-10 -5 0 5 10
Favours Ind-CBFT Favours Group-CBFT

Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 07 Depression Anxiety Stress Scale: Mother depression



Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 08 Depression Anxiety Stress Scale: Mother anxiety



Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 09 Depression Anxiety Stress Scale: Mother stress



Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 10 Depression Anxiety Stress Scale: Father depression



Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 11 Depression Anxiety Stress Scale: Father anxiety



Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 12 Depression Anxiety Stress Scale: Father stress



Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 13 Children's Depression Inventory: sibling's rating

Study or sub-category	Individual CBFT N	Individual CBFT Mean (SD)	Group CBFT N	Group CBFT Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
Barrett 2004	12	1.92(2.11)	10	3.20(3.94)		-0.40 [-1.25, 0.45]
Total (95% CI)	12		10			-0.40 [-1.25, 0.45]

Test for heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)



Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 14 Multidimensional Anxiety Scale for Children - sibling's ratings

Study or sub-category	Individual CBFT N	Individual CBFT Mean (SD)	Group CBFT N	Group CBFT Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
Barrett 2004	13	34.08(11.30)	10	30.50(10.16)		0.32 [-0.51, 1.15]
Total (95% CI)	13		10			0.32 [-0.51, 1.15]

Test for heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)



Review: OCD: psychological interventions
Comparison: 17 Children: Individual CBFT v Group CBFT
Outcome: 15 Sibling Accomodation Scale

Study or sub-category	Individual CBFT N	Individual CBFT Mean (SD)	Group CBFT N	Group CBFT Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
Barrett 2004	9	6.11(5.01)	10	6.30(5.46)		-0.03 [-0.94, 0.87]
Total (95% CI)	9		10			-0.03 [-0.94, 0.87]

Test for heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)



Psychological vs. Control (BDD)

Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control
Outcome: 01 Non-responders



Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control
Outcome: 02 Body Dysmorphic Disorder Examination



Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control
Outcome: 03 Multidimensional Body Self-Relations Questionnaire: Appearance Evaluation Scale



Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control
Outcome: 04 Body Shape Questionnaire



Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control
Outcome: 05 Rosenberg Self-Esteem Scale



Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control
Outcome: 06 Brief Symptom Inventory



Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control
Outcome: 07 Y-BOCS (BDD)



Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control
Outcome: 08 MADRS



Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control
Outcome: 09 Hospital Anxiety



Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control
Outcome: 10 Hospital Depression



Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control
Outcome: 11 Derriford Scale



Review: BDD: psychological interventions
Comparison: 01 CBT v No treatment/wait-list control
Outcome: 12 Social Phobia



Psychological vs. Psychological (BDD)

Review: BDD: psychological interventions
Comparison: 02 BT v CT (mid-treatment)
Outcome: 01 Non-responders (Y-BOCS reliable change index)



Review: BDD: psychological interventions
Comparison: 02 BT v CT (mid-treatment)
Outcome: 02 Y-BOCS (BDD)



Review: BDD: psychological interventions
Comparison: 02 BT v CT (mid-treatment)
Outcome: 03 BDD Examination



Review: BDD: psychological interventions
Comparison: 02 BT v CT (mid-treatment)
Outcome: 04 Defects Related Beliefs Test



Review: BDD: psychological interventions
Comparison: 02 BT v CT (mid-treatment)
Outcome: 05 Beck Anxiety Inventory



Review: BDD: psychological interventions
Comparison: 02 BT v CT (mid-treatment)
Outcome: 06 Beck Depression Inventory



Review: BDD: psychological interventions
Comparison: 02 BT v CT (mid-treatment)
Outcome: 07 Body Satisfaction Scale



Review: BDD: psychological interventions
Comparison: 02 BT v CT (mid-treatment)
Outcome: 08 Social Avoidance and Distress Scale



Review: BDD: psychological interventions
Comparison: 02 BT v CT (mid-treatment)
Outcome: 09 Quality of Life Inventory



Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 01 Non-responders (Y-BOCS reliable change index)




Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 02 Y-BOCS (BDD)
Study or sub-category
Behaviour therapy N Mean (SD)
CBT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Khemlani-Patel 2001 5 18.20(8.53) 5 14.20(6.26) 0.48 [-0.79, 1.75]
Total (95% CI) 5 5 0.48 [-0.79, 1.75]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
-4 -2 0 2 4
Favours BT Favours CBT


Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 03 BDD Examination
Study or sub-category
Behaviour therapy N Mean (SD)
CBT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Khemlani-Patel 2001 5 63.80(15.01) 5 37.60(22.07) 1.25 [-0.17, 2.68]
Total (95% CI) 5 5 1.25 [-0.17, 2.68]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.08)
-4 -2 0 2 4
Favours BT Favours CBT


Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 04 Defects Related Beliefs Test
Study or sub-category
Behaviour therapy N Mean (SD)
CBT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Khemlani-Patel 2001 5 33.00(7.78) 5 27.00(6.48) 0.76 [-0.55, 2.07]
Total (95% CI) 5 5 0.76 [-0.55, 2.07]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
-4 -2 0 2 4
Favours BT Favours CBT


Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 05 Beck Anxiety Inventory
Study or sub-category
Behaviour therapy N Mean (SD)
CBT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Khemlani-Patel 2001 5 10.00(9.27) 5 5.80(5.12) 0.51 [-0.77, 1.78]
Total (95% CI) 5 5 0.51 [-0.77, 1.78]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
-4 -2 0 2 4
Favours BT Favours CBT


Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 06 Beck Depression Inventory
Study or sub-category
Behaviour therapy N Mean (SD)
CBT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Khemlani-Patel 2001 5 14.40(15.65) 5 12.60(11.26) 0.12 [-1.12, 1.36]
Total (95% CI) 5 5 0.12 [-1.12, 1.36]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
-4 -2 0 2 4
Favours BT Favours CBT


Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 07 Body Satisfaction Scale
Study or sub-category
Behaviour therapy N Mean (SD)
CBT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Khemlani-Patel 2001 5 49.80(20.07) 5 46.80(16.60) 0.15 [-1.10, 1.39]
Total (95% CI) 5 5 0.15 [-1.10, 1.39]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
-4 -2 0 2 4
Favours BT Favours CBT

Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 08 Social Avoidance and Distress Scale



Review: BDD: psychological interventions
Comparison: 03 BT v CBT (post-treatment)
Outcome: 09 Quality of Life Inventory



Treatment Intensity Review

Review: OCD psychological intensity review
Comparison: 02 Before-after analysis
Outcome: 01 Change from baseline to endpoint



Review: OCD psychological intensity review
Comparison: 02 Before-after analysis
Outcome: 02 Change from baseline to endpoint: low intensity



Review: OCD psychological intensity review
Comparison: 02 Before-after analysis
Outcome: 03 Change from baseline to endpoint: medium intensity



Review: OCD psychological intensity review
Comparison: 02 Before-after analysis
Outcome: 04 Change from baseline to endpoint: high intensity



Review: OCD psychological intensity review
Comparison: 02 Before-after analysis
Outcome: 05 Change from baseline to endpoint: low intensity (Sensitivity Analysis - excluding Hughes2004)



Review: OCD psychological intensity review
Comparison: 02 Before-after analysis
Outcome: 06 Change from baseline to endpoint: high intensity (Sensitivity Analysis - excluding Foa2004)



Review: OCD psychological intensity review
Comparison: 02 Before-after analysis
Outcome: 07 Change from baseline to endpoint: low intensity (Sensitivity Analysis - excluding Hughes2004/ Emmelkamp1983



Review: OCD psychological intensity review
Comparison: 02 Before-after analysis
Outcome: 08 Change from baseline to endpoint: medium intensity (Sensitivity Analysis - excluding Lindsay1997)



Review: OCD psychological intensity review
Comparison: 02 Before-after analysis
Outcome: 09 Change from baseline to endpoint: high intensity (Sensitivity Analysis - excluding Foa2004/ Hiss1994_relaps




Review: OCD psychological intensity review
Comparison: 02 Before-after analysis
Outcome: 10 Change from baseline to endpoint
Study or sub-category | End of treatment N Mean (SD) | Before treatment N Mean (SD) | SMD (random) 95% CI | SMD (random) 95% CI
01 Low intensity
Cordioli 2003 23 15.10(7.80) 23 26.70(4.90) -1.75 [-2.44, -1.06]
Emmelkamp 1983_coupl 6 8.00(3.15) 6 16.20(3.15) -2.40 [-4.03, -0.77]
Emmelkamp 1983_patie 6 8.00(4.02) 6 16.50(4.02) -1.95 [-3.43, -0.47]
Enright 1991 24 12.96(6.03) 24 15.46(5.12) -0.44 [-1.01, 0.13]
Fritzler 1997 9 17.11(8.91) 9 22.90(7.27) -0.68 [-1.64, 0.28]
Hughes 2004 21 16.50(6.00) 24 22.90(4.40) -1.21 [-1.85, -0.57]
McLean 2001_BT 40 16.40(9.28) 40 23.28(5.29) -0.90 [-1.36, -0.44]
McLean 2001_CT 33 16.52(6.93) 33 22.00(5.89) -0.84 [-1.35, -0.34]
Taylor 2003_Del 15 6.60(2.90) 15 8.30(3.20) -0.54 [-1.27, 0.19]
Taylor 2003_Imm 11 6.10(3.60) 11 9.70(4.00) -0.91 [-1.80, -0.02]
VanNoppen 1998 73 16.60(6.10) 73 21.80(5.60) -0.88 [-1.22, -0.54]
Subtotal (95% CI) 261 264 -0.96 [-1.21, -0.71]
Test for heterogeneity: Chi² = 15.51, df = 10 (P = 0.11), I² = 35.5%
Test for overall effect: Z = 7.60 (P < 0.00001)
02 Medium intensity
Bouvard 2002 19 16.94(9.22) 19 27.55(7.15) -1.26 [-1.96, -0.56]
Chambless 1999 49 3.42(1.75) 49 6.68(1.04) -2.25 [-2.76, -1.74]
De Araujo 1995_Ex 23 7.90(3.90) 23 14.10(2.70) -1.82 [-2.51, -1.12]
De Araujo 1995_Exi 23 7.50(3.20) 23 13.80(2.10) -2.29 [-3.04, -1.53]
Emmelkamp 1988_BT 9 12.60(5.40) 9 15.60(4.00) -0.60 [-1.55, 0.35]
Emmelkamp 1988_CT 9 11.30(1.70) 9 15.60(2.90) -1.72 [-2.85, -0.60]
Emmelkamp1991_BT 11 11.70(6.10) 11 15.90(4.60) -0.75 [-1.62, 0.12]
Emmelkamp1991_CT 10 9.60(6.90) 10 15.80(6.70) -0.87 [-1.80, 0.05]
Greist 2002_clinicBT 55 17.60(6.20) 55 25.20(4.60) -1.38 [-1.80, -0.97]
Hiss 1994_associatio 10 9.60(9.60) 10 23.90(7.31) -1.61 [-2.64, -0.57]
Hiss 1994_relapse 8 7.88(2.95) 8 23.13(5.41) -3.31 [-4.95, -1.66]
Lindsay 1997 9 11.00(3.81) 9 28.70(4.56) -4.01 [-5.76, -2.26]
O'Connor 1999 6 13.30(8.60) 6 23.50(4.00) -1.40 [-2.73, -0.08]
Rothbaum 2000 39 14.61(9.47) 39 24.66(5.59) -1.28 [-1.77, -0.79]
Van Noppen1997_GBT 17 16.60(7.20) 17 23.90(7.20) -0.99 [-1.71, -0.27]
Van Noppen1997_MFBT 19 15.60(6.50) 19 23.90(5.40) -1.36 [-2.07, -0.65]
Van Oppen 1995_BT 29 17.30(8.30) 29 25.40(7.00) -1.04 [-1.59, -0.49]
Van Oppen 1995_CT 28 13.30(8.50) 28 24.10(5.50) -1.49 [-2.08, -0.89]
Vogel 2004_BT 19 16.10(7.30) 19 23.70(3.20) -1.32 [-2.03, -0.61]
Vogel 2004_CBT 16 16.70(7.20) 16 24.90(2.90) -1.46 [-2.25, -0.67]
Whittal2004_BT 37 13.57(9.27) 37 22.38(5.77) -1.13 [-1.62, -0.64]
Whittal2004_CT 34 11.94(8.21) 34 23.56(4.08) -1.77 [-2.34, -1.21]
Subtotal (95% CI) 479 479 -1.47 [-1.69, -1.25]
Test for heterogeneity: Chi² = 43.32, df = 21 (P = 0.003), I² = 51.5%
Test for overall effect: Z = 12.99 (P < 0.00001)
03 High intensity
Foa 1984_ERP 11 2.55(2.30) 11 6.73(1.21) -2.19 [-3.29, -1.09]
Foa 1984_Ex 12 4.00(1.99) 12 6.67(1.09) -1.61 [-2.55, -0.66]
Foa 1984_RP 9 4.33(1.60) 9 6.61(0.78) -1.73 [-2.85, -0.60]
Foa 1985_Exi 10 5.00(1.27) 10 6.55(0.64) -1.48 [-2.49, -0.46]
Foa 1985_Exv 9 5.44(1.33) 9 6.44(0.88) -0.84 [-1.82, 0.13]
Foa 2004 21 11.00(7.90) 29 24.60(4.80) -2.13 [-2.84, -1.42]
Freeston1997 15 12.20(9.60) 15 25.10(5.00) -1.64 [-2.48, -0.80]
McKay 1996 21 15.00(8.29) 21 30.19(3.68) -2.32 [-3.12, -1.52]
Neziroglu 2001 20 10.60(3.60) 20 14.50(3.30) -1.11 [-1.78, -0.44]
Rosqvist 2001 11 16.91(5.86) 11 22.46(5.20) -0.96 [-1.86, -0.07]
Subtotal (95% CI) 139 147 -1.60 [-1.93, -1.27]
Test for heterogeneity: Chi² = 12.85, df = 9 (P = 0.17), I² = 30.0%
Test for overall effect: Z = 9.41 (P < 0.00001)
Total (95% CI) 879 890 -1.37 [-1.54, -1.20]
Test for heterogeneity: Chi² = 96.31, df = 42 (P < 0.00001), I² = 56.4%
Test for overall effect: Z = 15.78 (P < 0.00001)
-10 -5 0 5 10
Favours treatment
Doesn't favour treat

Review: OCD psychological intensity review
Comparison: 02 Before-after analysis
Outcome: 12 Change from baseline to endpoint (Sensitivity Analysis)



Appendix 17b: Forest plots for clinical evidence reviews on pharmacological interventions

SSRIs (OCD, adults)
Clomipramine (OCD, adults)
TCAs (OCD)
SNRIs (OCD)
MAOIs (OCD)
Anxiolytics (OCD)
Other Pharmacological (OCD)
Augmentation (OCD)
SSRIs (OCD, children)
Clomipramine (OCD, children)
Pharmacological (BDD)

SSRIs (OCD, adults)




Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 02 Serious adverse events
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Kamijima 2004 3/95 3/94 0.99 [0.20, 4.78]
Subtotal (95% CI) 95 94 0.99 [0.20, 4.78]
Total events: 3 (SSRI), 3 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 95 94 0.99 [0.20, 4.78]
Total events: 3 (SSRI), 3 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 03 Suicide attempts
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Kamijima 2004 1/95 1/94 0.99 [0.06, 15.59]
Subtotal (95% CI) 95 94 0.99 [0.06, 15.59]
Total events: 1 (SSRI), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 95 94 0.99 [0.06, 15.59]
Total events: 1 (SSRI), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 04 Leaving study early
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram
Montgomery 2001 46/300 17/101 0.91 [0.55, 1.51]
Subtotal (95% CI) 300 101 0.91 [0.55, 1.51]
Total events: 46 (SSRI), 17 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
02 Fluoxetine
Jenike 1997 4/23 3/21 1.22 [0.31, 4.82]
Montgomery 1993 41/160 15/57 0.97 [0.59, 1.62]
Subtotal (95% CI) 183 78 1.00 [0.62, 1.62]
Total events: 45 (SSRI), 18 (Placebo)
Test for heterogeneity: Chi² = 0.09, df = 1 (P = 0.76), I² = 0%
Test for overall effect: Z = 0.02 (P = 0.99)
03 Fluvoxamine
Goodman 1989 2/23 6/23 0.33 [0.07, 1.48]
Goodman 1996 23/80 17/80 1.35 [0.78, 2.33]
Hollander 2003b 43/127 31/126 1.38 [0.93, 2.03]
Jenike 1990a 0/18 0/20 Not estimable
Mallya 1992 5/19 6/20 0.88 [0.32, 2.40]
Perse 1987 1/10 1/10 1.00 [0.07, 13.87]
Subtotal (95% CI) 277 279 1.21 [0.91, 1.62]
Total events: 74 (SSRI), 61 (Placebo)
Test for heterogeneity: Chi² = 3.85, df = 4 (P = 0.43), I² = 0%
Test for overall effect: Z = 1.30 (P = 0.19)
04 Paroxetine
Burnham 1993 28/82 20/77 1.31 [0.81, 2.13]
Hollander 2003d 53/259 15/89 1.21 [0.72, 2.04]
Zohar 1996a 49/201 39/99 0.62 [0.44, 0.87]
Subtotal (95% CI) 542 265 0.91 [0.71, 1.16]
Total events: 130 (SSRI), 74 (Placebo)
Test for heterogeneity: Chi² = 8.21, df = 2 (P = 0.02), I² = 75.6%
Test for overall effect: Z = 0.76 (P = 0.45)
05 Sertraline
Chouinard 1990 3/43 7/44 0.44 [0.12, 1.59]
Greist 1995a 65/241 24/84 0.94 [0.63, 1.40]
Jenike 1990b 0/10 0/9 Not estimable
Kronig 1999 25/86 25/81 0.94 [0.59, 1.50]
Subtotal (95% CI) 380 218 0.89 [0.67, 1.20]
Total events: 93 (SSRI), 56 (Placebo)
Test for heterogeneity: Chi² = 1.30, df = 2 (P = 0.52), I² = 0%
Test for overall effect: Z = 0.76 (P = 0.44)
Total (95% CI) 1682 941 0.98 [0.85, 1.13]
Total events: 388 (SSRI), 226 (Placebo)
Test for heterogeneity: Chi² = 16.94, df = 13 (P = 0.20), I² = 23.3%
Test for overall effect: Z = 0.26 (P = 0.79)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 05 Leaving study early due to adverse events
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram
Montgomery 2001 14/300 2/101 2.36 [0.54, 10.19]
Subtotal (95% CI) 300 101 2.36 [0.54, 10.19]
Total events: 14 (SSRI), 2 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
02 Fluoxetine
Beasley 1992 59/266 2/89 9.87 [2.46, 39.57]
Montgomery 1993 7/160 2/57 1.25 [0.27, 5.83]
Subtotal (95% CI) 426 146 5.59 [2.06, 15.16]
Total events: 66 (SSRI), 4 (Placebo)
Test for heterogeneity: Chi² = 4.28, df = 1 (P = 0.04), I² = 76.6%
Test for overall effect: Z = 3.38 (P = 0.0007)
03 Fluvoxamine
Goodman 1989 2/23 0/23 5.00 [0.25, 98.75]
Goodman 1996 15/80 6/80 2.50 [1.02, 6.12]
Hollander 2003b 23/127 8/126 2.85 [1.33, 6.13]
Subtotal (95% CI) 230 229 2.78 [1.57, 4.92]
Total events: 40 (SSRI), 14 (Placebo)
Test for heterogeneity: Chi² = 0.21, df = 2 (P = 0.90), I² = 0%
Test for overall effect: Z = 3.51 (P = 0.0004)
04 Paroxetine
Burnham 1993 15/82 8/77 1.76 [0.79, 3.92]
Hollander 2003d 29/259 7/89 1.42 [0.65, 3.14]
Kamijima 2004 9/95 9/96 1.01 [0.42, 2.43]
Zohar 1996a 18/201 6/99 1.48 [0.61, 3.61]
Subtotal (95% CI) 637 361 1.41 [0.93, 2.14]
Total events: 71 (SSRI), 30 (Placebo)
Test for heterogeneity: Chi² = 0.86, df = 3 (P = 0.84), I² = 0%
Test for overall effect: Z = 1.62 (P = 0.11)
05 Sertraline
Chouinard 1990 1/43 0/44 3.07 [0.13, 73.30]
Greist 1995a 23/241 5/84 1.60 [0.63, 4.08]
Kronig 1999 9/86 4/81 2.12 [0.68, 6.61]
Subtotal (95% CI) 370 209 1.84 [0.91, 3.71]
Total events: 33 (SSRI), 9 (Placebo)
Test for heterogeneity: Chi² = 0.24, df = 2 (P = 0.89), I² = 0%
Test for overall effect: Z = 1.70 (P = 0.09)
Total (95% CI) 1963 1046 2.15 [1.62, 2.86]
Total events: 224 (SSRI), 59 (Placebo)
Test for heterogeneity: Chi² = 11.30, df = 12 (P = 0.50), I² = 0%
Test for overall effect: Z = 5.30 (P < 0.00001)
0.01
0.1
1
10
100
Favours SSRI
Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 06 Non-responders (OCD) (CGI or Y-BOCS)
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram
Montgomery 2001 126/300 64/101 0.66 [0.54, 0.81]
Subtotal (95% CI) 300 101 0.66 [0.54, 0.81]
Total events: 126 (SSRI), 64 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.05 (P < 0.0001)
02 Fluoxetine
Beasley 1992 190/266 82/89 0.78 [0.70, 0.85]
Montgomery 1993 92/160 46/57 0.71 [0.59, 0.86]
Subtotal (95% CI) 426 146 0.75 [0.69, 0.82]
Total events: 282 (SSRI), 128 (Placebo)
Test for heterogeneity: Chi² = 0.69, df = 1 (P = 0.41), I² = 0%
Test for overall effect: Z = 6.18 (P < 0.00001)
03 Fluvoxamine
Hollander 2003b 74/127 90/126 0.82 [0.68, 0.98]
Mallya 1992 13/19 19/20 0.72 [0.52, 0.99]
Subtotal (95% CI) 146 146 0.80 [0.68, 0.94]
Total events: 87 (SSRI), 109 (Placebo)
Test for heterogeneity: Chi² = 0.45, df = 1 (P = 0.50), I² = 0%
Test for overall effect: Z = 2.69 (P = 0.007)
04 Paroxetine
Burnham 1993 47/82 45/77 0.98 [0.75, 1.28]
Hollander 2003d 161/259 65/89 0.85 [0.73, 1.00]
Kamijima 2004 48/95 74/96 0.66 [0.52, 0.82]
Zohar 1996a 92/201 64/99 0.71 [0.57, 0.87]
Subtotal (95% CI) 637 361 0.78 [0.71, 0.87]
Total events: 348 (SSRI), 248 (Placebo)
Test for heterogeneity: Chi² = 7.09, df = 3 (P = 0.07), I² = 57.7%
Test for overall effect: Z = 4.66 (P < 0.00001)
05 Sertraline
Greist 1995a 148/241 59/84 0.87 [0.74, 1.04]
Subtotal (95% CI) 241 84 0.87 [0.74, 1.04]
Total events: 148 (SSRI), 59 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 1750 838 0.77 [0.73, 0.82]
Total events: 991 (SSRI), 608 (Placebo)
Test for heterogeneity: Chi² = 12.76, df = 9 (P = 0.17), I² = 29.5%
Test for overall effect: Z = 8.51 (P < 0.00001)
0.5 0.7 1 1.5 2
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 07 Non-responders (MDD)
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluvoxamine
Goodman 1989 18/23 20/23 0.90 [0.69, 1.18]
Subtotal (95% CI) 23 23 0.90 [0.69, 1.18]
Total events: 18 (SSRI), 20 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 08 Non-remitters
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluvoxamine
Hollander 2003b 106/127 117/126 0.90 [0.82, 0.98]
Subtotal (95% CI) 127 126 0.90 [0.82, 0.98]
Total events: 106 (SSRI), 117 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.02)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 09 Y-BOCS
Study or sub-category
N
SSRI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Citalopram
Montgomery 2001 102 -8.40(7.30) 101 -5.60(6.90) -0.39 [-0.67, -0.11]
Subtotal (95% CI) 102 101 -0.39 [-0.67, -0.11]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.77 (P = 0.006)
02 Fluoxetine
Beasley 1992 75 18.90(8.30) 76 23.60(7.50) -0.59 [-0.92, -0.27]
Jenike 1997 19 16.20(6.30) 18 18.70(6.10) -0.39 [-1.05, 0.26]
Montgomery 1993 52 -5.13(6.41) 56 -3.70(5.98) -0.23 [-0.61, 0.15]
Subtotal (95% CI) 146 150 -0.43 [-0.66, -0.20]
Test for heterogeneity: Chi² = 2.03, df = 2 (P = 0.36), I² = 1.5%
Test for overall effect: Z = 3.66 (P = 0.0002)
03 Fluvoxamine
Goodman 1989 21 19.40(7.00) 21 28.00(7.00) -1.21 [-1.87, -0.54]
Goodman 1996 78 -3.95(6.28) 78 -1.71(4.88) -0.40 [-0.71, -0.08]
Hollander 2003b 117 -8.50(7.57) 120 -5.60(7.67) -0.38 [-0.64, -0.12]
Jenike 1990a 18 18.80(4.00) 20 21.80(7.60) -0.48 [-1.12, 0.17]
Subtotal (95% CI) 234 239 -0.46 [-0.64, -0.27]
Test for heterogeneity: Chi² = 5.39, df = 3 (P = 0.15), I² = 44.4%
Test for overall effect: Z = 4.88 (P < 0.00001)
04 Paroxetine
Burnham 1993 79 -5.61(7.47) 75 -4.60(7.53) -0.13 [-0.45, 0.18]
Kamijima 2004 94 -8.11(8.00) 94 -3.46(6.10) -0.65 [-0.94, -0.36]
Zohar 1996a 198 -8.00(8.00) 99 -5.00(7.90) -0.38 [-0.62, -0.13]
Subtotal (95% CI) 371 268 -0.40 [-0.56, -0.23]
Test for heterogeneity: Chi² = 5.56, df = 2 (P = 0.06), I² = 64.0%
Test for overall effect: Z = 4.82 (P < 0.00001)
05 Sertraline
Jenike 1990b 10 20.60(9.20) 8 22.30(7.80) -0.19 [-1.12, 0.74]
Subtotal (95% CI) 10 8 -0.19 [-1.12, 0.74]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 863 766 -0.42 [-0.52, -0.32]
Test for heterogeneity: Chi² = 13.50, df = 11 (P = 0.26), I² = 18.5%
Test for overall effect: Z = 8.23 (P < 0.00001)
-4 -2 0 2 4
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 10 NIMH-OC
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Citalopram
Montgomery 2001 102 -2.80(2.50) 101 -1.80(2.30) -0.41 [-0.69, -0.14]
Subtotal (95% CI) 102 101 -0.41 [-0.69, -0.14]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.92 (P = 0.003)
02 Fluoxetine
Jenike 1997 19 7.00(1.10) 18 7.20(1.30) -0.16 [-0.81, 0.48]
Subtotal (95% CI) 19 18 -0.16 [-0.81, 0.48]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
03 Fluvoxamine
Goodman 1996 78 -1.32(2.25) 78 -0.40(1.78) -0.45 [-0.77, -0.13]
Jenike 1990a 18 6.80(1.20) 20 8.00(2.20) -0.65 [-1.31, 0.00]
Subtotal (95% CI) 96 98 -0.49 [-0.78, -0.20]
Test for heterogeneity: Chi² = 0.30, df = 1 (P = 0.59), I² = 0%
Test for overall effect: Z = 3.36 (P = 0.0008)
04 Paroxetine
Burnham 1993 79 -1.42(2.04) 75 -1.04(2.08) -0.18 [-0.50, 0.13]
Zohar 1996a 198 -2.50(2.90) 99 -1.40(2.90) -0.38 [-0.62, -0.14]
Subtotal (95% CI) 277 174 -0.31 [-0.50, -0.11]
Test for heterogeneity: Chi² = 0.91, df = 1 (P = 0.34), I² = 0%
Test for overall effect: Z = 3.11 (P = 0.002)
05 Sertraline
Jenike 1990b 10 8.20(2.00) 9 9.30(2.50) -0.47 [-1.38, 0.45]
Subtotal (95% CI) 10 9 -0.47 [-1.38, 0.45]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 504 400 -0.37 [-0.50, -0.23]
Test for heterogeneity: Chi² = 2.84, df = 6 (P = 0.83), I² = 0%
Test for overall effect: Z = 5.39 (P < 0.00001)
-4 -2 0 2 4
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 11 General Rating Scale: compulsions
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluvoxamine
Perse 1987 8 3.56(2.00) 8 5.12(2.00) -0.74 [-1.76, 0.29]
Subtotal (95% CI) 8 8 -0.74 [-1.76, 0.29]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
-10 -5 0 5 10
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 12 General Rating Scale: obsessions
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluvoxamine
Perse 1987 8 3.07(1.98) 8 4.31(2.67) -0.50 [-1.50, 0.50]
Subtotal (95% CI) 8 8 -0.50 [-1.50, 0.50]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
-10 -5 0 5 10
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 13 Maudsley Obsessive Compulsive Inventory
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluvoxamine
Perse 1987 8 13.87(5.32) 8 16.12(4.59) -0.43 [-1.42, 0.57]
Subtotal (95% CI) 8 8 -0.43 [-1.42, 0.57]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
-10 -5 0 5 10
Favours SSRI Favours placebo

Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 14 Obsessive-Compulsive Checklist



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 15 OCD Scale (CPRS)



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 16 Beck Depression Inventory



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 17 Hamilton Rating Scale for Depression




Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 18 Montgomery-Asberg Depression Rating Scale
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Citalopram
Montgomery 2001 102 -3.40(6.30) 101 -1.30(6.70) -0.32 [-0.60, -0.04]
Subtotal (95% CI) 102 101 -0.32 [-0.60, -0.04]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.02)
02 Fluoxetine
Montgomery 1993 52 -2.96(8.09) 56 -2.88(9.27) -0.01 [-0.39, 0.37]
Subtotal (95% CI) 52 56 -0.01 [-0.39, 0.37]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
03 Paroxetine
Zohar 1996a 198 -3.40(7.90) 99 -0.60(7.90) -0.35 [-0.60, -0.11]
Subtotal (95% CI) 198 99 -0.35 [-0.60, -0.11]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.85 (P = 0.004)
Total (95% CI) 352 256 -0.28 [-0.44, -0.11]
Test for heterogeneity: Chi² = 2.42, df = 2 (P = 0.30), I² = 17.2%
Test for overall effect: Z = 3.30 (P = 0.0010)
-1 -0.5 0 0.5 1
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 19 Hamilton Anxiety Scale
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluvoxamine
Perse 1987 8 7.69(3.60) 8 12.37(7.56) -0.75 [-1.77, 0.28]
Subtotal (95% CI) 8 8 -0.75 [-1.77, 0.28]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
-10 -5 0 5 10
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 20 Clinical Global Impression
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Jenike 1997 19 3.10(1.00) 18 3.20(1.00) -0.10 [-0.74, 0.55]
Subtotal (95% CI) 19 18 -0.10 [-0.74, 0.55]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
-10 -5 0 5 10
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 21 Clinical Global Impressions: severity
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Paroxetine
Zohar 1996a 194 -1.20(1.40) 99 -0.70(1.30) -0.36 [-0.61, -0.12]
Subtotal (95% CI) 194 99 -0.36 [-0.61, -0.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.93 (P = 0.003)
-10 -5 0 5 10
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 22 Sheehan Disability Scale: family
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Citalopram
Montgomery 2001 102 -1.80(2.40) 101 -1.00(2.40) -0.33 [-0.61, -0.06]
Subtotal (95% CI) 102 101 -0.33 [-0.61, -0.06]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.02)
-10 -5 0 5 10
Favours SSRI Favours placebo

Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 23 Sheehan Disability Scale: social

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Citalopram						
Montgomery 2001	102	-2.00(2.20)	101	-1.30(2.00)		-0.33 [-0.61, -0.05]
Subtotal (95% CI)	102		101			-0.33 [-0.61, -0.05]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.35 (P = 0.02)						



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 24 Sheehan Disability Scale: work

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Citalopram						
Montgomery 2001	102	-1.90(2.40)	101	-1.10(2.10)		-0.35 [-0.63, -0.08]
Subtotal (95% CI)	102		101			-0.35 [-0.63, -0.08]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.50 (P = 0.01)						



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 25 Symptom Checklist-90

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Paroxetine						
Zohar 1996a	169	-29.00(47.10)	77	-19.50(37.30)		-0.21 [-0.48, 0.06]
Subtotal (95% CI)	169		77			-0.21 [-0.48, 0.06]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 1.55 (P = 0.12)						



Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 26 Subanalysis: Y-BOCS in patients with comorbid depression

Study or sub-category	N	SSRI Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
02 Fluoxetine						
Beasley 1992	75	18.90(8.30)	76	23.60(7.50)		-0.59 [-0.92, -0.27]
Montgomery 1993	52	-5.13(6.41)	56	-3.70(5.98)		-0.23 [-0.61, 0.15]
Subtotal (95% CI)	127		132			-0.44 [-0.68, -0.19]
Test for heterogeneity: Chi² = 2.02, df = 1 (P = 0.16), I² = 50.4%						
Test for overall effect: Z = 3.47 (P = 0.0005)						
03 Fluvoxamine						
Goodman 1989	21	19.40(7.00)	21	28.00(7.00)		-1.21 [-1.87, -0.54]
Subtotal (95% CI)	21		21			-1.21 [-1.87, -0.54]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 3.56 (P = 0.0004)						
04 Paroxetine						
Kamijima 2004	94	-8.11(8.00)	94	-3.46(6.10)		-0.65 [-0.94, -0.36]
Subtotal (95% CI)	94		94			-0.65 [-0.94, -0.36]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 4.35 (P < 0.0001)						
Total (95% CI)	242		247			-0.58 [-0.76, -0.40]
Test for heterogeneity: Chi² = 6.94, df = 3 (P = 0.07), I² = 56.8%						
Test for overall effect: Z = 6.22 (P < 0.00001)						




Review: OCD adults: SSRIs
Comparison: 01 SSRIs vs placebo (acute phase)
Outcome: 27 Subanalysis: Non-responders (OCD) (CGI or Y-BOCS) in patients with comorbid depression
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
02 Fluoxetine
Beasley 1992 190/266 82/89 0.78 [0.70, 0.85]
Montgomery 1993 92/160 46/57 0.71 [0.59, 0.86]
Subtotal (95% CI) 426 146 0.75 [0.69, 0.82]
Total events: 282 (SSRI), 128 (Placebo)
Test for heterogeneity: Chi² = 0.69, df = 1 (P = 0.41), I² = 0%
Test for overall effect: Z = 6.18 (P < 0.00001)
04 Paroxetine
Kamijima 2004 48/95 74/96 0.66 [0.52, 0.82]
Subtotal (95% CI) 95 96 0.66 [0.52, 0.82]
Total events: 48 (SSRI), 74 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.65 (P = 0.0003)
Total (95% CI) 521 242 0.73 [0.66, 0.79]
Total events: 330 (SSRI), 202 (Placebo)
Test for heterogeneity: Chi² = 2.58, df = 2 (P = 0.28), I² = 22.4%
Test for overall effect: Z = 7.03 (P < 0.00001)
0.5
0.7
1
1.5
2
Favours SSRI
Favours placebo


Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 01 Adverse events
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram 40mg vs Citalopram 20mg
Montgomery 2001 67/98 74/102 0.94 [0.79, 1.13]
Subtotal (95% CI) 98 102 0.94 [0.79, 1.13]
Total events: 67 (Dose 1), 74 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
02 Citalopram 60mg vs Citalopram 20mg
Montgomery 2001 72/100 74/102 0.99 [0.84, 1.18]
Subtotal (95% CI) 100 102 0.99 [0.84, 1.18]
Total events: 72 (Dose 1), 74 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
03 Citalopram 60mg vs Citalopram 40mg
Montgomery 2001 72/100 67/98 1.05 [0.88, 1.26]
Subtotal (95% CI) 100 98 1.05 [0.88, 1.26]
Total events: 72 (Dose 1), 67 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
04 Sertraline rapid titration vs slow titration
Bogetto 2002 13/17 11/15 1.04 [0.70, 1.56]
Subtotal (95% CI) 17 15 1.04 [0.70, 1.56]
Total events: 13 (Dose 1), 11 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
0.5
0.7
1
1.5
2
Favours Dose 1
Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 02 Leaving study early
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram 40mg vs Citalopram 20mg
Montgomery 2001 15/98 16/102 0.98 [0.51, 1.86]
Subtotal (95% CI) 98 102 0.98 [0.51, 1.86]
Total events: 15 (Dose 1), 16 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
02 Citalopram 60mg vs Citalopram 20mg
Montgomery 2001 15/100 16/102 0.96 [0.50, 1.83]
Subtotal (95% CI) 100 102 0.96 [0.50, 1.83]
Total events: 15 (Dose 1), 16 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
03 Citalopram 60mg vs Citalopram 40mg
Montgomery 2001 15/100 15/98 0.98 [0.51, 1.89]
Subtotal (95% CI) 100 98 0.98 [0.51, 1.89]
Total events: 15 (Dose 1), 15 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
04 Fluoxetine 40mg vs Fluoxetine 20mg
Montgomery 1993 13/52 14/53 0.95 [0.49, 1.81]
Subtotal (95% CI) 52 53 0.95 [0.49, 1.81]
Total events: 13 (Dose 1), 14 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
05 Fluoxetine 60mg vs Fluoxetine 20mg
Montgomery 1993 14/55 14/53 0.96 [0.51, 1.82]
Subtotal (95% CI) 55 53 0.96 [0.51, 1.82]
Total events: 14 (Dose 1), 14 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
06 Fluoxetine 60mg vs Fluoxetine 40mg
Montgomery 1993 14/55 13/52 1.02 [0.53, 1.96]
Subtotal (95% CI) 55 52 1.02 [0.53, 1.96]
Total events: 14 (Dose 1), 13 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
07 Paroxetine 40mg vs Paroxetine 20mg
Hollander 2003d 20/86 14/88 1.46 [0.79, 2.70]
Subtotal (95% CI) 86 88 1.46 [0.79, 2.70]
Total events: 20 (Dose 1), 14 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
08 Paroxetine 60mg vs Paroxetine 20mg
Hollander 2003d 19/85 14/88 1.41 [0.75, 2.62]
Subtotal (95% CI) 85 88 1.41 [0.75, 2.62]
Total events: 19 (Dose 1), 14 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
09 Paroxetine 60mg vs Paroxetine 40mg
Hollander 2003d 19/85 20/86 0.96 [0.55, 1.67]
Subtotal (95% CI) 85 86 0.96 [0.55, 1.67]
Total events: 19 (Dose 1), 20 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
10 Sertraline 100mg vs Sertraline 50mg
Greist 1995a 27/81 17/80 1.57 [0.93, 2.64]
Subtotal (95% CI) 81 80 1.57 [0.93, 2.64]
Total events: 27 (Dose 1), 17 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.09)
11 Sertraline 200mg vs Sertraline 50mg
Greist 1995a 21/80 17/80 1.24 [0.71, 2.16]
Subtotal (95% CI) 80 80 1.24 [0.71, 2.16]
Total events: 21 (Dose 1), 17 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
12 Sertraline 200mg vs Sertraline 100mg
Greist 1995a 21/80 27/81 0.79 [0.49, 1.27]
Subtotal (95% CI) 80 81 0.79 [0.49, 1.27]
Total events: 21 (Dose 1), 27 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
13 Sertraline rapid titration vs slow titration
Bogetto 2002 3/17 2/15 1.32 [0.25, 6.88]
Subtotal (95% CI) 17 15 1.32 [0.25, 6.88]
Total events: 3 (Dose 1), 2 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
0.1 0.2 0.5 1 2 5 10
Favours Dose 1 Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 03 Leaving study early due to adverse events
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram 40mg vs Citalopram 20mg
Montgomery 2001 6/98 4/102 1.56 [0.45, 5.36]
Subtotal (95% CI) 98 102 1.56 [0.45, 5.36]
Total events: 6 (Dose 1), 4 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
02 Citalopram 60mg vs Citalopram 20mg
Montgomery 2001 4/100 4/102 1.02 [0.26, 3.97]
Subtotal (95% CI) 100 102 1.02 [0.26, 3.97]
Total events: 4 (Dose 1), 4 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
03 Citalopram 60mg vs Citalopram 40mg
Montgomery 2001 4/100 6/98 0.65 [0.19, 2.24]
Subtotal (95% CI) 100 98 0.65 [0.19, 2.24]
Total events: 4 (Dose 1), 6 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
04 Fluoxetine 40mg vs Fluoxetine 20mg
Beasley 1992 12/89 30/87 0.39 [0.21, 0.71]
Montgomery 1993 2/52 4/53 0.51 [0.10, 2.66]
Subtotal (95% CI) 141 140 0.40 [0.23, 0.71]
Total events: 14 (Dose 1), 34 (Dose 2)
Test for heterogeneity: Chi² = 0.09, df = 1 (P = 0.77), I² = 0%
Test for overall effect: Z = 3.14 (P = 0.002)
05 Fluoxetine 60mg vs Fluoxetine 20mg
Beasley 1992 17/90 30/87 0.55 [0.33, 0.92]
Montgomery 1993 1/55 4/53 0.24 [0.03, 2.09]
Subtotal (95% CI) 145 140 0.51 [0.31, 0.85]
Total events: 18 (Dose 1), 34 (Dose 2)
Test for heterogeneity: Chi² = 0.53, df = 1 (P = 0.46), I² = 0%
Test for overall effect: Z = 2.61 (P = 0.009)
06 Fluoxetine 60mg vs Fluoxetine 40mg
Beasley 1992 17/90 12/89 1.40 [0.71, 2.76]
Montgomery 1993 1/55 2/52 0.47 [0.04, 5.06]
Subtotal (95% CI) 145 141 1.27 [0.66, 2.41]
Total events: 18 (Dose 1), 14 (Dose 2)
Test for heterogeneity: Chi² = 0.75, df = 1 (P = 0.39), I² = 0%
Test for overall effect: Z = 0.72 (P = 0.47)
07 Paroxetine 40mg vs Paroxetine 20mg
Hollander 2003d 8/86 9/88 0.91 [0.37, 2.25]
Subtotal (95% CI) 86 88 0.91 [0.37, 2.25]
Total events: 8 (Dose 1), 9 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.84)
08 Paroxetine 60mg vs Paroxetine 20mg
Hollander 2003d 12/85 9/88 1.38 [0.61, 3.11]
Subtotal (95% CI) 85 88 1.38 [0.61, 3.11]
Total events: 12 (Dose 1), 9 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
09 Paroxetine 60mg vs Paroxetine 40mg
Hollander 2003d 12/85 8/86 1.52 [0.65, 3.53]
Subtotal (95% CI) 85 86 1.52 [0.65, 3.53]
Total events: 12 (Dose 1), 8 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
10 Sertraline 100mg vs Sertraline 50mg
Greist 1995a 11/81 6/80 1.81 [0.70, 4.66]
Subtotal (95% CI) 81 80 1.81 [0.70, 4.66]
Total events: 11 (Dose 1), 6 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
11 Sertraline 200mg vs Sertraline 50mg
Greist 1995a 6/80 6/80 1.00 [0.34, 2.97]
Subtotal (95% CI) 80 80 1.00 [0.34, 2.97]
Total events: 6 (Dose 1), 6 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
12 Sertraline 200mg vs Sertraline 100mg
Greist 1995a 6/80 11/81 0.55 [0.21, 1.42]
Subtotal (95% CI) 80 81 0.55 [0.21, 1.42]
Total events: 6 (Dose 1), 11 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
13 Sertraline rapid titration vs slow titration
Bogetto 2002 2/17 2/15 0.88 [0.14, 5.52]
Subtotal (95% CI) 17 15 0.88 [0.14, 5.52]
Total events: 2 (Dose 1), 2 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.89)
0.1 0.2 0.5 1 2 5 10
Favours Dose 1
Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 04 Non-responders
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram 40mg vs Citalopram 20mg
Montgomery 2001 47/98 44/102 1.11 [0.82, 1.51]
Subtotal (95% CI) 98 102 1.11 [0.82, 1.51]
Total events: 47 (Dose 1), 44 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
02 Citalopram 60mg vs Citalopram 20mg
Montgomery 2001 35/100 44/102 0.81 [0.57, 1.15]
Subtotal (95% CI) 100 102 0.81 [0.57, 1.15]
Total events: 35 (Dose 1), 44 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
03 Citalopram 60mg vs Citalopram 40mg
Montgomery 2001 35/100 47/98 0.73 [0.52, 1.02]
Subtotal (95% CI) 100 98 0.73 [0.52, 1.02]
Total events: 35 (Dose 1), 47 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.07)
04 Fluoxetine 40mg vs Fluoxetine 20mg
Beasley 1992 65/89 62/87 1.02 [0.85, 1.23]
Montgomery 1993 33/52 39/53 0.86 [0.66, 1.12]
Subtotal (95% CI) 141 140 0.96 [0.83, 1.12]
Total events: 98 (Dose 1), 101 (Dose 2)
Test for heterogeneity: Chi² = 1.12, df = 1 (P = 0.29), I² = 10.9%
Test for overall effect: Z = 0.49 (P = 0.62)
05 Fluoxetine 60mg vs Fluoxetine 20mg
Beasley 1992 63/90 62/87 0.98 [0.81, 1.19]
Montgomery 1993 34/55 39/53 0.84 [0.65, 1.09]
Subtotal (95% CI) 145 140 0.93 [0.79, 1.08]
Total events: 97 (Dose 1), 101 (Dose 2)
Test for heterogeneity: Chi² = 0.89, df = 1 (P = 0.34), I² = 0%
Test for overall effect: Z = 0.96 (P = 0.34)
06 Fluoxetine 60mg vs Fluoxetine 40mg
Beasley 1992 63/90 65/89 0.96 [0.80, 1.15]
Montgomery 1993 34/55 33/52 0.97 [0.73, 1.31]
Subtotal (95% CI) 145 141 0.96 [0.82, 1.13]
Total events: 97 (Dose 1), 98 (Dose 2)
Test for heterogeneity: Chi² = 0.01, df = 1 (P = 0.93), I² = 0%
Test for overall effect: Z = 0.46 (P = 0.65)
07 Paroxetine 40mg vs Paroxetine 20mg
Hollander 2003d 51/86 62/88 0.84 [0.67, 1.05]
Subtotal (95% CI) 86 88 0.84 [0.67, 1.05]
Total events: 51 (Dose 1), 62 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
08 Paroxetine 60mg vs Paroxetine 20mg
Hollander 2003d 48/85 62/88 0.80 [0.64, 1.01]
Subtotal (95% CI) 85 88 0.80 [0.64, 1.01]
Total events: 48 (Dose 1), 62 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.06)
09 Paroxetine 60mg vs Paroxetine 40mg
Hollander 2003d 48/85 51/86 0.95 [0.74, 1.23]
Subtotal (95% CI) 85 86 0.95 [0.74, 1.23]
Total events: 48 (Dose 1), 51 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
0.5
0.7
1
1.5
2
Favours Dose 1
Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 05 Y-BOCS
Study or sub-category | N | Dose 1 Mean (SD) | N | Dose 2 Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Citalopram 40mg vs Citalopram 20mg
Montgomery 2001 98 -8.90(7.00) 102 -8.40(7.30) -0.07 [-0.35, 0.21]
Subtotal (95% CI) 98 102 -0.07 [-0.35, 0.21]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
02 Citalopram 60mg vs Citalopram 20mg
Montgomery 2001 100 -10.40(6.90) 102 -8.40(7.30) -0.28 [-0.56, 0.00]
Subtotal (95% CI) 100 102 -0.28 [-0.56, 0.00]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.05)
03 Citalopram 60mg vs Citalopram 40mg
Montgomery 2001 100 -10.40(6.90) 98 -8.90(7.00) -0.22 [-0.49, 0.06]
Subtotal (95% CI) 100 98 -0.22 [-0.49, 0.06]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
04 Fluoxetine 40mg vs Fluoxetine 20mg
Beasley 1992 67 18.10(7.90) 75 18.90(8.30) -0.10 [-0.43, 0.23]
Montgomery 1993 52 -4.76(6.89) 52 -5.13(6.41) 0.06 [-0.33, 0.44]
Subtotal (95% CI) 119 127 -0.03 [-0.28, 0.22]
Test for heterogeneity: Chi² = 0.35, df = 1 (P = 0.55), I² = 0%
Test for overall effect: Z = 0.26 (P = 0.80)
05 Fluoxetine 60mg vs Fluoxetine 20mg
Beasley 1992 68 16.80(7.80) 75 18.90(8.30) -0.26 [-0.59, 0.07]
Montgomery 1993 54 -6.07(6.92) 52 -5.13(6.41) -0.14 [-0.52, 0.24]
Subtotal (95% CI) 122 127 -0.21 [-0.46, 0.04]
Test for heterogeneity: Chi² = 0.21, df = 1 (P = 0.64), I² = 0%
Test for overall effect: Z = 1.63 (P = 0.10)
06 Fluoxetine 60mg vs Fluoxetine 40mg
Beasley 1992 68 16.80(7.80) 67 18.10(7.90) -0.16 [-0.50, 0.17]
Montgomery 1993 54 -6.07(6.92) 52 -4.76(6.89) -0.19 [-0.57, 0.19]
Subtotal (95% CI) 122 119 -0.18 [-0.43, 0.08]
Test for heterogeneity: Chi² = 0.01, df = 1 (P = 0.93), I² = 0%
Test for overall effect: Z = 1.36 (P = 0.18)
07 Sertraline rapid titration vs slow titration
Bogetto 2002 14 12.43(3.78) 13 13.54(4.03) -0.28 [-1.03, 0.48]
Subtotal (95% CI) 14 13 -0.28 [-1.03, 0.48]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
-4 -2 0 2 4
Favours Dose 1 Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 06 NIMH-OC
Study or sub-category | N | Dose 1 Mean (SD) | N | Dose 2 Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Citalopram 40mg vs Citalopram 20mg
Montgomery 2001 98 -2.90(2.80) 102 -2.80(2.50) -0.04 [-0.31, 0.24]
Subtotal (95% CI) 98 102 -0.04 [-0.31, 0.24]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
02 Citalopram 60mg vs Citalopram 20mg
Montgomery 2001 100 -3.10(2.60) 102 -2.80(2.50) -0.12 [-0.39, 0.16]
Subtotal (95% CI) 100 102 -0.12 [-0.39, 0.16]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
03 Citalopram 60mg vs Citalopram 40mg
Montgomery 2001 100 -3.10(2.60) 98 -2.90(2.80) -0.07 [-0.35, 0.20]
Subtotal (95% CI) 100 98 -0.07 [-0.35, 0.20]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
-1 -0.5 0 0.5 1
Favours Dose 1 Favours Dose 2

Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 07 Hamilton Rating Scale for Depression



Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 08 Montgomery-Asberg Depression Rating Scale



Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 09 Sheehan Disability Score: family



Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 10 Sheehan Disability Score: social



Review: OCD adults: SSRIs
Comparison: 02 SSRIs at different doses (acute phase)
Outcome: 11 Sheehan Disability Score: work




Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 01 Leaving study early
Study or sub-category
SSRI 1 n/N
SSRI 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram vs Fluvoxamine
Mundo 1997a 0/11 0/10 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (SSRI 1), 0 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Citalopram vs Paroxetine
Mundo 1997a 0/11 0/9 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (SSRI 1), 0 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 Fluoxetine vs Sertraline
Bergeron 2002 22/73 22/77 1.05 [0.64, 1.73]
Subtotal (95% CI) 73 77 1.05 [0.64, 1.73]
Total events: 22 (SSRI 1), 22 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
04 Fluvoxamine vs Paroxetine
Mundo 1997a 0/10 0/9 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (SSRI 1), 0 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.5 0.7 1 1.5 2
Favours SSRI 1 Favours SSRI 2


Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 02 Leaving study early due to adverse events
Study or sub-category
SSRI 1 n/N
SSRI 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram vs Fluvoxamine
Mundo 1997a 0/11 0/10 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (SSRI 1), 0 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Citalopram vs Paroxetine
Mundo 1997a 0/11 0/9 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (SSRI 1), 0 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 Fluoxetine vs Sertraline
Bergeron 2002 10/73 15/77 0.70 [0.34, 1.46]
Subtotal (95% CI) 73 77 0.70 [0.34, 1.46]
Total events: 10 (SSRI 1), 15 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
04 Fluvoxamine vs Paroxetine
Mundo 1997a 0/10 0/9 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (SSRI 1), 0 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours SSRI 1 Favours SSRI 2


Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 03 Non-responders
Study or sub-category
SSRI 1 n/N
SSRI 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Citalopram vs Paroxetine
Mundo 1997a 7/11 5/9 1.15 [0.55, 2.39]
Subtotal (95% CI) 11 9 1.15 [0.55, 2.39]
Total events: 7 (SSRI 1), 5 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
03 Fluvoxamine vs Citalopram
Mundo 1997a 4/10 7/11 0.63 [0.26, 1.52]
Subtotal (95% CI) 10 11 0.63 [0.26, 1.52]
Total events: 4 (SSRI 1), 7 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
04 Fluvoxamine vs Paroxetine
Mundo 1997a 4/10 5/9 0.72 [0.28, 1.88]
Subtotal (95% CI) 10 9 0.72 [0.28, 1.88]
Total events: 4 (SSRI 1), 5 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
0.1 0.2 0.5 1 2 5 10
Favours SSRI 1
Favours SSRI 2


Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 04 Non-remitters
Study or sub-category
SSRI 1 n/N
SSRI 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine vs Sertraline
Bergeron 2002 57/73 50/77 1.20 [0.98, 1.47]
Subtotal (95% CI) 73 77 1.20 [0.98, 1.47]
Total events: 57 (SSRI 1), 50 (SSRI 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.08)
0.5 0.7 1 1.5 2
Favours SSRI 1
Favours SSRI 2


Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 05 Y-BOCS
Study or sub-category
N
SSRI 1 Mean (SD)
N
SSRI 2 Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
02 Fluoxetine vs Sertraline at 12 weeks
Bergeron 2002 72 -6.10(5.40) 76 -8.40(6.20) 0.39 [0.07, 0.72]
Subtotal (95% CI) 72 76 0.39 [0.07, 0.72]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.02)
03 Fluvoxamine vs Citalopram
Mundo 1997a 10 16.20(8.90) 11 19.80(10.10) -0.36 [-1.23, 0.50]
Subtotal (95% CI) 10 11 -0.36 [-1.23, 0.50]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
04 Fluvoxamine vs Paroxetine
Mundo 1997a 10 16.20(8.90) 9 21.60(7.60) -0.62 [-1.55, 0.31]
Subtotal (95% CI) 10 9 -0.62 [-1.55, 0.31]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
05 Paroxetine vs Citalopram
Mundo 1997a 9 21.60(7.60) 11 19.80(10.10) 0.19 [-0.69, 1.07]
Subtotal (95% CI) 9 11 0.19 [-0.69, 1.07]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
-10 -5 0 5 10
Favours SSRI 1
Favours SSRI 2


Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 06 NIMH-OC
Study or sub-category
N
SSRI 1 Mean (SD)
N
SSRI 2 Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Sertraline
Bergeron 2002 72 5.70(2.60) 76 5.50(2.80) 0.07 [-0.25, 0.40]
Subtotal (95% CI) 72 76 0.07 [-0.25, 0.40]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
02 Fluvoxamine vs Citalopram
Mundo 1997a 10 6.23(1.81) 11 8.58(1.88) -1.22 [-2.17, -0.27]
Subtotal (95% CI) 10 11 -1.22 [-2.17, -0.27]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.01)
03 Fluvoxamine vs Paroxetine
Mundo 1997a 10 6.23(1.81) 9 7.77(2.02) -0.77 [-1.71, 0.17]
Subtotal (95% CI) 10 9 -0.77 [-1.71, 0.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
04 Paroxetine vs Citalopram
Mundo 1997a 9 7.77(2.02) 11 8.58(1.88) -0.40 [-1.29, 0.49]
Subtotal (95% CI) 9 11 -0.40 [-1.29, 0.49]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
-4 -2 0 2 4
Favours SSRI 1 Favours SSRI 2


Review: OCD adults: SSRIs
Comparison: 03 SSRIs vs other SSRIs (acute phase)
Outcome: 07 Hamilton Rating Scale for Depression
Study or sub-category
N
SSRI 1 Mean (SD)
N
SSRI 2 Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Sertraline
Bergeron 2002 72 7.10(5.40) 76 6.20(4.60) 0.18 [-0.14, 0.50]
Subtotal (95% CI) 72 76 0.18 [-0.14, 0.50]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
-1 -0.5 0 0.5 1
Favours SSRI 1 Favours SSRI 2


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 01 Adverse events
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluvoxamine vs Clomipramine
Freeman 1994 30/34 24/30 1.10 [0.89, 1.37]
Koran 1996a 35/37 39/41 0.99 [0.90, 1.10]
Mundo 2001 81/115 84/112 0.94 [0.80, 1.10]
Subtotal (95% CI) 186 183 0.98 [0.89, 1.09]
Total events: 146 (SSRI), 147 (Clomipramine)
Test for heterogeneity: Chi² = 1.47, df = 2 (P = 0.48), I² = 0%
Test for overall effect: Z = 0.36 (P = 0.72)
02 Paroxetine vs Clomipramine
Burnham 1993 77/82 80/82 0.96 [0.90, 1.03]
Zohar 1996a 163/201 85/99 0.94 [0.85, 1.05]
Subtotal (95% CI) 283 181 0.95 [0.89, 1.02]
Total events: 240 (SSRI), 165 (Clomipramine)
Test for heterogeneity: Chi² = 0.13, df = 1 (P = 0.72), I² = 0%
Test for overall effect: Z = 1.45 (P = 0.15)
03 Sertraline vs Clomipramine
Askin 1999 7/18 13/18 0.54 [0.28, 1.03]
Bisserbe 1997 56/86 57/82 0.94 [0.76, 1.16]
Subtotal (95% CI) 104 100 0.86 [0.71, 1.06]
Total events: 63 (SSRI), 70 (Clomipramine)
Test for heterogeneity: Chi² = 2.62, df = 1 (P = 0.11), I² = 61.8%
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 573 464 0.95 [0.89, 1.00]
Total events: 449 (SSRI), 382 (Clomipramine)
Test for heterogeneity: Chi² = 5.93, df = 6 (P = 0.43), I² = 0%
Test for overall effect: Z = 1.80 (P = 0.07)
0.5 0.7 1 1.5 2
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 02 Attempted suicide
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Sertraline vs Clomipramine
Bisserbe 1997 1/86 3/82 0.32 [0.03, 2.99]
Subtotal (95% CI) 86 82 0.32 [0.03, 2.99]
Total events: 1 (SSRI), 3 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
0.01 0.1 1 10 100
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 03 Leaving study early
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 5/30 4/25 1.04 [0.31, 3.47]
Subtotal (95% CI) 5/30 4/25 1.04 [0.31, 3.47]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
02 Fluvoxamine vs Clomipramine
Freeman 1994 6/34 11/32 0.51 [0.22, 1.23]
Koran 1996a 8/37 15/42 0.61 [0.29, 1.26]
Milanfranchi 1997 0/13 1/13 0.33 [0.01, 7.50]
Mundo 2001 19/115 26/112 0.71 [0.42, 1.21]
Smeraldi 1992 1/6 1/6 1.00 [0.08, 12.56]
Subtotal (95% CI) 34/205 54/205 0.64 [0.44, 0.93]
Test for heterogeneity: Chi² = 0.71, df = 4 (P = 0.95), I² = 0%
Test for overall effect: Z = 2.34 (P = 0.02)
03 Paroxetine vs Clomipramine
Burnham 1993 28/82 28/82 1.00 [0.65, 1.53]
Zohar 1996a 49/201 34/99 0.71 [0.49, 1.02]
Subtotal (95% CI) 77/283 62/181 0.82 [0.62, 1.08]
Test for heterogeneity: Chi² = 1.44, df = 1 (P = 0.23), I² = 30.4%
Test for overall effect: Z = 1.41 (P = 0.16)
04 Sertraline vs Clomipramine
Askin 1999 2/20 4/22 0.55 [0.11, 2.69]
Bisserbe 1997 23/86 35/82 0.63 [0.41, 0.96]
Subtotal (95% CI) 25/106 39/104 0.62 [0.41, 0.94]
Test for heterogeneity: Chi² = 0.02, df = 1 (P = 0.88), I² = 0%
Test for overall effect: Z = 2.25 (P = 0.02)
Total (95% CI) 141/624 159/515 0.72 [0.59, 0.88]
Test for heterogeneity: Chi² = 4.26, df = 9 (P = 0.89), I² = 0%
Test for overall effect: Z = 3.29 (P = 0.001)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 04 Leaving study early due to adverse events
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 1/30 1/25 0.83 [0.05, 12.66]
Subtotal (95% CI) 30 25 0.83 [0.05, 12.66]
Total events: 1 (SSRI), 1 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
02 Fluvoxamine vs Clomipramine
Freeman 1994 5/34 4/30 1.10 [0.33, 3.73]
Koran 1996a 5/37 7/42 0.81 [0.28, 2.34]
Milanfranchi 1997 0/13 0/13 Not estimable
Mundo 2001 9/115 18/112 0.49 [0.23, 1.04]
Smeraldi 1992 1/6 0/6 3.00 [0.15, 61.74]
Subtotal (95% CI) 205 203 0.69 [0.41, 1.17]
Total events: 20 (SSRI), 29 (Clomipramine)
Test for heterogeneity: Chi² = 2.38, df = 3 (P = 0.50), I² = 0%
Test for overall effect: Z = 1.38 (P = 0.17)
03 Paroxetine vs Clomipramine
Burnham 1993 15/82 17/82 0.88 [0.47, 1.65]
Zohar 1996a 18/201 17/99 0.52 [0.28, 0.97]
Subtotal (95% CI) 283 181 0.68 [0.44, 1.04]
Total events: 33 (SSRI), 34 (Clomipramine)
Test for heterogeneity: Chi² = 1.38, df = 1 (P = 0.24), I² = 27.5%
Test for overall effect: Z = 1.77 (P = 0.08)
04 Sertraline vs Clomipramine
Bisserbe 1997 9/86 21/82 0.41 [0.20, 0.84]
Subtotal (95% CI) 86 82 0.41 [0.20, 0.84]
Total events: 9 (SSRI), 21 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.01)
Total (95% CI) 604 491 0.62 [0.46, 0.84]
Total events: 63 (SSRI), 85 (Clomipramine)
Test for heterogeneity: Chi² = 5.41 , df = 7 (P = 0.61), I² = 0%
Test for overall effect: Z = 3.11 (P = 0.002)
0.01
0.1
1
10
100
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 05 Non-responders
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 22/30 11/25 1.67 [1.02, 2.73]
Subtotal (95% CI) 30 25 1.67 [1.02, 2.73]
Total events: 22 (SSRI), 11 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.04)
02 Fluvoxamine vs Clomipramine
Koran 1996a 18/37 21/42 0.97 [0.62, 1.52]
Milanfranchi 1997 2/13 3/13 0.67 [0.13, 3.35]
Mundo 2001 46/115 44/112 1.02 [0.74, 1.40]
Subtotal (95% CI) 165 167 0.99 [0.76, 1.28]
Total events: 66 (SSRI), 68 (Clomipramine)
Test for heterogeneity: Chi² = 0.27, df = 2 (P = 0.88), I² = 0%
Test for overall effect: Z = 0.08 (P = 0.93)
03 Paroxetine vs Clomipramine
Burnham 1993 47/82 42/82 1.12 [0.84, 1.48]
Zohar 1996a 92/201 47/99 0.96 [0.75, 1.25]
Subtotal (95% CI) 283 181 1.03 [0.85, 1.24]
Total events: 139 (SSRI), 89 (Clomipramine)
Test for heterogeneity: Chi² = 0.59, df = 1 (P = 0.44), I² = 0%
Test for overall effect: Z = 0.27 (P = 0.79)
04 Sertraline vs Clomipramine
Bisserbe 1997 24/86 29/82 0.79 [0.50, 1.24]
Subtotal (95% CI) 86 82 0.79 [0.50, 1.24]
Total events: 24 (SSRI), 29 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 564 455 1.02 [0.89, 1.17]
Total events: 251 (SSRI), 197 (Clomipramine)
Test for heterogeneity: Chi² = 6.01, df = 6 (P = 0.42), I² = 0.1%
Test for overall effect: Z = 0.24 (P = 0.81)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 06 Y-BOCS
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 30 -7.50(9.29) 24 -8.90(7.13) 0.16 [-0.37, 0.70]
Subtotal (95% CI) 30 24 0.16 [-0.37, 0.70]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
02 Fluvoxamine vs Clomipramine
Koran 1996a 34 17.80(7.70) 39 17.00(8.55) 0.10 [-0.36, 0.56]
Milanfranchi 1997 13 18.40(9.20) 12 16.50(11.00) 0.18 [-0.60, 0.97]
Mundo 2001 67 14.70(10.10) 61 12.50(8.00) 0.24 [-0.11, 0.59]
Smeraldi 1992 5 18.20(2.50) 5 15.20(12.40) 0.30 [-0.95, 1.55]
Subtotal (95% CI) 119 117 0.19 [-0.06, 0.45]
Test for heterogeneity: Chi² = 0.26, df = 3 (P = 0.97), I² = 0%
Test for overall effect: Z = 1.46 (P = 0.14)
03 Paroxetine vs Clomipramine
Burnham 1993 79 -5.61(7.47) 78 -7.73(7.42) 0.28 [-0.03, 0.60]
Zohar 1996a 198 -8.00(8.00) 94 -8.00(8.20) 0.00 [-0.25, 0.25]
Subtotal (95% CI) 277 172 0.11 [-0.09, 0.30]
Test for heterogeneity: Chi² = 1.94, df = 1 (P = 0.16), I² = 48.4%
Test for overall effect: Z = 1.09 (P = 0.28)
Total (95% CI) 426 313 0.14 [-0.01, 0.29]
Test for heterogeneity: Chi² = 2.47, df = 6 (P = 0.87), I² = 0%
Test for overall effect: Z = 1.85 (P = 0.06)
-1 -0.5 0 0.5 1
Favours SSRI
Favours Clomipramine

Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 07 NIMH-OC



Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 08 Comprehensive Psychopathological Rating Scale: obsessive-compulsive



Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 09 Hamilton Rating Scale for Depression




Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 10 Montgomery-Asberg Depression Rating Scale
Study or sub-category | N | SSRI Mean (SD) | N | Clomipramine Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 30 -10.10(8.20) 24 -13.80(9.09) 0.42 [-0.12, 0.97]
Subtotal (95% CI) 30 24 0.42 [-0.12, 0.97]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
02 Fluvoxamine vs Clomipramine
Smeraldi 1992 5 11.80(6.80) 5 9.60(10.30) 0.23 [-1.02, 1.47]
Subtotal (95% CI) 5 5 0.23 [-1.02, 1.47]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
03 Paroxetine vs Clomipramine
Zohar 1996a 198 -3.40(7.90) 94 -2.40(7.30) -0.13 [-0.38, 0.12]
Subtotal (95% CI) 198 94 -0.13 [-0.38, 0.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 233 123 -0.03 [-0.25, 0.19]
Test for heterogeneity: Chi² = 3.47, df = 2 (P = 0.18), I² = 42.4%
Test for overall effect: Z = 0.24 (P = 0.81)
-4 -2 0 2 4
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 11 Depression (HRSD; MADRS)
Study or sub-category | N | SSRI Mean (SD) | N | Clomipramine Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluvoxamine vs Clomipramine
Koran 1996a 34 6.10(3.30) 39 5.80(4.70) 0.07 [-0.39, 0.53]
Mundo 2001 112 7.70(6.00) 105 7.00(4.50) 0.13 [-0.14, 0.40]
Smeraldi 1992 5 11.80(6.80) 5 9.60(10.30) 0.23 [-1.02, 1.47]
Subtotal (95% CI) 151 149 0.12 [-0.11, 0.35]
Test for heterogeneity: Chi² = 0.08, df = 2 (P = 0.96), I² = 0%
Test for overall effect: Z = 1.04 (P = 0.30)
02 Paroxetine vs Clomipramine
Zohar 1996a 198 -3.40(7.90) 94 -2.40(7.30) -0.13 [-0.38, 0.12]
Subtotal (95% CI) 198 94 -0.13 [-0.38, 0.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 349 243 0.01 [-0.16, 0.17]
Test for heterogeneity: Chi² = 2.21, df = 3 (P = 0.53), I² = 0%
Test for overall effect: Z = 0.06 (P = 0.95)
-4 -2 0 2 4
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 12 Clinical Anxiety Scale
Study or sub-category | N | SSRI Mean (SD) | N | Clomipramine Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluvoxamine vs Clomipramine
Mundo 2001 112 7.00(4.60) 105 6.70(4.30) 0.07 [-0.20, 0.33]
Subtotal (95% CI) 112 105 0.07 [-0.20, 0.33]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
-1 -0.5 0 0.5 1
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 13 Covi Anxiety Scale
Study or sub-category | N | SSRI Mean (SD) | N | Clomipramine Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 30 -2.40(3.10) 24 -2.40(3.09) 0.00 [-0.54, 0.54]
Subtotal (95% CI) 30 24 0.00 [-0.54, 0.54]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
-1 -0.5 0 0.5 1
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 14 Anxiety (Clinical Anxiety Scale; Covi Anxiety Scale)
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 30 -2.40(3.10) 24 -2.40(3.09) 0.00 [-0.54, 0.54]
Subtotal (95% CI) 30 24 0.00 [-0.54, 0.54]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
02 Fluvoxamine vs Clomipramine
Mundo 2001 112 7.00(4.60) 105 6.70(4.30) 0.07 [-0.20, 0.33]
Subtotal (95% CI) 112 105 0.07 [-0.20, 0.33]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Total (95% CI) 142 129 0.05 [-0.18, 0.29]
Test for heterogeneity: Chi² = 0.05, df = 1 (P = 0.83), I² = 0%
Test for overall effect: Z = 0.44 (P = 0.66)
-1
-0.5
0
0.5
1
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 15 Clinical Global Impressions: global improvement
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 30 -2.60(1.13) 24 -2.60(1.19) 0.00 [-0.54, 0.54]
Subtotal (95% CI) 30 24 0.00 [-0.54, 0.54]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
02 Fluvoxamine vs Clomipramine
Mundo 2001 112 2.30(1.00) 105 2.30(1.00) 0.00 [-0.27, 0.27]
Subtotal (95% CI) 112 105 0.00 [-0.27, 0.27]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
Total (95% CI) 142 129 0.00 [-0.24, 0.24]
Test for heterogeneity: Chi² = 0.00, df = 1 (P = 1.00), I² = 0%
Test for overall effect: Z = 0.00 (P = 1.00)
-1
-0.5
0
0.5
1
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 16 Clinical Global Impressions: severity of illness
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 30 -0.90(1.23) 24 -1.90(1.14) 0.83 [0.27, 1.39]
Subtotal (95% CI) 30 24 0.83 [0.27, 1.39]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.89 (P = 0.004)
02 Fluvoxamine vs Clomipramine
Mundo 2001 112 3.40(1.30) 105 3.20(1.20) 0.16 [-0.11, 0.43]
Subtotal (95% CI) 112 105 0.16 [-0.11, 0.43]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
03 Paroxetine vs Clomipramine
Zohar 1996a 194 -1.20(1.40) 94 -1.10(1.20) -0.07 [-0.32, 0.17]
Subtotal (95% CI) 194 94 -0.07 [-0.32, 0.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
Total (95% CI) 336 223 0.11 [-0.06, 0.28]
Test for heterogeneity: Chi² = 8.57, df = 2 (P = 0.01), I² = 76.7%
Test for overall effect: Z = 1.23 (P = 0.22)
-4
-2
0
2
4
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 17 Symptom Checklist-90
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Paroxetine vs Clomipramine
Zohar 1996a 169 -29.00(47.10) 74 -31.90(39.90) 0.06 [-0.21, 0.34]
Subtotal (95% CI) 169 74 0.06 [-0.21, 0.34]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
-1 -0.5 0 0.5 1
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 18 Subanalysis: Non-responders in patients with comorbid depression
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 22/30 11/25 1.67 [1.02, 2.73]
Subtotal (95% CI) 30 25 1.67 [1.02, 2.73]
Total events: 22 (SSRI), 11 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.04)
02 Fluvoxamine vs Clomipramine
Mundo 2001 46/115 44/112 1.02 [0.74, 1.40]
Subtotal (95% CI) 115 112 1.02 [0.74, 1.40]
Total events: 46 (SSRI), 44 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Total (95% CI) 145 137 1.16 [0.88, 1.51]
Total events: 68 (SSRI), 55 (Clomipramine)
Test for heterogeneity: Chi² = 2.72, df = 1 (P = 0.10), I² = 63.3%
Test for overall effect: Z = 1.06 (P = 0.29)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 19 Subanalysis: Y-BOCS in patients with comorbid depression
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 30 -7.50(9.29) 24 -8.90(7.13) 0.16 [-0.37, 0.70]
Subtotal (95% CI) 30 24 0.16 [-0.37, 0.70]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
02 Fluvoxamine vs Clomipramine
Mundo 2001 67 14.70(10.10) 61 12.50(8.00) 0.24 [-0.11, 0.59]
Smeraldi 1992 5 18.20(2.50) 5 15.20(12.40) 0.30 [-0.95, 1.55]
Subtotal (95% CI) 72 66 0.24 [-0.09, 0.58]
Test for heterogeneity: Chi² = 0.01, df = 1 (P = 0.92), I² = 0%
Test for overall effect: Z = 1.42 (P = 0.16)
Total (95% CI) 102 90 0.22 [-0.06, 0.51]
Test for heterogeneity: Chi² = 0.07, df = 2 (P = 0.97), I² = 0%
Test for overall effect: Z = 1.52 (P = 0.13)
-1 -0.5 0 0.5 1
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 04 SSRIs vs Clomipramine (acute phase)
Outcome: 20 Subanalysis: Hamilton Rating Scale for Depression in patients with comorbid depression
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Clomipramine
Lopez-Ibor 1996 30 -7.50(5.93) 24 -9.40(7.71) 0.28 [-0.26, 0.82]
Subtotal (95% CI) 30 24 0.28 [-0.26, 0.82]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
02 Fluvoxamine vs Clomipramine
Mundo 2001 112 7.70(6.00) 105 7.00(4.50) 0.13 [-0.14, 0.40]
Subtotal (95% CI) 112 105 0.13 [-0.14, 0.40]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 142 129 0.16 [-0.08, 0.40]
Test for heterogeneity: Chi² = 0.22, df = 1 (P = 0.64), I² = 0%
Test for overall effect: Z = 1.31 (P = 0.19)
-1
-0.5
0
0.5
1
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase)
Outcome: 01 Y-BOCS
Study or sub-category
N
SSRI Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Phenelzine
Jenike 1997 19 16.20(6.30) 17 16.30(7.00) -0.01 [-0.67, 0.64]
Subtotal (95% CI) 19 17 -0.01 [-0.67, 0.64]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.96)
02 Fluvoxamine vs Desipramine
Goodman 1990a 21 19.50(9.00) 19 25.80(6.00) -0.80 [-1.45, -0.15]
Subtotal (95% CI) 21 19 -0.80 [-1.45, -0.15]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.02)
03 Clomipramine vs Buspirone
Pato 1991 9 17.67(4.97) 9 16.78(6.46) 0.15 [-0.78, 1.07]
Subtotal (95% CI) 9 9 0.15 [-0.78, 1.07]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
04 Sertraline vs Desipramine
Hoehn-Saric 2000 79 -8.40(8.00) 85 -6.00(8.30) -0.29 [-0.60, 0.02]
Subtotal (95% CI) 79 85 -0.29 [-0.60, 0.02]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.06)
Total (95% CI) 128 130 -0.30 [-0.54, -0.05]
Test for heterogeneity: Chi² = 3.91, df = 3 (P = 0.27), I² = 23.3%
Test for overall effect: Z = 2.35 (P = 0.02)
-4
-2
0
2
4
Favours SSRI
Favours other drug


Review: OCD adults: SSRIs
Comparison: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase)
Outcome: 02 NIMH-OC
Study or sub-category
N
SSRI Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine vs Phenelzine
Jenike 1997 19 7.00(1.10) 17 6.80(1.40) 0.16 [-0.50, 0.81]
Subtotal (95% CI) 19 17 0.16 [-0.50, 0.81]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
02 Sertraline vs Desipramine
Hoehn-Saric 2000 79 -2.70(2.67) 85 -1.70(2.77) -0.37 [-0.67, -0.06]
Subtotal (95% CI) 79 85 -0.37 [-0.67, -0.06]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.02)
03 Clomipramine vs Buspirone
Pato 1991 9 21.22(5.49) 9 19.22(5.97) 0.33 [-0.60, 1.26]
Subtotal (95% CI) 9 9 0.33 [-0.60, 1.26]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 107 111 -0.22 [-0.49, 0.05]
Test for heterogeneity: Chi² = 3.47, df = 2 (P = 0.18), I² = 42.3%
Test for overall effect: Z = 1.62 (P = 0.11)
-1
-0.5
0
0.5
1
Favours SSRI
Favours other drug


Review: OCD adults: SSRIs
Comparison: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase)
Outcome: 03 Adverse events
Study or sub-category
SSRI n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Sertraline vs Desipramine
Hoehn-Saric 2000 79/80 84/86 1.01 [0.97, 1.05]
Subtotal (95% CI) 80 86 1.01 [0.97, 1.05]
Total events: 79 (SSRI), 84 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Total (95% CI) 80 86 1.01 [0.97, 1.05]
Total events: 79 (SSRI), 84 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
0.5 0.7 1 1.5 2
Favours SSRI Favours other drug


Review: OCD adults: SSRIs
Comparison: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase)
Outcome: 04 Leaving study early due to adverse events
Study or sub-category
SSRI n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Sertraline vs Desipramine
Hoehn-Saric 2000 8/80 22/86 0.39 [0.18, 0.83]
Subtotal (95% CI) 80 86 0.39 [0.18, 0.83]
Total events: 8 (SSRI), 22 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.01)
02 Clomipramine vs Imipramine
Volavka 1985 2/11 2/12 1.09 [0.18, 6.48]
Subtotal (95% CI) 11 12 1.09 [0.18, 6.48]
Total events: 2 (SSRI), 2 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
03 Fluvoxamine vs Desipramine
Goodman 1990a 0/21 2/19 0.18 [0.01, 3.56]
Subtotal (95% CI) 21 19 0.18 [0.01, 3.56]
Total events: 0 (SSRI), 2 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
04 Clomipramine vs Buspirone
Pato 1991 1/10 0/10 3.00 [0.14, 65.90]
Subtotal (95% CI) 10 10 3.00 [0.14, 65.90]
Total events: 1 (SSRI), 0 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
05 Clomipramine vs Phenelzine
Vallejo 1992 1/16 0/14 2.65 [0.12, 60.21]
Subtotal (95% CI) 16 14 2.65 [0.12, 60.21]
Total events: 1 (SSRI), 0 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 138 141 0.51 [0.28, 0.95]
Total events: 12 (SSRI), 26 (Other drug)
Test for heterogeneity: Chi² = 3.98, df = 4 (P = 0.41), I² = 0%
Test for overall effect: Z = 2.14 (P = 0.03)
0.001 0.01 0.1 1 10 100 1000
Favours SSRI Favours other drug


Review: OCD adults: SSRIs
Comparison: 05 SSRIs/Clomipramine vs Non-SRIs (acute phase)
Outcome: 05 Non-responders (OCD)
Study or sub-category
SSRI n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
02 Sertraline vs Desipramine
Hoehn-Saric 2000 42/80 40/86 1.13 [0.83, 1.54]
Subtotal (95% CI) 80 86 1.13 [0.83, 1.54]
Total events: 42 (SSRI), 40 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Total (95% CI) 80 86 1.13 [0.83, 1.54]
Total events: 42 (SSRI), 40 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
0.5 0.7 1 1.5 2
Favours SSRI Favours other drug


Review: OCD adults: SSRIs
Comparison: 06 SSRIs vs placebo (continuation phase)
Outcome: 01 Leaving study early
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Beasley 1992 3/23 2/6 0.39 [0.08, 1.84]
Montgomery 1993 16/61 2/12 1.57 [0.41, 5.97]
Romano 2001 16/36 23/35 0.68 [0.44, 1.05]
Subtotal (95% CI) 120 53 0.75 [0.50, 1.12]
Total events: 35 (SSRI), 27 (Placebo)
Test for heterogeneity: Chi² = 2.07, df = 2 (P = 0.36), I² = 3.3%
Test for overall effect: Z = 1.40 (P = 0.16)
02 Paroxetine
Hollander 2003d 19/53 37/52 0.50 [0.34, 0.75]
Subtotal (95% CI) 53 52 0.50 [0.34, 0.75]
Total events: 19 (SSRI), 37 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.36 (P = 0.0008)
Total (95% CI) 173 105 0.61 [0.46, 0.81]
Total events: 54 (SSRI), 64 (Placebo)
Test for heterogeneity: Chi² = 3.36, df = 3 (P = 0.34), I² = 10.7%
Test for overall effect: Z = 3.39 (P = 0.0007)
0.01 0.1 1 10 100
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 06 SSRIs vs placebo (continuation phase)
Outcome: 02 Leaving study early due to adverse events
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Montgomery 1993 2/61 0/12 1.05 [0.05, 20.58]
Romano 2001 2/36 1/35 1.94 [0.18, 20.49]
Subtotal (95% CI) 97 47 1.54 [0.25, 9.58]
Total events: 4 (SSRI), 1 (Placebo)
Test for heterogeneity: Chi² = 0.10, df = 1 (P = 0.75), I² = 0%
Test for overall effect: Z = 0.46 (P = 0.64)
02 Paroxetine
Hollander 2003d 3/53 20/52 0.15 [0.05, 0.47]
Subtotal (95% CI) 53 52 0.15 [0.05, 0.47]
Total events: 3 (SSRI), 20 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.26 (P = 0.001)
Total (95% CI) 150 99 0.26 [0.11, 0.63]
Total events: 7 (SSRI), 21 (Placebo)
Test for heterogeneity: Chi² = 4.58, df = 2 (P = 0.10), I² = 56.3%
Test for overall effect: Z = 3.00 (P = 0.003)
0.01 0.1 1 10 100
Favours SSRI Favours placebo

Review: OCD adults: SSRIs
Comparison: 06 SSRIs vs placebo (continuation phase)
Outcome: 03 Non-responders



Review: OCD adults: SSRIs
Comparison: 06 SSRIs vs placebo (continuation phase)
Outcome: 04 Y-BOCS



Review: OCD adults: SSRIs
Comparison: 06 SSRIs vs placebo (continuation phase)
Outcome: 05 Hamilton Rating Scale for Depression



Review: OCD adults: SSRIs
Comparison: 06 SSRIs vs placebo (continuation phase)
Outcome: 06 SF-36: social functioning



Review: OCD adults: SSRIs
Comparison: 07 SSRIs vs placebo (discontinuation phase)
Outcome: 01 Death




Review: OCD adults: SSRIs
Comparison: 07 SSRIs vs placebo (discontinuation phase)
Outcome: 02 Leaving study early
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Sertraline
Koran 2002 33/109 59/114 0.58 [0.42, 0.82]
Subtotal (95% CI) 109 114 0.58 [0.42, 0.82]
Total events: 33 (SSRI), 59 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.002)
0.2 0.5 1 2 5
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 07 SSRIs vs placebo (discontinuation phase)
Outcome: 03 Leaving study early due to adverse effects
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Sertraline
Koran 2002 5/109 12/114 0.44 [0.16, 1.20]
Subtotal (95% CI) 109 114 0.44 [0.16, 1.20]
Total events: 5 (SSRI), 12 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 07 SSRIs vs placebo (discontinuation phase)
Outcome: 04 Relapse
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Sertraline
Koran 2002 4/109 6/114 0.70 [0.20, 2.40]
Subtotal (95% CI) 109 114 0.70 [0.20, 2.40]
Total events: 4 (SSRI), 6 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
0.2 0.5 1 2 5
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 07 SSRIs vs placebo (discontinuation phase)
Outcome: 05 Y-BOCS
Study or sub-category
N
SSRI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Sertraline
Koran 2002 108 11.40(7.50) 113 14.20(7.70) -0.37 [-0.63, -0.10]
Subtotal (95% CI) 108 113 -0.37 [-0.63, -0.10]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.70 (P = 0.007)
-1 -0.5 0 0.5 1
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 07 SSRIs vs placebo (discontinuation phase)
Outcome: 06 NIMH-OC
Study or sub-category
N
SSRI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Sertraline
Koran 2002 108 4.80(2.60) 113 5.70(2.70) -0.34 [-0.60, -0.07]
Subtotal (95% CI) 108 113 -0.34 [-0.60, -0.07]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.01)
-1 -0.5 0 0.5 1
Favours SSRI Favours placebo


Review: OCD adults: SSRIs
Comparison: 07 SSRIs vs placebo (discontinuation phase)
Outcome: 07 QoL Enjoyment and Satisfaction
Study or sub-category
N
SSRI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Sertraline
Koran 2002 106 -77.30(16.10) 109 -67.50(20.30) -0.53 [-0.80, -0.26]
Subtotal (95% CI) 106 109 -0.53 [-0.80, -0.26]
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.83 (P = 0.0001)
-1 -0.5 0 0.5 1
Favours SSRI
Favours placebo


Review: OCD adults: SSRIs
Comparison: 08 SSRIs at different doses (continuation phase)
Outcome: 01 Leaving study early
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 40mg Fluoxetine v 20mg Fluoxetine
Beasley 1992 6/21 3/23 2.19 [0.63, 7.67]
Montgomery 1993 6/20 5/18 1.08 [0.40, 2.94]
Subtotal (95% CI) 41 41 1.47 [0.68, 3.19]
Total events: 12 (Dose 1), 8 (Dose 2)
Test for heterogeneity: Chi² = 0.75, df = 1 (P = 0.39), I² = 0%
Test for overall effect: Z = 0.98 (P = 0.33)
02 60mg Fluoxetine v 20mg Fluoxetine
Beasley 1992 3/26 3/23 0.88 [0.20, 3.96]
Montgomery 1993 5/23 5/18 0.78 [0.27, 2.29]
Subtotal (95% CI) 49 41 0.82 [0.34, 1.97]
Total events: 8 (Dose 1), 8 (Dose 2)
Test for heterogeneity: Chi² = 0.02, df = 1 (P = 0.90), I² = 0%
Test for overall effect: Z = 0.45 (P = 0.66)
03 60mg Fluoxetine v 40mg Fluoxetine
Beasley 1992 3/26 6/21 0.40 [0.11, 1.43]
Montgomery 1993 5/23 6/20 0.72 [0.26, 2.02]
Subtotal (95% CI) 49 41 0.56 [0.26, 1.24]
Total events: 8 (Dose 1), 12 (Dose 2)
Test for heterogeneity: Chi² = 0.50, df = 1 (P = 0.48), I² = 0%
Test for overall effect: Z = 1.43 (P = 0.15)
0.1 0.2 0.5 1 2 5 10
Favours Dose 1
Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 08 SSRIs at different doses (continuation phase)
Outcome: 02 Leaving study early due to adverse events
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 40mg Fluoxetine v 20mg Fluoxetine
Montgomery 1993 1/20 0/18 2.71 [0.12, 62.70]
Subtotal (95% CI) 20 18 2.71 [0.12, 62.70]
Total events: 1 (Dose 1), 0 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
02 60mg Fluoxetine v 20mg Fluoxetine
Montgomery 1993 1/23 0/18 2.38 [0.10, 55.06]
Subtotal (95% CI) 23 18 2.38 [0.10, 55.06]
Total events: 1 (Dose 1), 0 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
03 60mg Fluoxetine v 40mg Fluoxetine
Montgomery 1993 1/23 1/20 0.87 [0.06, 13.02]
Subtotal (95% CI) 23 20 0.87 [0.06, 13.02]
Total events: 1 (Dose 1), 1 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
0.01 0.1 1 10 100
Favours Dose 1
Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 08 SSRIs at different doses (continuation phase)
Outcome: 03 Non-responders
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine 40mg v Fluoxetine 20mg
Beasley 1992 12/21 14/23 0.94 [0.57, 1.54]
Subtotal (95% CI) 21 23 0.94 [0.57, 1.54]
Total events: 12 (Dose 1), 14 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
02 Fluoxetine 60mg v Fluoxetine 20mg
Beasley 1992 11/26 14/23 0.70 [0.40, 1.21]
Subtotal (95% CI) 26 23 0.70 [0.40, 1.21]
Total events: 11 (Dose 1), 14 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
03 Fluoxetine 60mg v Fluoxetine 40mg
Beasley 1992 11/26 12/21 0.74 [0.41, 1.32]
Subtotal (95% CI) 26 21 0.74 [0.41, 1.32]
Total events: 11 (Dose 1), 12 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
0.2 0.5 1 2 5
Favours Dose 1 Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 08 SSRIs at different doses (continuation phase)
Outcome: 04 Y-BOCS
Study or sub-category
N
Dose 1 Mean (SD)
N
Dose 2 Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine 40mg v Fluoxetine 20mg
Beasley 1992 21 9.40(6.00) 23 9.80(7.30) -0.06 [-0.65, 0.53]
Subtotal (95% CI) 21 23 -0.06 [-0.65, 0.53]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
02 Fluoxetine 60mg v Fluoxetine 20mg
Beasley 1992 26 7.00(5.40) 23 9.80(7.30) -0.43 [-1.00, 0.13]
Subtotal (95% CI) 26 23 -0.43 [-1.00, 0.13]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
03 Fluoxetine 60mg v Fluoxetine 40mg
Beasley 1992 26 7.00(5.40) 21 9.40(6.00) -0.42 [-1.00, 0.17]
Subtotal (95% CI) 26 21 -0.42 [-1.00, 0.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
-4 -2 0 2 4
Favours Dose 1 Favours Dose 2


Review: OCD adults: SSRIs
Comparison: 09 SSRIs v Clomipramine (continuation phase)
Outcome: 01 Leaving study early
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine 60mg vs Clomipramine 200mg (non-responders)
Lopez-Ibor 1996 6/14 3/8 1.14 [0.39, 3.36]
Subtotal (95% CI) 14 8 1.14 [0.39, 3.36]
Total events: 6 (SSRI), 3 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
02 Fluoxetine 20mg vs Clomipramine 100mg (responders)
Lopez-Ibor 1996 3/11 6/13 0.59 [0.19, 1.83]
Subtotal (95% CI) 11 13 0.59 [0.19, 1.83]
Total events: 3 (SSRI), 6 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 09 SSRIs vs Clomipramine (continuation phase)
Outcome: 02 Leaving study early due to adverse events
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine 60mg vs Clomipramine 200mg (non-responders)
Lopez-Ibor 1996 2/14 0/8 3.00 [0.16, 55.72]
Subtotal (95% CI) 14 8 3.00 [0.16, 55.72]
Total events: 2 (SSRI), 0 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
02 Fluoxetine 20mg vs Clomipramine 100mg (responders)
Lopez-Ibor 1996 1/11 1/13 1.18 [0.08, 16.78]
Subtotal (95% CI) 11 13 1.18 [0.08, 16.78]
Total events: 1 (SSRI), 1 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
0.01 0.1 1 10 100
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 09 SSRIs vs Clomipramine (continuation phase)
Outcome: 03 Y-BOCS
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine 60mg vs Clomipramine 200mg (non-responders)
Lopez-Ibor 1996 11 8.80(5.79) 13 13.70(11.79) -0.50 [-1.31, 0.32]
Subtotal (95% CI) 11 13 -0.50 [-1.31, 0.32]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
02 Fluoxetine 20mg vs Clomipramine 100mg (responders)
Lopez-Ibor 1996 14 24.00(7.54) 8 15.00(9.32) 1.05 [0.12, 1.99]
Subtotal (95% CI) 14 8 1.05 [0.12, 1.99]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.03)
Total (95% CI) 25 21 0.18 [-0.44, 0.79]
Test for heterogeneity: Chi² = 5.99, df = 1 (P = 0.01), I² = 83.3%
Test for overall effect: Z = 0.56 (P = 0.57)
-4 -2 0 2 4
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 10 Sertraline standard dose vs high dose (non-responders)
Outcome: 01 Leaving study early
Study or sub-category
Standard dose 200mg n/N
High dose 250-400mg n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Koran 2002a 6/36 9/30 0.56 [0.22, 1.38]
Total (95% CI) 36 30 0.56 [0.22, 1.38]
Total events: 6 (Standard dose 200mg), 9 (High dose 250-400mg)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
0.1 0.2 0.5 1 2 5 10
Favours standard Favours high


Review: OCD adults: SSRIs
Comparison: 10 Sertraline standard dose vs high dose (non-responders)
Outcome: 02 Leaving study early due to adverse events
Study or sub-category
Standard dose 200mg n/N
High dose 250-400mg n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Koran 2002a 2/36 0/30 4.19 [0.21, 84.03]
Total (95% CI) 36 30 4.19 [0.21, 84.03]
Total events: 2 (Standard dose 200mg), 0 (High dose 250-400mg)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
0.01 0.1 1 10 100
Favours standard Favours high


Review: OCD adults: SSRIs
Comparison: 10 Sertraline standard dose vs high dose (non-responders)
Outcome: 03 Non-responders
Study or sub-category
Standard dose 200mg n/N
High dose 250-400mg n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Koran 2002a 24/36 18/30 1.11 [0.77, 1.61]
Total (95% CI) 36 30 1.11 [0.77, 1.61]
Total events: 24 (Standard dose 200mg), 18 (High dose 250-400mg)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
0.1 0.2 0.5 1 2 5 10
Favours standard Favours high


Review: OCD adults: SSRIs
Comparison: 11 SSRI vs Placebo (maintenance)
Outcome: 01 Leaving the study early
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 19/51 7/12 0.64 [0.35, 1.16]
Subtotal (95% CI) 51 12 0.64 [0.35, 1.16]
Total events: 19 (SSRI), 7 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 11 SSRI vs Placebo (maintenance)
Outcome: 02 Leaving the study early due to adverse events
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 8/51 2/12 0.94 [0.23, 3.88]
Subtotal (95% CI) 51 12 0.94 [0.23, 3.88]
Total events: 8 (SSRI), 2 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 11 SSRI vs Placebo (maintenance)
Outcome: 03 Adverse events
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 42/51 8/12 1.24 [0.81, 1.88]
Subtotal (95% CI) 51 12 1.24 [0.81, 1.88]
Total events: 42 (SSRI), 8 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 11 SSRI vs Placebo (maintenance)
Outcome: 04 Severe adverse events
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 18/51 3/12 1.41 [0.49, 4.03]
Subtotal (95% CI) 51 12 1.41 [0.49, 4.03]
Total events: 18 (SSRI), 3 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 11 SSRI vs Placebo (maintenance)
Outcome: 05 Non-responders (Y-BOCS 25% reduction)
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 8/51 3/12 0.63 [0.20, 2.02]
Subtotal (95% CI) 51 12 0.63 [0.20, 2.02]
Total events: 8 (SSRI), 3 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 11 SSRI vs Placebo (maintenance)
Outcome: 06 Y-BOCS
Study or sub-category
N
SSRI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Paroxetine
Ansseau 1995 51 -14.70(7.20) 12 -11.00(6.90) -0.51 [-1.15, 0.12]
Subtotal (95% CI) 51 12 -0.51 [-1.15, 0.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
-10 -5 0 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 11 SSRI vs Placebo (maintenance)
Outcome: 07 NIMH-OCS
Study or sub-category
N
SSRI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Paroxetine
Ansseau 1995 51 -5.20(2.60) 12 -3.60(2.60) -0.61 [-1.25, 0.03]
Subtotal (95% CI) 51 12 -0.61 [-1.25, 0.03]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.06)
-10 -5 0 5 10
Favours SSRI Favours Placebo


Review: OCD adults: SSRIs
Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 01 Leaving the study early
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 19/51 8/20 0.93 [0.49, 1.77]
Subtotal (95% CI) 51 20 0.93 [0.49, 1.77]
Total events: 19 (SSRI), 8 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 02 Leaving the study early due to adverse events
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 8/51 6/20 0.52 [0.21, 1.32]
Subtotal (95% CI) 51 20 0.52 [0.21, 1.32]
Total events: 8 (SSRI), 6 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 03 Adverse events
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 42/51 15/20 1.10 [0.83, 1.46]
Subtotal (95% CI) 51 20 1.10 [0.83, 1.46]
Total events: 42 (SSRI), 15 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 04 Severe adverse events
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 18/51 2/20 3.53 [0.90, 13.84]
Subtotal (95% CI) 51 20 3.53 [0.90, 13.84]
Total events: 18 (SSRI), 2 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.07)
0.01 0.1 1 10 100
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 05 Responders (Y-BOCS 25% reduction)
Study or sub-category
SSRI n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Ansseau 1995 8/51 3/20 1.05 [0.31, 3.55]
Subtotal (95% CI) 51 20 1.05 [0.31, 3.55]
Total events: 8 (SSRI), 3 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 06 Y-BOCS
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Paroxetine
Ansseau 1995 51 -14.70(7.20) 20 -14.60(7.10) -0.01 [-0.53, 0.50]
Subtotal (95% CI) 51 20 -0.01 [-0.53, 0.50]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
-10 -5 0 5 10
Favours SSRI
Favours Clomipramine


Review: OCD adults: SSRIs
Comparison: 12 SSRI vs Clomipramine (maintenance)
Outcome: 07 NIMH-OCS
Study or sub-category
N
SSRI Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Paroxetine
Ansseau 1995 51 -5.20(2.60) 19 -4.20(2.20) -0.40 [-0.93, 0.14]
Subtotal (95% CI) 51 19 -0.40 [-0.93, 0.14]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
-10 -5 0 5 10
Favours SSRI
Favours Clomipramine

Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 01 Leaving the study early



Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 02 Leaving the study early due to adverse events



Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 03 Full relapse (Y-BOCS and CGI Severity increase)




Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 04 Partial relapse (Y-BOCS or CGI Severity increase)
Study or sub-category
Paroxetine n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine at 2 months
Ansseau 1995 2/14 7/18 0.37 [0.09, 1.50]
Subtotal (95% CI) 14 18 0.37 [0.09, 1.50]
Total events: 2 (Paroxetine), 7 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
02 Paroxetine at 6 months
Bailer 1995 9/20 16/24 0.68 [0.39, 1.18]
Subtotal (95% CI) 20 24 0.68 [0.39, 1.18]
Total events: 9 (Paroxetine), 16 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
0.01 0.1 1 10 100
Favours Paroxetine
Favours Placebo

Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 05 Adverse events
Study or sub-category
Paroxetine n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine at 2 months
Ansseau 1995 8/14 9/18 1.14 [0.60, 2.18]
Subtotal (95% CI) 14 18 1.14 [0.60, 2.18]
Total events: 8 (Paroxetine), 9 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
0.1 0.2 0.5 1 2 5 10
Favours Paroxetine
Favours Placebo

Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 06 Severe adverse events
Study or sub-category
Paroxetine n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine at 2 months
Ansseau 1995 1/14 4/18 0.32 [0.04, 2.57]
Subtotal (95% CI) 14 18 0.32 [0.04, 2.57]
Total events: 1 (Paroxetine), 4 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
0.01 0.1 1 10 100
Favours Paroxetine
Favours Placebo


Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 07 Y-BOCS
Study or sub-category
N
Paroxetine Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Paroxetine at 2 months
Ansseau 1995 12 0.80(1.60) 12 0.90(3.20) -0.04 [-0.84, 0.76]
Subtotal (95% CI) 12 12 -0.04 [-0.84, 0.76]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
02 Paroxetine at 6 months
Bailer 1995 12 -3.50(3.60) 8 0.88(3.59) -1.17 [-2.15, -0.19]
Subtotal (95% CI) 12 8 -1.17 [-2.15, -0.19]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.33 (P = 0.02)
Total (95% CI) 24 20 -0.49 [-1.11, 0.13]
Test for heterogeneity: Chi² = 3.05, df = 1 (P = 0.08), I² = 67.2%
Test for overall effect: Z = 1.54 (P = 0.12)
-10 -5 0 5 10
Favours Paroxetine
Favours Placebo


Review: OCD adults: SSRIs
Comparison: 13 SSRI vs Placebo (relapse prevention)
Outcome: 08 NIMH-OC
Study or sub-category
N
Paroxetine Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Paroxetine at 2 months
Ansseau 1995 11 0.20(0.90) 9 1.30(2.30) -0.63 [-1.54, 0.28]
Subtotal (95% CI) 11 9 -0.63 [-1.54, 0.28]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
02 Paroxetine at 6 months
Bailer 1995 12 -0.67(1.66) 8 0.38(1.67) -0.60 [-1.52, 0.31]
Subtotal (95% CI) 12 8 -0.60 [-1.52, 0.31]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Total (95% CI) 23 17 -0.62 [-1.26, 0.03]
Test for heterogeneity: Chi² = 0.00, df = 1 (P = 0.97), I² = 0%
Test for overall effect: Z = 1.87 (P = 0.06)
-10 -5 0 5 10
Favours Paroxetine
Favours Placebo

Clomipramine (OCD, adults)









Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 05 Non-responders (CGI)



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 06 Non-responders (all)



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 07 Non-remitters



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 08 Y-BOCS



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 09 OCD Scale (CPRS)



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 10 6-item OCD Scale - amelioration



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 11 OCD (OCD-CPRS; 6-item OCD Scale-amelioration)



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 12 Y-BOCS/CPRS



Removing heterogeneity from Clomipramine v Placebo (Y-BOCS/CPRS): Burnham1993 and Zohar1996a removed because they reported change scores









Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 16 Leyton Obsessional Inventory: resistance



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 17 Leyton Obsessional Inventory: interference



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 18 Self-Rating Obsessive-Compulsive Personality Inventory



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 19 Montgomery-Asberg Depression Rating Scale



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 20 Clinical Global Impressions: severity of illness



Review: OCD adults: Clomipramine
Comparison: 01 Clomipramine vs placebo: acute phase
Outcome: 21 Symptom Checklist-90




Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 01 Adverse events
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluvoxamine
Freeman 1994 24/30 30/34 0.91 [0.73, 1.13]
Koran 1996a 39/41 35/37 1.01 [0.91, 1.12]
Mundo 2001 84/112 81/115 1.06 [0.91, 1.25]
Subtotal (95% CI) 183 186 1.02 [0.92, 1.13]
Total events: 147 (Clomipramine), 146 (SSRI)
Test for heterogeneity: Chi² = 1.47, df = 2 (P = 0.48), I² = 0%
Test for overall effect: Z = 0.36 (P = 0.72)
02 Clomipramine vs Paroxetine
Burnham 1993 80/82 77/82 1.04 [0.97, 1.11]
Zohar 1996a 85/99 163/201 1.06 [0.95, 1.17]
Subtotal (95% CI) 181 283 1.05 [0.98, 1.12]
Total events: 165 (Clomipramine), 240 (SSRI)
Test for heterogeneity: Chi² = 0.13, df = 1 (P = 0.72), I² = 0%
Test for overall effect: Z = 1.45 (P = 0.15)
03 Clomipramine vs Sertraline
Askin 1999 13/18 7/18 1.86 [0.97, 3.54]
Bisserbe 1997 57/82 56/86 1.07 [0.86, 1.32]
Subtotal (95% CI) 100 104 1.16 [0.95, 1.42]
Total events: 70 (Clomipramine), 63 (SSRI)
Test for heterogeneity: Chi² = 2.62, df = 1 (P = 0.11), I² = 61.8%
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 464 573 1.06 [1.00, 1.12]
Total events: 382 (Clomipramine), 449 (SSRI)
Test for heterogeneity: Chi² = 5.93, df = 6 (P = 0.43), I² = 0%
Test for overall effect: Z = 1.80 (P = 0.07)
0.2
0.5
1
2
5
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 02 Attempted suicide
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Sertraline
Bisserbe 1997 3/82 1/86 3.15 [0.33, 29.64]
Subtotal (95% CI) 82 86 3.15 [0.33, 29.64]
Total events: 3 (Clomipramine), 1 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
0.01
0.1
1
10
100
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 03 Leaving study early
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluoxetine
Lopez-Ibor 1996 4/25 5/30 0.96 [0.29, 3.20]
Subtotal (95% CI) 25 30 0.96 [0.29, 3.20]
Total events: 4 (Clomipramine), 5 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
02 Clomipramine vs Fluvoxamine
Freeman 1994 11/32 6/34 1.95 [0.82, 4.65]
Koran 1996a 15/42 8/37 1.65 [0.79, 3.45]
Milanfranchi 1997 1/13 0/13 3.00 [0.13, 67.51]
Mundo 2001 26/112 19/115 1.41 [0.83, 2.39]
Smeraldi 1992 1/6 1/6 1.00 [0.08, 12.56]
Subtotal (95% CI) 205 205 1.57 [1.07, 2.29]
Total events: 54 (Clomipramine), 34 (SSRI)
Test for heterogeneity: Chi² = 0.71, df = 4 (P = 0.95), I² = 0%
Test for overall effect: Z = 2.34 (P = 0.02)
03 Clomipramine vs Paroxetine
Burnham 1993 28/82 28/82 1.00 [0.65, 1.53]
Zohar 1996a 34/99 49/201 1.41 [0.98, 2.03]
Subtotal (95% CI) 181 283 1.22 [0.92, 1.61]
Total events: 62 (Clomipramine), 77 (SSRI)
Test for heterogeneity: Chi² = 1.44, df = 1 (P = 0.23), I² = 30.4%
Test for overall effect: Z = 1.41 (P = 0.16)
04 Clomipramine vs Sertraline
Askin 1999 4/22 2/20 1.82 [0.37, 8.88]
Bisserbe 1997 35/82 23/86 1.60 [1.04, 2.45]
Subtotal (95% CI) 104 106 1.61 [1.06, 2.45]
Total events: 39 (Clomipramine), 25 (SSRI)
Test for heterogeneity: Chi² = 0.02, df = 1 (P = 0.88), I² = 0%
Test for overall effect: Z = 2.25 (P = 0.02)
Total (95% CI) 515 624 1.39 [1.14, 1.68]
Total events: 159 (Clomipramine), 141 (SSRI)
Test for heterogeneity: Chi² = 4.26, df = 9 (P = 0.89), I² = 0%
Test for overall effect: Z = 3.29 (P = 0.001)
0.01
0.1
1
10
100
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 04 Leaving study early due to adverse events
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluoxetine
Lopez-Ibor 1996 1/25 1/30 1.20 [0.08, 18.23]
Subtotal (95% CI) 25 30 1.20 [0.08, 18.23]
Total events: 1 (Clomipramine), 1 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
02 Clomipramine vs Fluvoxamine
Freeman 1994 4/30 5/34 0.91 [0.27, 3.07]
Koran 1996a 7/42 5/37 1.23 [0.43, 3.56]
Milanfranchi 1997 0/13 0/13 Not estimable
Mundo 2001 18/112 9/115 2.05 [0.96, 4.38]
Smeraldi 1992 0/6 1/6 0.33 [0.02, 6.86]
Subtotal (95% CI) 203 205 1.45 [0.85, 2.46]
Total events: 29 (Clomipramine), 20 (SSRI)
Test for heterogeneity: Chi² = 2.38, df = 3 (P = 0.50), I² = 0%
Test for overall effect: Z = 1.38 (P = 0.17)
03 Clomipramine vs Paroxetine
Burnham 1993 17/82 15/82 1.13 [0.61, 2.11]
Zohar 1996a 17/99 18/201 1.92 [1.03, 3.56]
Subtotal (95% CI) 181 283 1.48 [0.96, 2.29]
Total events: 34 (Clomipramine), 33 (SSRI)
Test for heterogeneity: Chi² = 1.38, df = 1 (P = 0.24), I² = 27.5%
Test for overall effect: Z = 1.77 (P = 0.08)
04 Clomipramine vs Sertraline
Bisserbe 1997 21/82 9/86 2.45 [1.19, 5.03]
Subtotal (95% CI) 82 86 2.45 [1.19, 5.03]
Total events: 21 (Clomipramine), 9 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.01)
Total (95% CI) 491 604 1.61 [1.19, 2.18]
Total events: 85 (Clomipramine), 63 (SSRI)
Test for heterogeneity: Chi² = 5.41, df = 7 (P = 0.61), I² = 0%
Test for overall effect: Z = 3.11 (P = 0.002)
0.01 0.1 1 10 100
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 05 Non-responders (25% Y-BOCS)
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluvoxamine
Koran 1996a 21/42 18/37 1.03 [0.66, 1.61]
Subtotal (95% CI) 42 37 1.03 [0.66, 1.61]
Total events: 21 (Clomipramine), 18 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
02 Clomipramine vs Paroxetine
Zohar 1996a 47/99 92/201 1.04 [0.80, 1.34]
Subtotal (95% CI) 99 201 1.04 [0.80, 1.34]
Total events: 47 (Clomipramine), 92 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 141 238 1.03 [0.83, 1.29]
Total events: 68 (Clomipramine), 110 (SSRI)
Test for heterogeneity: Chi² = 0.00, df = 1 (P = 0.97), I² = 0%
Test for overall effect: Z = 0.30 (P = 0.76)
0.1 0.2 0.5 1 2 5 10
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 06 Non-responders (35% Y-BOCS)
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluvoxamine
Mundo 2001 44/112 46/115 0.98 [0.71, 1.35]
Subtotal (95% CI) 112 115 0.98 [0.71, 1.35]
Total events: 44 (Clomipramine), 46 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
0.1 0.2 0.5 1 2 5 10
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 07 Non-responders (CGI; 25% Y-BOCS)
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluoxetine
Lopez-Ibor 1996 11/25 22/30 0.60 [0.37, 0.98]
Subtotal (95% CI) 25 30 0.60 [0.37, 0.98]
Total events: 11 (Clomipramine), 22 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.04)
02 Clomipramine vs Paroxetine
Burnham 1993 42/82 47/82 0.89 [0.67, 1.18]
Subtotal (95% CI) 82 82 0.89 [0.67, 1.18]
Total events: 42 (Clomipramine), 47 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
Total (95% CI) 107 112 0.81 [0.63, 1.03]
Total events: 53 (Clomipramine), 69 (SSRI)
Test for heterogeneity: Chi² = 1.90, df = 1 (P = 0.17), I² = 47.3%
Test for overall effect: Z = 1.73 (P = 0.08)
0.1 0.2 0.5 1 2 5 10
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 09 Non-responders (CGI-I)
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluvoxamine
Milanfranchi 1997 3/13 2/13 1.50 [0.30, 7.55]
Subtotal (95% CI) 13 13 1.50 [0.30, 7.55]
Total events: 3 (Clomipramine), 2 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
02 Clomipramine vs Sertraline
Bisserbe 1997 29/82 24/86 1.27 [0.81, 1.98]
Subtotal (95% CI) 82 86 1.27 [0.81, 1.98]
Total events: 29 (Clomipramine), 24 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 95 99 1.29 [0.83, 1.98]
Total events: 32 (Clomipramine), 26 (SSRI)
Test for heterogeneity: Chi² = 0.04, df = 1 (P = 0.84), I² = 0%
Test for overall effect: Z = 1.14 (P = 0.25)
0.1 0.2 0.5 1 2 5 10
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 10 Non-responders (all)
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Fluoxetine
Lopez-Ibor 1996 11/25 22/30 0.60 [0.37, 0.98]
Subtotal (95% CI) 25 30 0.60 [0.37, 0.98]
Total events: 11 (Clomipramine), 22 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.04)
02 Clomipramine vs Fluvoxamine
Koran 1996a 21/42 18/37 1.03 [0.66, 1.61]
Milanfranchi 1997 3/13 2/13 1.50 [0.30, 7.55]
Mundo 2001 44/112 46/115 0.98 [0.71, 1.35]
Subtotal (95% CI) 167 165 1.01 [0.78, 1.31]
Total events: 68 (Clomipramine), 66 (SSRI)
Test for heterogeneity: Chi² = 0.27, df = 2 (P = 0.88), I² = 0%
Test for overall effect: Z = 0.08 (P = 0.93)
03 Clomipramine vs Paroxetine
Burnham 1993 42/82 47/82 0.89 [0.67, 1.18]
Zohar 1996a 47/99 92/201 1.04 [0.80, 1.34]
Subtotal (95% CI) 181 283 0.97 [0.81, 1.18]
Total events: 89 (Clomipramine), 139 (SSRI)
Test for heterogeneity: Chi² = 0.59, df = 1 (P = 0.44), I² = 0%
Test for overall effect: Z = 0.27 (P = 0.79)
04 Clomipramine vs Sertraline
Bisserbe 1997 29/82 24/86 1.27 [0.81, 1.98]
Subtotal (95% CI) 82 86 1.27 [0.81, 1.98]
Total events: 29 (Clomipramine), 24 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 455 564 0.98 [0.85, 1.13]
Total events: 197 (Clomipramine), 251 (SSRI)
Test for heterogeneity: Chi² = 6.01, df = 6 (P = 0.42), I² = 0.1%
Test for overall effect: Z = 0.24 (P = 0.81)
0.1 0.2 0.5 1 2 5 10
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 11 Y-BOCS
Study or sub-category
N
Clomipramine Mean (SD)
N
SSRI Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Fluoxetine
Lopez-Ibor 1996 24 -8.90(7.13) 30 -7.50(9.29) -0.16 [-0.70, 0.37]
Subtotal (95% CI) 24 30 -0.16 [-0.70, 0.37]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
02 Clomipramine vs Fluvoxamine
Koran 1996a 39 17.00(8.55) 34 17.80(7.70) -0.10 [-0.56, 0.36]
Milanfranchi 1997 12 16.50(11.00) 13 18.40(9.20) -0.18 [-0.97, 0.60]
Mundo 2001 61 12.50(8.00) 67 14.70(10.10) -0.24 [-0.59, 0.11]
Smeraldi 1992 5 15.20(12.40) 5 18.20(2.50) -0.30 [-1.55, 0.95]
Subtotal (95% CI) 117 119 -0.19 [-0.45, 0.06]
Test for heterogeneity: Chi² = 0.26, df = 3 (P = 0.97), I² = 0%
Test for overall effect: Z = 1.46 (P = 0.14)
03 Clomipramine vs Paroxetine
Burnham 1993 78 -7.73(7.42) 79 -5.61(7.47) -0.28 [-0.60, 0.03]
Zohar 1996a 94 -8.00(8.20) 198 -8.00(8.00) 0.00 [-0.25, 0.25]
Subtotal (95% CI) 172 277 -0.11 [-0.30, 0.09]
Test for heterogeneity: Chi² = 1.94, df = 1 (P = 0.16), I² = 48.4%
Test for overall effect: Z = 1.09 (P = 0.28)
Total (95% CI) 313 426 -0.14 [-0.29, 0.01]
Test for heterogeneity: Chi² = 2.47, df = 6 (P = 0.87), I² = 0%
Test for overall effect: Z = 1.85 (P = 0.06)
-1 -0.5 0 0.5 1
Favours Clomipramine
Favours SSRI

Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 12 NIMH-OC



Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 13 Comprehensive Psychopathological Rating Scale: obsessive-compulsive



Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 14 Hamilton Rating Scale for Depression




Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 15 Montgomery-Asberg Depression Rating Scale
Study or sub-category | N | Clomipramine Mean (SD) | N | SSRI Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Clomipramine vs Fluoxetine
Lopez-Ibor 1996 24 -13.80(9.09) 30 -10.10(8.20) -0.42 [-0.97, 0.12]
Subtotal (95% CI) 24 30 -0.42 [-0.97, 0.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
02 Clomipramine vs Fluvoxamine
Smeraldi 1992 5 9.60(10.30) 5 11.80(6.80) -0.23 [-1.47, 1.02]
Subtotal (95% CI) 5 5 -0.23 [-1.47, 1.02]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
03 Clomipramine vs Paroxetine
Zohar 1996a 94 -2.40(7.30) 198 -3.40(7.90) 0.13 [-0.12, 0.38]
Subtotal (95% CI) 94 198 0.13 [-0.12, 0.38]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 123 233 0.03 [-0.19, 0.25]
Test for heterogeneity: Chi² = 3.47, df = 2 (P = 0.18), I² = 42.4%
Test for overall effect: Z = 0.24 (P = 0.81)
-4 -2 0 2 4
Favours Clomipramine Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 16 Depression (HRSD; MADRS)
Study or sub-category | N | Clomipramine Mean (SD) | N | SSRI Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Clomipramine vs Fluvoxamine
Koran 1996a 39 5.80(4.70) 34 6.10(3.30) -0.07 [-0.53, 0.39]
Mundo 2001 105 7.00(4.50) 112 7.70(6.00) -0.13 [-0.40, 0.14]
Smeraldi 1992 5 9.60(10.30) 5 11.80(6.80) -0.23 [-1.47, 1.02]
Subtotal (95% CI) 149 151 -0.12 [-0.35, 0.11]
Test for heterogeneity: Chi² = 0.08, df = 2 (P = 0.96), I² = 0%
Test for overall effect: Z = 1.04 (P = 0.30)
02 Clomipramine vs Paroxetine
Zohar 1996a 94 -2.40(7.30) 198 -3.40(7.90) 0.13 [-0.12, 0.38]
Subtotal (95% CI) 94 198 0.13 [-0.12, 0.38]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 243 349 -0.01 [-0.17, 0.16]
Test for heterogeneity: Chi² = 2.21, df = 3 (P = 0.53), I² = 0%
Test for overall effect: Z = 0.06 (P = 0.95)
-4 -2 0 2 4
Favours Clomipramine Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 17 Clinical Anxiety Scale
Study or sub-category | N | Clomipramine Mean (SD) | N | SSRI Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Clomipramine vs Fluvoxamine
Mundo 2001 105 6.70(4.30) 112 7.00(4.60) -0.07 [-0.33, 0.20]
Subtotal (95% CI) 105 112 -0.07 [-0.33, 0.20]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
-1 -0.5 0 0.5 1
Favours Clomipramine Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 18 Covi Anxiety Scale
Study or sub-category | N | Clomipramine Mean (SD) | N | SSRI Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Clomipramine vs Fluoxetine
Lopez-Ibor 1996 24 -2.40(3.09) 30 -2.40(3.10) 0.00 [-0.54, 0.54]
Subtotal (95% CI) 24 30 0.00 [-0.54, 0.54]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
-10 -5 0 5 10
Favours Clomipramine Favours SSRI

Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 19 Anxiety (Clinical Anxiety Scale; Covi Anxiety Scale)



Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 20 Clinical Global Impressions: global improvement



Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 21 Clinical Global Impressions: severity of illness




Review: OCD adults: Clomipramine
Comparison: 02 Clomipramine vs SSRIs: acute phase
Outcome: 22 Symptom Checklist-90
Study or sub-category
Clomipramine N Mean (SD)
SSRI N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Paroxetine
Zohar 1996a 74 -31.90(39.90) 169 -29.00(47.10) -0.06 [-0.34, 0.21]
Subtotal (95% CI) 74 169 -0.06 [-0.34, 0.21]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
-1 -0.5 0 0.5 1
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 01 Leaving study early
Study or sub-category
Clomipramine n/N
TCA n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Imipramine
Volavka 1985 3/11 4/12 0.82 [0.23, 2.87]
Subtotal (95% CI) 11 12 0.82 [0.23, 2.87]
Total events: 3 (Clomipramine), 4 (TCA)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
02 Clomipramine vs Amitriptyline
Ananth 1981 1/10 2/10 0.50 [0.05, 4.67]
Subtotal (95% CI) 10 10 0.50 [0.05, 4.67]
Total events: 1 (Clomipramine), 2 (TCA)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 21 22 0.71 [0.24, 2.12]
Total events: 4 (Clomipramine), 6 (TCA)
Test for heterogeneity: Chi² = 0.14, df = 1 (P = 0.70), I² = 0%
Test for overall effect: Z = 0.62 (P = 0.54)
0.01 0.1 1 10 100
Favours Clomipramine
Favours TCA


Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 02 Leaving study early due to adverse effects
Study or sub-category
Clomipramine n/N
TCA n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Imipramine
Volavka 1985 2/11 2/12 1.09 [0.18, 6.48]
Subtotal (95% CI) 11 12 1.09 [0.18, 6.48]
Total events: 2 (Clomipramine), 2 (TCA)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
0.1 0.2 0.5 1 2 5 10
Favours Clomipramine
Favours TCA


Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 03 Leyton Obsessional Inventory: symptom
Study or sub-category
Clomipramine N Mean (SD)
TCA N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Nortriptyline
Thoren 1980a 8 -4.40(9.60) 8 -3.00(3.10) -0.19 [-1.17, 0.80]
Subtotal (95% CI) 8 8 -0.19 [-1.17, 0.80]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
-4 -2 0 2 4
Favours Clomipramine
Favours TCA


Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 04 Leyton Obsessional Inventory: trait
Study or sub-category | N | Clomipramine Mean (SD) | N | TCA Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Clomipramine vs Nortriptyline
Thoren 1980a | 8 | -1.90(2.30) | 8 | -1.50(1.10) | -0.21 [-1.19, 0.77]
Subtotal (95% CI) | 8 | | 8 | | -0.21 [-1.19, 0.77]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
-4 -2 0 2 4
Favours Clomipramine Favours TCA
Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 05 Leyton Obsessional Inventory: resistance
Study or sub-category | N | Clomipramine Mean (SD) | N | TCA Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Clomipramine vs Nortriptyline
Thoren 1980a | 8 | -13.00(19.60) | 8 | -4.60(15.90) | -0.45 [-1.44, 0.55]
Subtotal (95% CI) | 8 | | 8 | | -0.45 [-1.44, 0.55]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
-4 -2 0 2 4
Favours Clomipramine Favours TCA
Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 06 Leyton Obsessional Inventory: interference
Study or sub-category | N | Clomipramine Mean (SD) | N | TCA Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Clomipramine vs Nortriptyline
Thoren 1980a | 8 | -12.30(24.00) | 8 | -19.00(15.90) | 0.31 [-0.68, 1.30]
Subtotal (95% CI) | 8 | | 8 | | 0.31 [-0.68, 1.30]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
-4 -2 0 2 4
Favours Clomipramine Favours TCA
Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 07 CPRS: obsessive-compulsive
Study or sub-category | N | Clomipramine Mean (SD) | N | TCA Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Clomipramine vs Nortriptyline
Thoren 1980a | 8 | 6.38(2.75) | 8 | 7.31(2.89) | -0.31 [-1.30, 0.68]
Subtotal (95% CI) | 8 | | 8 | | -0.31 [-1.30, 0.68]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
-4 -2 0 2 4
Favours Clomipramine Favours TCA
Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 08 Self-Rating Obsessive Compulsive Personality Inventory
Study or sub-category | N | Clomipramine Mean (SD) | N | TCA Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Clomipramine vs Imipramine
Volavka 1985 | 8 | 47.90(14.40) | 8 | 68.70(12.90) | -1.44 [-2.57, -0.30]
Subtotal (95% CI) | 8 | | 8 | | -1.44 [-2.57, -0.30]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.01)
-4 -2 0 2 4
Favours Clomipramine Favours TCA
Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 09 Self-Rating Obsessional Neurotic Scale
Study or sub-category | N | Clomipramine Mean (SD) | N | TCA Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Clomipramine vs Imipramine
Volavka 1985 | 8 | 41.90(13.90) | 8 | 63.60(20.50) | -1.17 [-2.26, -0.09]
Subtotal (95% CI) | 8 | | 8 | | -1.17 [-2.26, -0.09]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.03)
-4 -2 0 2 4
Favours Clomipramine Favours TCA


Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 10 Hamilton Rating Scale for Depression
Study or sub-category
Clomipramine N Mean (SD)
TCA N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Imipramine
Volavka 1985 8 2.01(2.20) 8 6.20(4.90) -1.04 [-2.11, 0.02]
Subtotal (95% CI) 8 8 -1.04 [-2.11, 0.02]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.05)
-4 -2 0 2 4
Favours Clomipramine
Favours TCA


Review: OCD adults: Clomipramine
Comparison: 03 Clomipramine vs TCAs
Outcome: 11 Global Evaluation of Efficacy
Study or sub-category
Clomipramine N Mean (SD)
TCA N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Imipramine
Volavka 1985 8 1.75(0.89) 8 2.88(1.13) -1.05 [-2.12, 0.02]
Subtotal (95% CI) 8 8 -1.05 [-2.12, 0.02]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.05)
-4 -2 0 2 4
Favours Clomipramine
Favours TCA


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 01 Adverse effects
Study or sub-category
Clomipramine n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Venlafaxine
Albert 2002 43/47 16/26 1.49 [1.08, 2.04]
Subtotal (95% CI) 47 26 1.49 [1.08, 2.04]
Total events: 43 (Clomipramine), 16 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.01)
0.2 0.5 1 2 5
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 02 Leaving study early
Study or sub-category
Clomipramine n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Buspirone
Pato 1991 1/10 1/10 1.00 [0.07, 13.87]
Subtotal (95% CI) 10 10 1.00 [0.07, 13.87]
Total events: 1 (Clomipramine), 1 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
02 Clomipramine vs Phenelzine
Vallejo 1992 2/16 2/14 0.88 [0.14, 5.42]
Subtotal (95% CI) 16 14 0.88 [0.14, 5.42]
Total events: 2 (Clomipramine), 2 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
03 Clomipramine vs Venlafaxine
Albert 2002 7/47 1/26 3.87 [0.50, 29.77]
Subtotal (95% CI) 47 26 3.87 [0.50, 29.77]
Total events: 7 (Clomipramine), 1 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
0.01 0.1 1 10 100
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 03 Leaving study early due to adverse effects
Study or sub-category
Clomipramine n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Buspirone
Pato 1991 1/10 0/10 3.00 [0.14, 65.90]
Subtotal (95% CI) 10 10 3.00 [0.14, 65.90]
Total events: 1 (Clomipramine), 0 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
02 Clomipramine vs Phenelzine
Vallejo 1992 1/16 0/14 2.65 [0.12, 60.21]
Subtotal (95% CI) 16 14 2.65 [0.12, 60.21]
Total events: 1 (Clomipramine), 0 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
03 Clomipramine vs Venlafaxine
Albert 2002 5/47 0/26 6.19 [0.36, 107.66]
Subtotal (95% CI) 47 26 6.19 [0.36, 107.66]
Total events: 5 (Clomipramine), 0 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
0.001 0.01 0.1 1 10 100 1000
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 04 Non-responders
Study or sub-category
Clomipramine n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine vs Venlafaxine
Albert 2002 27/47 17/26 0.88 [0.61, 1.28]
Subtotal (95% CI) 47 26 0.88 [0.61, 1.28]
Total events: 27 (Clomipramine), 17 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
0.5 0.7 1 1.5 2
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 05 Y-BOCS
Study or sub-category
N
Clomipramine Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Buspirone
Pato 1991 9 17.67(4.97) 9 16.78(6.46) 0.15 [-0.78, 1.07]
Subtotal (95% CI) 9 9 0.15 [-0.78, 1.07]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
02 Clomipramine vs Venlafaxine
Albert 2002 47 17.30(6.15) 26 18.36(7.11) -0.16 [-0.64, 0.32]
Subtotal (95% CI) 47 26 -0.16 [-0.64, 0.32]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
-4 -2 0 2 4
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 06 NIMH-OC
Study or sub-category
N
Clomipramine Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Buspirone
Pato 1991 9 5.22(1.20) 9 5.11(1.27) 0.08 [-0.84, 1.01]
Subtotal (95% CI) 9 9 0.08 [-0.84, 1.01]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
-4 -2 0 2 4
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 07 Maudsley Obsessive-Compulsive Inventory
Study or sub-category
Clomipramine N Mean (SD)
Other drug N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Phenelzine
Vallejo 1992 14 12.10(4.70) 12 10.10(6.90) 0.33 [-0.44, 1.11]
Subtotal (95% CI) 14 12 0.33 [-0.44, 1.11]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
-4 -2 0 2 4
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 08 Hamilton Rating Scale for Depression
Study or sub-category
Clomipramine N Mean (SD)
Other drug N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Buspirone
Pato 1991 9 9.33(4.58) 9 9.89(6.75) -0.09 [-1.02, 0.83]
Subtotal (95% CI) 9 9 -0.09 [-1.02, 0.83]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
02 Clomipramine vs Phenelzine
Vallejo 1992 14 11.50(6.90) 12 7.00(5.70) 0.68 [-0.11, 1.48]
Subtotal (95% CI) 14 12 0.68 [-0.11, 1.48]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.09)
-4 -2 0 2 4
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 04 Clomipramine vs other drugs
Outcome: 09 Hamilton Rating Scale for Anxiety
Study or sub-category
Clomipramine N Mean (SD)
Other drug N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clomipramine vs Phenelzine
Vallejo 1992 14 14.10(8.70) 12 7.00(6.60) 0.88 [0.07, 1.69]
Subtotal (95% CI) 14 12 0.88 [0.07, 1.69]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.03)
-4 -2 0 2 4
Favours Clomipramine
Favours other drug


Review: OCD adults: Clomipramine
Comparison: 05 Intravenous Clomipramine vs IV placebo
Outcome: 01 Leaving study early
Study or sub-category
IV Clomipramine n/N
IV Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Fallon 1998 1/29 2/25 0.43 [0.04, 4.48]
Total (95% CI) 29 25 0.43 [0.04, 4.48]
Total events: 1 (IV Clomipramine), 2 (IV Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
0.01 0.1 1 10 100
Favours Clomipramine
Favours Placebo


Review: OCD adults: Clomipramine
Comparison: 05 Intravenous Clomipramine vs IV placebo
Outcome: 02 Non-responders
Study or sub-category
IV Clomipramine n/N
IV Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Fallon 1998 23/29 25/25 0.79 [0.66, 0.96]
Total (95% CI) 29 25 0.79 [0.66, 0.96]
Total events: 23 (IV Clomipramine), 25 (IV Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.01)
0.5 0.7 1 1.5 2
Favours Clomipramine
Favours Placebo


Review: OCD adults: Clomipramine
Comparison: 05 Intravenous Clomipramine vs IV placebo
Outcome: 03 Y-BOCS
Study or sub-category
IV Clomipramine N Mean (SD)
IV Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Fallon 1998 28 25.20(7.00) 23 26.10(5.00) -0.14 [-0.70, 0.41]
Total (95% CI) 28 23 -0.14 [-0.70, 0.41]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
-1 -0.5 0 0.5 1
Favours Clomipramine Favours Placebo


Review: OCD adults: Clomipramine
Comparison: 05 Intravenous Clomipramine vs IV placebo
Outcome: 04 NIMH-OC
Study or sub-category
IV Clomipramine N Mean (SD)
IV Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Fallon 1998 28 10.40(2.00) 23 10.80(1.00) -0.24 [-0.80, 0.31]
Total (95% CI) 28 23 -0.24 [-0.80, 0.31]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
-1 -0.5 0 0.5 1
Favours Clomipramine Favours Placebo


Review: OCD adults: Clomipramine
Comparison: 05 Intravenous Clomipramine vs IV placebo
Outcome: 05 Clinical Global Impressions: severity
Study or sub-category
IV Clomipramine N Mean (SD)
IV Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Fallon 1998 28 5.30(1.00) 23 5.70(5.00) -0.11 [-0.67, 0.44]
Total (95% CI) 28 23 -0.11 [-0.67, 0.44]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
-1 -0.5 0 0.5 1
Favours Clomipramine Favours Placebo


Review: OCD adults: Clomipramine
Comparison: 05 Intravenous Clomipramine vs IV placebo
Outcome: 06 Hamilton Rating Scale for Depression
Study or sub-category
IV Clomipramine N Mean (SD)
IV Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Fallon 1998 28 12.00(6.00) 23 12.70(7.00) -0.11 [-0.66, 0.45]
Total (95% CI) 28 23 -0.11 [-0.66, 0.45]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
-1 -0.5 0 0.5 1
Favours Clomipramine Favours Placebo


Review: OCD adults: Clomipramine
Comparison: 06 Intravenous Clomipramine vs oral Clomipramine
Outcome: 01 Adverse effects
Study or sub-category
IV Clomipramine n/N
Oral Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Koran 1997 4/7 5/8 0.91 [0.40, 2.11]
Total (95% CI) 7 8 0.91 [0.40, 2.11]
Total events: 4 (IV Clomipramine), 5 (Oral Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
0.2 0.5 1 2 5
Favours IV Favours Oral


Review: OCD adults: Clomipramine
Comparison: 06 Intravenous Clomipramine vs oral Clomipramine
Outcome: 02 Leaving study early
Study or sub-category
IV Clomipramine n/N
Oral Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Koran 1997 1/7 0/8 3.38 [0.16, 71.67]
Total (95% CI) 7 8 3.38 [0.16, 71.67]
Total events: 1 (IV Clomipramine), 0 (Oral Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
0.01 0.1 1 10 100
Favours IV Favours Oral


Review: OCD adults: Clomipramine
Comparison: 06 Intravenous Clomipramine vs oral Clomipramine
Outcome: 03 Non-responders
Study or sub-category
IV Clomipramine n/N
Oral Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Koran 1997 1/7 7/8 0.16 [0.03, 1.02]
Total (95% CI) 7 8 0.16 [0.03, 1.02]
Total events: 1 (IV Clomipramine), 7 (Oral Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.05)
0.01 0.1 1 10 100
Favours IV Favours Oral


Review: OCD adults: Clomipramine
Comparison: 06 Intravenous Clomipramine vs oral Clomipramine
Outcome: 04 Y-BOCS
Study or sub-category
IV Clomipramine N Mean (SD)
Oral Clomipramine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Koran 1997 7 16.71(3.30) 8 25.00(7.86) -1.26 [-2.40, -0.12]
Total (95% CI) 7 8 -1.26 [-2.40, -0.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.03)
-4 -2 0 2 4
Favours IV Favours Oral


Review: OCD adults: Clomipramine
Comparison: 07 Clomipramine vs placebo: continuation phase
Outcome: 01 Adverse effects
Study or sub-category
Clomipramine n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Katz 1990 108/110 9/14 1.53 [1.03, 2.26]
Total (95% CI) 110 14 1.53 [1.03, 2.26]
Total events: 108 (Clomipramine), 9 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.03)
0.2 0.5 1 2 5
Favours Clomipramine Favours Placebo


Review: OCD adults: Clomipramine
Comparison: 07 Clomipramine vs placebo: continuation phase
Outcome: 02 Leaving study early due to adverse effects
Study or sub-category
Clomipramine n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Katz 1990 17/110 0/14 4.73 [0.30, 74.65]
Total (95% CI) 110 14 4.73 [0.30, 74.65]
Total events: 17 (Clomipramine), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
0.01 0.1 1 10 100
Favours Clomipramine Favours Placebo


Review: OCD adults: Clomipramine
Comparison: 07 Clomipramine vs placebo: continuation phase
Outcome: 03 NIMH-OC
Study or sub-category
Clomipramine N Mean (SD)
Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Katz 1990 101 5.10(2.70) 12 9.00(2.50) -1.44 [-2.07, -0.82]
Total (95% CI) 101 12 -1.44 [-2.07, -0.82]
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.51 (P < 0.00001)
-4 -2 0 2 4
Favours Clomipramine
Favours Placebo


Review: OCD adults: Clomipramine
Comparison: 07 Clomipramine vs placebo: continuation phase
Outcome: 04 Physician's Global Evaluation
Study or sub-category
Clomipramine N Mean (SD)
Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Katz 1990 101 1.89(0.94) 12 3.33(0.89) -1.53 [-2.16, -0.90]
Total (95% CI) 101 12 -1.53 [-2.16, -0.90]
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.74 (P < 0.00001)
-4 -2 0 2 4
Favours Clomipramine
Favours Placebo


Review: OCD adults: Clomipramine
Comparison: 08 Clomipramine vs SSRIs: continuation phase
Outcome: 01 Leaving study early
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine 200mg vs Fluoxetine 60mg (non-responders)
Lopez-Ibor 1996 3/8 6/14 0.88 [0.30, 2.58]
Subtotal (95% CI) 8 14 0.88 [0.30, 2.58]
Total events: 3 (Clomipramine), 6 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
02 Clomipramine 100mg vs Fluoxetine 20mg (responders)
Lopez-Ibor 1996 6/13 3/11 1.69 [0.55, 5.24]
Subtotal (95% CI) 13 11 1.69 [0.55, 5.24]
Total events: 6 (Clomipramine), 3 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
0.1 0.2 0.5 1 2 5 10
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 08 Clomipramine vs SSRIs: continuation phase
Outcome: 02 Leaving study early due to adverse effects
Study or sub-category
Clomipramine n/N
SSRI n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Clomipramine 200mg vs Fluoxetine 60mg (non-responders)
Lopez-Ibor 1996 0/8 2/14 0.33 [0.02, 6.19]
Subtotal (95% CI) 8 14 0.33 [0.02, 6.19]
Total events: 0 (Clomipramine), 2 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
02 Clomipramine 100mg vs Fluoxetine 20mg (responders)
Lopez-Ibor 1996 1/13 1/11 0.85 [0.06, 12.01]
Subtotal (95% CI) 13 11 0.85 [0.06, 12.01]
Total events: 1 (Clomipramine), 1 (SSRI)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
0.01 0.1 1 10 100
Favours Clomipramine
Favours SSRI


Review: OCD adults: Clomipramine
Comparison: 09 Clomipramine same dose vs half dose vs none: continuation/discontinuation
Outcome: 01 Leaving study early
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Same dose (150mg) vs half dose (75mg)
Ravizza 1996a 2/14 0/15 5.33 [0.28, 102.26]
Subtotal (95% CI) 14 15 5.33 [0.28, 102.26]
Total events: 2 (Dose 1), 0 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
02 Same dose (150mg) vs none
Ravizza 1996a 2/14 1/14 2.00 [0.20, 19.62]
Subtotal (95% CI) 14 14 2.00 [0.20, 19.62]
Total events: 2 (Dose 1), 1 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
03 Half dose (75mg) vs none
Ravizza 1996a 0/15 1/14 0.31 [0.01, 7.09]
Subtotal (95% CI) 15 14 0.31 [0.01, 7.09]
Total events: 0 (Dose 1), 1 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
0.001 0.01 0.1 1 10 100 1000
Favours Dose 1
Favours Dose 2


Review: OCD adults: Clomipramine
Comparison: 09 Clomipramine same dose vs half dose vs none: continuation/discontinuation
Outcome: 02 Relapse (CGI; 25% Y-BOCS)
Study or sub-category
Dose 1 n/N
Dose 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Same dose (150mg) vs half dose (75mg)
Ravizza 1996a 5/14 4/15 1.34 [0.45, 4.00]
Subtotal (95% CI) 14 15 1.34 [0.45, 4.00]
Total events: 5 (Dose 1), 4 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
02 Same dose (150mg) vs none
Ravizza 1996a 5/14 11/14 0.45 [0.21, 0.97]
Subtotal (95% CI) 14 14 0.45 [0.21, 0.97]
Total events: 5 (Dose 1), 11 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.04)
03 Half dose (75mg) vs none
Ravizza 1996a 4/15 11/14 0.34 [0.14, 0.82]
Subtotal (95% CI) 15 14 0.34 [0.14, 0.82]
Total events: 4 (Dose 1), 11 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.02)
04 Continuation v discontinuation
Ravizza 1996a 9/29 11/14 0.39 [0.22, 0.73]
Subtotal (95% CI) 29 14 0.39 [0.22, 0.73]
Total events: 9 (Dose 1), 11 (Dose 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.003)
0.1 0.2 0.5 1 2 5 10
Favours Dose 1
Favours Dose 2

TCAs (OCD)


Review: OCD: TCAs
Comparison: 01 TCAs vs placebo (adults)
Outcome: 01 Leyton Obsessional Inventory: symptom
Study or sub-category
N
TCA Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Nortriptyline
Thoren 1980a 8 -3.00(3.10) 8 -1.00(2.30) -0.69 [-1.71, 0.33]
Subtotal (95% CI) 8 8 -0.69 [-1.71, 0.33]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
-4 -2 0 2 4
Favours TCA
Favours placebo


Review: OCD: TCAs
Comparison: 01 TCAs vs placebo (adults)
Outcome: 02 Leyton Obsessional Inventory: trait
Study or sub-category
N
TCA Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Nortriptyline
Thoren 1980a 8 -1.50(1.10) 8 -0.50(3.00) -0.42 [-1.41, 0.58]
Subtotal (95% CI) 8 8 -0.42 [-1.41, 0.58]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
-4 -2 0 2 4
Favours TCA
Favours placebo


Review: OCD: TCAs
Comparison: 01 TCAs vs placebo (adults)
Outcome: 03 Leyton Obsessional Inventory: resistance
Study or sub-category
N
TCA Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Nortriptyline
Thoren 1980a 8 -4.60(15.90) 8 -4.30(18.60) -0.02 [-1.00, 0.96]
Subtotal (95% CI) 8 8 -0.02 [-1.00, 0.96]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
-1 -0.5 0 0.5 1
Favours TCA
Favours placebo


Review: OCD: TCAs
Comparison: 01 TCAs vs placebo (adults)
Outcome: 04 Leyton Obsessional Inventory: interference
Study or sub-category
N
TCA Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Nortriptyline
Thoren 1980a 8 -19.00(15.90) 8 -8.40(15.90) -0.63 [-1.64, 0.38]
Subtotal (95% CI) 8 8 -0.63 [-1.64, 0.38]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
-4 -2 0 2 4
Favours TCA
Favours placebo


Review: OCD: TCAs
Comparison: 01 TCAs vs placebo (adults)
Outcome: 05 OCD Scale (CPRS)
Study or sub-category
N
TCA Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Nortriptyline
Thoren 1980a 8 7.31(2.89) 8 8.75(3.18) -0.45 [-1.44, 0.55]
Subtotal (95% CI) 8 8 -0.45 [-1.44, 0.55]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
-4 -2 0 2 4
Favours TCA
Favours placebo


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 01 Adverse effects
Study or sub-category
TCA n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Desipramine vs Sertraline
Hoehn-Saric 2000 85/86 80/80 0.99 [0.97, 1.01]
Subtotal (95% CI) 86 80 0.99 [0.97, 1.01]
Total events: 85 (TCA), 80 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
0.5 0.7 1 1.5 2
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 02 Leaving study early
Study or sub-category
TCA n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Amitriptyline vs Clomipramine
Ananth 1981 2/10 1/10 2.00 [0.21, 18.69]
Subtotal (95% CI) 10 10 2.00 [0.21, 18.69]
Total events: 2 (TCA), 1 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
02 Desipramine vs Fluvoxamine
Goodman 1990a 6/19 2/21 3.32 [0.76, 14.49]
Subtotal (95% CI) 19 21 3.32 [0.76, 14.49]
Total events: 6 (TCA), 2 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
03 Desipramine vs Sertraline
Hoehn-Saric 2000 33/86 14/80 2.19 [1.27, 3.79]
Subtotal (95% CI) 86 80 2.19 [1.27, 3.79]
Total events: 33 (TCA), 14 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.005)
04 Imipramine vs Clomipramine
Volavka 1985 4/12 3/11 1.22 [0.35, 4.28]
Subtotal (95% CI) 12 11 1.22 [0.35, 4.28]
Total events: 4 (TCA), 3 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
0.01 0.1 1 10 100
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 03 Leaving study early due to adverse effects
Study or sub-category
TCA n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Desipramine vs Fluvoxamine
Goodman 1990a 2/19 0/21 5.50 [0.28, 107.78]
Subtotal (95% CI) 19 21 5.50 [0.28, 107.78]
Total events: 2 (TCA), 0 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
02 Desipramine vs Sertraline
Hoehn-Saric 2000 23/86 9/80 2.38 [1.17, 4.83]
Subtotal (95% CI) 86 80 2.38 [1.17, 4.83]
Total events: 23 (TCA), 9 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.02)
03 Imipramine vs Clomipramine
Volavka 1985 2/12 2/11 0.92 [0.15, 5.44]
Subtotal (95% CI) 12 11 0.92 [0.15, 5.44]
Total events: 2 (TCA), 2 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
0.001 0.01 0.1 1 10 100 1000
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 04 Non-responders (OCD)
Study or sub-category
TCA n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Desipramine vs Sertraline
Hoehn-Saric 2000 40/86 42/80 0.89 [0.65, 1.21]
Subtotal (95% CI) 86 80 0.89 [0.65, 1.21]
Total events: 40 (TCA), 42 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
0.5 0.7 1 1.5 2
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 05 Non-responders (MDD)
Study or sub-category
TCA n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Desipramine vs Sertraline
Hoehn-Saric 2000 43/86 29/80 1.38 [0.96, 1.98]
Subtotal (95% CI) 86 80 1.38 [0.96, 1.98]
Total events: 43 (TCA), 29 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.08)
0.5 0.7 1 1.5 2
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 06 Non-remitters (HRSD>17)
Study or sub-category
TCA n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Desipramine vs Sertraline
Hoehn-Saric 2000 56/86 41/80 1.27 [0.98, 1.65]
Subtotal (95% CI) 86 80 1.27 [0.98, 1.65]
Total events: 56 (TCA), 41 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.08)
0.5 0.7 1 1.5 2
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 07 Y-BOCS
Study or sub-category | N | TCA Mean (SD) | N | Other drug Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Desipramine vs Fluvoxamine
Goodman 1990a 19 25.80(6.00) 21 19.50(9.00) 0.80 [0.15, 1.45]
Subtotal (95% CI) 19 21 0.80 [0.15, 1.45]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.02)
02 Desipramine vs Sertraline
Hoehn-Saric 2000 85 -6.00(8.30) 79 -8.40(8.00) 0.29 [-0.02, 0.60]
Subtotal (95% CI) 85 79 0.29 [-0.02, 0.60]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.06)
Total (95% CI) 104 100 0.39 [0.11, 0.66]
Test for heterogeneity: Chi² = 1.92, df = 1 (P = 0.17), I² = 47.8%
Test for overall effect: Z = 2.72 (P = 0.006)
-4 -2 0 2 4
Favours TCA Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 08 NIMH-OC
Study or sub-category | N | TCA Mean (SD) | N | Other drug Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Desipramine vs Sertraline
Hoehn-Saric 2000 85 -1.70(2.77) 79 -2.70(2.67) 0.37 [0.06, 0.67]
Subtotal (95% CI) 85 79 0.37 [0.06, 0.67]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.02)
-1 -0.5 0 0.5 1
Favours TCA Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 09 Leyton Obsessional Inventory: symptom
Study or sub-category | N | TCA Mean (SD) | N | Other drug Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Nortriptyline vs Clomipramine
Thoren 1980a 8 -3.00(3.10) 8 -4.40(9.60) 0.19 [-0.80, 1.17]
Subtotal (95% CI) 8 8 0.19 [-0.80, 1.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
-4 -2 0 2 4
Favours TCA Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 10 Leyton Obsessional Inventory: trait
Study or sub-category | N | TCA Mean (SD) | N | Other drug Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Nortriptyline vs Clomipramine
Thoren 1980a 8 -1.50(1.10) 8 -1.90(2.30) 0.21 [-0.77, 1.19]
Subtotal (95% CI) 8 8 0.21 [-0.77, 1.19]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
-4 -2 0 2 4
Favours TCA Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 11 Leyton Obsessional Inventory: resistance
Study or sub-category | N | TCA Mean (SD) | N | Other drug Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Nortriptyline vs Clomipramine
Thoren 1980a 8 -4.60(15.90) 8 -13.00(19.60) 0.45 [-0.55, 1.44]
Subtotal (95% CI) 8 8 0.45 [-0.55, 1.44]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
-4 -2 0 2 4
Favours TCA Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 12 Leyton Obsessional Inventory: interference
Study or sub-category
N
TCA Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Nortriptyline vs Clomipramine
Thoren 1980a 8 -19.00(15.90) 8 -12.30(24.00) -0.31 [-1.30, 0.68]
Subtotal (95% CI) 8 8 -0.31 [-1.30, 0.68]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
-4 -2 0 2 4
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 13 CPRS: obsessive-compulsive
Study or sub-category
N
TCA Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Nortriptyline vs Clomipramine
Thoren 1980a 8 7.31(2.89) 8 6.38(2.75) 0.31 [-0.68, 1.30]
Subtotal (95% CI) 8 8 0.31 [-0.68, 1.30]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
-4 -2 0 2 4
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 14 Self-Rating Obsessive Compulsive Personality Inventory
Study or sub-category
N
TCA Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Imipramine vs Clomipramine
Volavka 1985 8 68.70(12.90) 8 47.90(14.40) 1.44 [0.30, 2.57]
Subtotal (95% CI) 8 8 1.44 [0.30, 2.57]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.01)
-4 -2 0 2 4
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 15 Self-Rating Obsessional Neurotic Scale
Study or sub-category
N
TCA Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Imipramine vs Clomipramine
Volavka 1985 8 63.60(20.50) 8 41.90(13.90) 1.17 [0.09, 2.26]
Subtotal (95% CI) 8 8 1.17 [0.09, 2.26]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.03)
-4 -2 0 2 4
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 16 Hamilton Rating Scale for Depression
Study or sub-category
N
TCA Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Desipramine vs Fluvoxamine
Goodman 1990a 19 22.30(13.00) 21 17.70(15.00) 0.32 [-0.30, 0.94]
Subtotal (95% CI) 19 21 0.32 [-0.30, 0.94]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
02 Desipramine vs Sertraline
Hoehn-Saric 2000 85 -11.50(10.14) 79 -14.80(9.78) 0.33 [0.02, 0.64]
Subtotal (95% CI) 85 79 0.33 [0.02, 0.64]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.04)
03 Imipramine vs Clomipramine
Volavka 1985 8 6.20(4.90) 8 2.01(2.20) 1.04 [-0.02, 2.11]
Subtotal (95% CI) 8 8 1.04 [-0.02, 2.11]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.05)
-4 -2 0 2 4
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 02 TCAs vs other drugs (adults)
Outcome: 17 Global Evaluation of Efficacy
Study or sub-category
N
TCA Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Imipramine vs Clomipramine
Volavka 1985 8 2.88(1.13) 8 1.75(0.89) 1.05 [-0.02, 2.12]
Subtotal (95% CI) 8 8 1.05 [-0.02, 2.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.05)
-4 -2 0 2 4
Favours TCA
Favours other drug


Review: OCD: TCAs
Comparison: 03 Desipramine substitution vs Clomipramine continuation (child/adolescent)
Outcome: 01 Leaving the study early (only during the 2-month substitution period)
Study or sub-category
Desipramine n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Leonard 1991a 1/10 0/11 3.27 [0.15, 72.23]
Total (95% CI) 10 11 3.27 [0.15, 72.23]
Total events: 1 (Desipramine), 0 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
0.01 0.1 1 10 100
Favours Desipramine
Favours Clomipramine


Review: OCD: TCAs
Comparison: 03 Desipramine substitution vs Clomipramine continuation (child/adolescent)
Outcome: 02 Relapse (Physician's Relapse Scale)
Study or sub-category
Desipramine n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Leonard 1991a 8/9 2/11 4.89 [1.37, 17.49]
Total (95% CI) 9 11 4.89 [1.37, 17.49]
Total events: 8 (Desipramine), 2 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.01)
0.01 0.1 1 10 100
Favours Desipramine
Favours Clomipramine


Review: OCD: TCAs
Comparison: 03 Desipramine substitution vs Clomipramine continuation (child/adolescent)
Outcome: 03 Comprehensive Psychopathological Rating Scale: obsessive-compulsive
Study or sub-category
N
Desipramine Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Leonard 1991a 9 6.30(3.30) 11 5.20(4.00) 0.28 [-0.60, 1.17]
Total (95% CI) 9 11 0.28 [-0.60, 1.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
-4 -2 0 2 4
Favours Desipramine
Favours Clomipramine


Review: OCD: TCAs
Comparison: 03 Desipramine substitution vs Clomipramine continuation (child/adolescent)
Outcome: 04 NIMH-OC
Study or sub-category
N
Desipramine Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Leonard 1991a 9 5.80(0.40) 11 5.00(2.30) 0.44 [-0.45, 1.34]
Total (95% CI) 9 11 0.44 [-0.45, 1.34]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
-4 -2 0 2 4
Favours Desipramine
Favours Clomipramine

SNRIs (OCD)


Review: OCD: SNRIs
Comparison: 01 SNRIs vs other drugs
Outcome: 01 Adverse effects
Study or sub-category
SNRI n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Venlafaxine vs Clomipramine
Albert 2002 16/26 43/47 0.67 [0.49, 0.92]
Subtotal (95% CI) 26 47 0.67 [0.49, 0.92]
Total events: 16 (SNRI), 43 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.01)
0.2 0.5 1 2 5
Favours SNRI
Favours other drug


Review: OCD: SNRIs
Comparison: 01 SNRIs vs other drugs
Outcome: 02 Leaving study early
Study or sub-category
SNRI n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Venlafaxine vs Clomipramine
Albert 2002 1/26 7/47 0.26 [0.03, 1.99]
Subtotal (95% CI) 26 47 0.26 [0.03, 1.99]
Total events: 1 (SNRI), 7 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
0.01 0.1 1 10 100
Favours SNRI
Favours other drug


Review: OCD: SNRIs
Comparison: 01 SNRIs vs other drugs
Outcome: 03 Leaving study early due to adverse effects
Study or sub-category
SNRI n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Venlafaxine vs Paroxetine
Denys 2003a 2/75 6/75 0.33 [0.07, 1.60]
Subtotal (95% CI) 75 75 0.33 [0.07, 1.60]
Total events: 2 (SNRI), 6 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
02 Venlafaxine vs Clomipramine
Albert 2002 0/26 5/47 0.16 [0.01, 2.81]
Subtotal (95% CI) 26 47 0.16 [0.01, 2.81]
Total events: 0 (SNRI), 5 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
0.001 0.01 0.1 1 10 100 1000
Favours SNRI
Favours other drug


Review: OCD: SNRIs
Comparison: 01 SNRIs vs other drugs
Outcome: 04 Non-responders
Study or sub-category
SNRI n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Venlafaxine vs Paroxetine
Denys 2003a 47/75 42/75 1.12 [0.86, 1.46]
Subtotal (95% CI) 75 75 1.12 [0.86, 1.46]
Total events: 47 (SNRI), 42 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
02 Venlafaxine vs Clomipramine
Albert 2002 17/26 27/47 1.14 [0.78, 1.65]
Subtotal (95% CI) 26 47 1.14 [0.78, 1.65]
Total events: 17 (SNRI), 27 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
0.5 0.7 1 1.5 2
Favours SNRI Favours other drug


Review: OCD: SNRIs
Comparison: 01 SNRIs vs other drugs
Outcome: 05 Y-BOCS
Study or sub-category
N
SNRI Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Venlafaxine vs Paroxetine
Denys 2003a 73 -7.20(7.50) 72 -7.80(5.40) 0.09 [-0.23, 0.42]
Subtotal (95% CI) 73 72 0.09 [-0.23, 0.42]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
02 Venlafaxine vs Clomipramine
Albert 2002 26 18.36(7.11) 47 17.30(6.15) 0.16 [-0.32, 0.64]
Subtotal (95% CI) 26 47 0.16 [-0.32, 0.64]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
-1 -0.5 0 0.5 1
Favours SNRI Favours other drug


Review: OCD: SNRIs
Comparison: 01 SNRIs vs other drugs
Outcome: 06 Hamilton Rating Scale for Depression
Study or sub-category
N
SNRI Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Venlafaxine vs Paroxetine
Denys 2003a 73 -2.80(5.60) 72 -3.50(4.60) 0.14 [-0.19, 0.46]
Subtotal (95% CI) 73 72 0.14 [-0.19, 0.46]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
-0.5 -0.25 0 0.25 0.5
Favours SNRI Favours other drug


Review: OCD: SNRIs
Comparison: 01 SNRIs vs other drugs
Outcome: 07 Hamilton Anxiety Scale
Study or sub-category
N
SNRI Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Venlafaxine vs Paroxetine
Denys 2003a 73 -4.90(5.00) 72 -4.70(7.00) -0.03 [-0.36, 0.29]
Subtotal (95% CI) 73 72 -0.03 [-0.36, 0.29]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
-0.5 -0.25 0 0.25 0.5
Favours SNRI Favours other drug

MAOIs (OCD)


Review: OCD: MAOIs
Comparison: 01 MAOIs vs placebo
Outcome: 01 Leaving study early
Study or sub-category
MAOI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Phenelzine vs Placebo
Jenike 1997 3/20 3/21 1.05 [0.24, 4.61]
Subtotal (95% CI) 20 21 1.05 [0.24, 4.61]
Total events: 3 (MAOI), 3 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
0.2 0.5 1 2 5
Favours MAOI Favours placebo


Review: OCD: MAOIs
Comparison: 01 MAOIs vs placebo
Outcome: 02 Y-BOCS
Study or sub-category
N
MAOI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Phenelzine vs Placebo
Jenike 1997 17 16.30(7.00) 18 18.70(6.10) -0.36 [-1.03, 0.31]
Subtotal (95% CI) 17 18 -0.36 [-1.03, 0.31]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
-4 -2 0 2 4
Favours MAOI Favours placebo


Review: OCD: MAOIs
Comparison: 01 MAOIs vs placebo
Outcome: 03 NIMH-OC
Study or sub-category
N
MAOI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Phenelzine vs Placebo
Jenike 1997 17 6.80(1.40) 18 7.20(1.30) -0.29 [-0.96, 0.38]
Subtotal (95% CI) 17 18 -0.29 [-0.96, 0.38]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
-1 -0.5 0 0.5 1
Favours MAOI Favours placebo


Review: OCD: MAOIs
Comparison: 01 MAOIs vs placebo
Outcome: 04 OCD Scale (CPRS)
Study or sub-category
N
MAOI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Phenelzine vs Placebo
Jenike 1997 17 6.50(3.80) 18 5.80(3.30) 0.19 [-0.47, 0.86]
Subtotal (95% CI) 17 18 0.19 [-0.47, 0.86]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
-1 -0.5 0 0.5 1
Favours MAOI Favours placebo


Review: OCD: MAOIs
Comparison: 01 MAOIs vs placebo
Outcome: 05 Clinical Global Impression
Study or sub-category
N
MAOI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Phenelzine vs Placebo
Jenike 1997 17 3.20(1.00) 18 3.20(1.00) 0.00 [-0.66, 0.66]
Subtotal (95% CI) 17 18 0.00 [-0.66, 0.66]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
-1 -0.5 0 0.5 1
Favours MAOI Favours placebo


Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 01 Leaving study early
Study or sub-category
MAOI n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Phenelzine vs Clomipramine
Vallejo 1992 2/14 2/16 1.14 [0.18, 7.08]
Subtotal (95% CI) 14 16 1.14 [0.18, 7.08]
Total events: 2 (MAOI), 2 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
02 Phenelzine vs Fluoxetine
Jenike 1997 3/20 4/23 0.86 [0.22, 3.40]
Subtotal (95% CI) 20 23 0.86 [0.22, 3.40]
Total events: 3 (MAOI), 4 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
0.1 0.2 0.5 1 2 5 10
Favours MAOI
Favours other drug


Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 02 Leaving study early due to adverse effects
Study or sub-category
MAOI n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Phenelzine vs Clomipramine
Vallejo 1992 0/14 1/16 0.38 [0.02, 8.59]
Subtotal (95% CI) 14 16 0.38 [0.02, 8.59]
Total events: 0 (MAOI), 1 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
0.01 0.1 1 10 100
Favours MAOI
Favours other drug


Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 03 Y-BOCS
Study or sub-category
N
MAOI Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Phenelzine vs Fluoxetine
Jenike 1997 17 16.30(7.00) 19 16.20(6.30) 0.01 [-0.64, 0.67]
Subtotal (95% CI) 17 19 0.01 [-0.64, 0.67]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.96)
-1 -0.5 0 0.5 1
Favours MAOI
Favours other drug


Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 04 NIMH-OC
Study or sub-category
N
MAOI Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Phenelzine vs Fluoxetine
Jenike 1997 17 6.80(1.40) 19 7.00(1.10) -0.16 [-0.81, 0.50]
Subtotal (95% CI) 17 19 -0.16 [-0.81, 0.50]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
-1 -0.5 0 0.5 1
Favours MAOI
Favours other drug


Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 05 Maudsley Obsessive-Compulsive Inventory
Study or sub-category
N
MAOI Mean (SD)
N
Other drug Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Phenelzine vs Clomipramine
Vallejo 1992 12 10.10(6.90) 14 12.10(4.70) -0.33 [-1.11, 0.44]
Subtotal (95% CI) 12 14 -0.33 [-1.11, 0.44]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
-4 -2 0 2 4
Favours MAOI
Favours other drug

Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 06 OCD Scale (CPRS)



Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 07 Hamilton Rating Scale for Depression



Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 08 Hamilton Rating Scale for Anxiety



Review: OCD: MAOIs
Comparison: 02 MAOIs vs other drugs
Outcome: 09 Clinical Global Impression



Anxiolytics (OCD)












Review: OCD: anxiolytics
Comparison: 01 Anxiolytics vs placebo
Outcome: 06 Hamilton Rating Scale for Depression
Study or sub-category
Anxiolytic N Mean (SD)
Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clonazepam
Hollander 2003c 16 0.44(5.20) 9 1.10(8.10) -0.10 [-0.92, 0.72]
Subtotal (95% CI) 16 9 -0.10 [-0.92, 0.72]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
-10 -5 0 5 10
Favours anxiolytic Favours placebo


Review: OCD: anxiolytics
Comparison: 01 Anxiolytics vs placebo
Outcome: 07 Hamilton Anxiety Scale
Study or sub-category
Anxiolytic N Mean (SD)
Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Clonazepam
Hollander 2003c 16 -1.10(7.70) 9 0.33(9.80) -0.16 [-0.98, 0.66]
Subtotal (95% CI) 16 9 -0.16 [-0.98, 0.66]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
-10 -5 0 5 10
Favours anxiolytic Favours placebo


Review: OCD: anxiolytics
Comparison: 02 Anxiolytics vs other drugs
Outcome: 01 Leaving study early
Study or sub-category
Anxiolytic n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Buspirone vs Clomipramine
Pato 1991 1/10 1/10 1.00 [0.07, 13.87]
Subtotal (95% CI) 10 10 1.00 [0.07, 13.87]
Total events: 1 (Anxiolytic), 1 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
0.01 0.1 1 10 100
Favours anxiolytic Favours other drug


Review: OCD: anxiolytics
Comparison: 02 Anxiolytics vs other drugs
Outcome: 02 Leaving study early due to adverse effects
Study or sub-category
Anxiolytic n/N
Other drug n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Buspirone vs Clomipramine
Pato 1991 0/10 1/10 0.33 [0.02, 7.32]
Subtotal (95% CI) 10 10 0.33 [0.02, 7.32]
Total events: 0 (Anxiolytic), 1 (Other drug)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
0.01 0.1 1 10 100
Favours anxiolytic Favours other drug


Review: OCD: anxiolytics
Comparison: 02 Anxiolytics vs other drugs
Outcome: 03 Y-BOCS
Study or sub-category
Anxiolytic N Mean (SD)
Other drug N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Buspirone vs Clomipramine
Pato 1991 9 16.78(6.46) 9 17.67(4.97) -0.15 [-1.07, 0.78]
Subtotal (95% CI) 9 9 -0.15 [-1.07, 0.78]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
-10 -5 0 5 10
Favours anxiolytic Favours other drug

Review: OCD: anxiolytics
Comparison: 02 Anxiolytics vs other drugs
Outcome: 04 NIMH-OC



Review: OCD: anxiolytics
Comparison: 02 Anxiolytics vs other drugs
Outcome: 05 Hamilton Rating Scale for Depression



Other Pharmacological (OCD)











Review: OCD: other pharmacological
Comparison: 02 Oxytocin vs placebo
Outcome: 05 Hamilton Anxiety Scale



Review: OCD: other pharmacological
Comparison: 02 Oxytocin vs placebo
Outcome: 06 State Anxiety Inventory



Review: OCD: other pharmacological
Comparison: 02 Oxytocin vs placebo
Outcome: 07 General Symptom Index



Augmentation (OCD)












Review: OCD: augmentation strategies
Comparison: 02 Citalopram+Clomipramine vs Citalopram
Outcome: 02 Y-BOCS
Study or sub-category
Citalopram+CMI N Mean (SD)
Citalopram N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Pallanti 1999 9 15.90(3.80) 7 25.60(4.80) -2.15 [-3.46, -0.84]
Total (95% CI) 9 7 -2.15 [-3.46, -0.84]
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.22 (P = 0.001)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 02 Citalopram+Clomipramine vs Citalopram
Outcome: 03 Hamilton Depression Rating Scale
Study or sub-category
Citalopram+CMI N Mean (SD)
Citalopram N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Pallanti 1999 9 5.60(2.60) 7 6.40(1.80) -0.33 [-1.33, 0.67]
Total (95% CI) 9 7 -0.33 [-1.33, 0.67]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 03 Desipramine vs placebo
Outcome: 01 Y-BOCS at 6 weeks
Study or sub-category
SSRI+Desipramine N Mean (SD)
SSRI+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 SSRI+Desipramine v SSRI+Placebo
Barr 1997 10 18.52(2.94) 13 24.52(2.94) -1.97 [-3.00, -0.93]
Subtotal (95% CI) 10 13 -1.97 [-3.00, -0.93]
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.73 (P = 0.0002)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 03 Desipramine vs placebo
Outcome: 02 Y-BOCS at 10 weeks
Study or sub-category
SSRI+Desipramine N Mean (SD)
SSRI+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 SSRI+Desipramine v SSRI+Placebo
Barr 1997 10 19.30(3.78) 13 22.43(3.78) -0.80 [-1.66, 0.06]
Subtotal (95% CI) 10 13 -0.80 [-1.66, 0.06]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.07)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 04 Haloperidol vs placebo
Outcome: 01 Non-responders
Study or sub-category
FLV+Haloperidol n/N
FLV+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLV+Haloperidol v FLV+Placebo
McDougle 1994a 10/17 17/17 0.59 [0.40, 0.88]
Subtotal (95% CI) 17 17 0.59 [0.40, 0.88]
Total events: 10 (FLV+Haloperidol), 17 (FLV+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.009)
0.2 0.5 1 2 5
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 04 Haloperidol vs placebo
Outcome: 02 Y-BOCS
Study or sub-category
FLV+Haloperidol N Mean (SD)
FLV+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 FLV+Haloperidol v FLV+Placebo
McDougle 1994a 17 18.53(2.71) 17 23.18(1.10) -2.20 [-3.07, -1.32]
Subtotal (95% CI) 17 17 -2.20 [-3.07, -1.32]
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.94 (P < 0.00001)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 05 Inositol vs placebo
Outcome: 01 Y-BOCS
Study or sub-category
SRI+Inositol N Mean (SD)
SRI+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 SRI+Inositol v SRI+Placebo
Fux 1999 6 16.33(9.46) 4 18.75(8.85) -0.24 [-1.51, 1.04]
Subtotal (95% CI) 6 4 -0.24 [-1.51, 1.04]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 06 Lithium vs placebo
Outcome: 01 Non-responders
Study or sub-category
FLV+Lithium n/N
FLV+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLV+Lithium v FLV+Placebo at 2 weeks
McDougle 1991 (1) 9/11 9/9 0.82 [0.62, 1.08]
Subtotal (95% CI) 11 9 0.82 [0.62, 1.08]
Total events: 9 (FLV+Lithium), 9 (FLV+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
02 FLV+Lithium v FLV+Placebo at 4 weeks
McDougle 1991 (2) 5/5 5/5 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (FLV+Lithium), 0 (FLV+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 16 14 0.82 [0.62, 1.08]
Total events: 14 (FLV+Lithium), 14 (FLV+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
0.5 0.7 1 1.5 2
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 06 Lithium vs placebo
Outcome: 02 Y-BOCS change score
Study or sub-category
FLV+Lithium N Mean (SD)
FLV+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 FLV+Lithium v FLV+Placebo at 2 weeks
McDougle 1991 (1) 11 -4.00(5.23) 9 1.22(5.24) -0.96 [-1.90, -0.01]
Subtotal (95% CI) 11 9 -0.96 [-1.90, -0.01]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.05)
02 FLV+Lithium v FLV+Placebo at 4 weeks
McDougle 1991 (2) 5 2.60(3.58) 5 -1.40(2.07) 1.24 [-0.19, 2.66]
Subtotal (95% CI) 5 5 1.24 [-0.19, 2.66]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.09)
Total (95% CI) 16 14 -0.29 [-1.07, 0.50]
Test for heterogeneity: Chi² = 6.34, df = 1 (P = 0.01), I² = 84.2%
Test for overall effect: Z = 0.72 (P = 0.47)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 06 Lithium vs placebo
Outcome: 03 Hamilton Depression Scale change score
Study or sub-category
FLV+Lithium N Mean (SD)
FLV+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 FLV+Lithium v FLV+Placebo at 2 weeks
McDougle 1991 (1) 11 -7.00(8.81) 9 0.00(9.06) -0.75 [-1.67, 0.17]
Subtotal (95% CI) 11 9 -0.75 [-1.67, 0.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
02 FLV+Lithium v FLV+Placebo at 4 weeks
McDougle 1991 (2) 5 4.60(6.15) 5 -3.40(4.28) 1.36 [-0.09, 2.82]
Subtotal (95% CI) 5 5 1.36 [-0.09, 2.82]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.07)
Total (95% CI) 16 14 -0.15 [-0.93, 0.63]
Test for heterogeneity: Chi² = 5.79, df = 1 (P = 0.02), I² = 82.7%
Test for overall effect: Z = 0.38 (P = 0.70)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 06 Lithium vs placebo
Outcome: 04 Hamilton Anxiety Scale change score
Study or sub-category
FLV+Lithium N Mean (SD)
FLV+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 FLV+Lithium v FLV+Placebo at 2 weeks
McDougle 1991 (1) 11 -0.73(4.67) 9 -1.11(3.26) 0.09 [-0.79, 0.97]
Subtotal (95% CI) 11 9 0.09 [-0.79, 0.97]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
02 FLV+Lithium v FLV+Placebo at 4 weeks
McDougle 1991 (2) 5 1.40(3.51) 5 -3.20(3.27) 1.22 [-0.19, 2.64]
Subtotal (95% CI) 5 5 1.22 [-0.19, 2.64]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.09)
Total (95% CI) 16 14 0.41 [-0.34, 1.15]
Test for heterogeneity: Chi² = 1.78, df = 1 (P = 0.18), I² = 43.8%
Test for overall effect: Z = 1.06 (P = 0.29)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 07 Nortriptyline vs placebo
Outcome: 01 Y-BOCS
Study or sub-category
CMI+Nortriptyline N Mean (SD)
CMI+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 CMI+Nortriptyline v CMI+Placebo
Noorbala 1998 15 8.33(5.56) 15 19.17(5.56) -1.90 [-2.78, -1.02]
Subtotal (95% CI) 15 15 -1.90 [-2.78, -1.02]
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.22 (P < 0.0001)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 08 Olanzapine vs placebo
Outcome: 01 Leaving the study early
Study or sub-category
FLX+Olanzapine n/N
FLX+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLX+Olanzapine v FLX+Placebo
Shapira 2004 5/22 2/22 2.50 [0.54, 11.54]
Subtotal (95% CI) 22 22 2.50 [0.54, 11.54]
Total events: 5 (FLX+Olanzapine), 2 (FLX+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
0.01 0.1 1 10 100
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 08 Olanzapine vs placebo
Outcome: 02 Leaving the study early due to adverse effects
Study or sub-category
FLX+Olanzapine n/N
FLX+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLX+Olanzapine v FLX+Placebo
Shapira 2004 2/22 2/22 1.00 [0.15, 6.48]
Subtotal (95% CI) 22 22 1.00 [0.15, 6.48]
Total events: 2 (FLX+Olanzapine), 2 (FLX+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
0.1 0.2 0.5 1 2 5 10
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 08 Olanzapine vs placebo
Outcome: 03 Non-responders (Y-BOCS 25%)
Study or sub-category
FLX+Olanzapine n/N
FLX+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLX+Olanzapine v FLX+Placebo
Shapira 2004 13/22 13/22 1.00 [0.61, 1.64]
Subtotal (95% CI) 22 22 1.00 [0.61, 1.64]
Total events: 13 (FLX+Olanzapine), 13 (FLX+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
0.5 0.7 1 1.5 2
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 08 Olanzapine vs placebo
Outcome: 04 Y-BOCS change score
Study or sub-category
FLX+Olanzapine N Mean (SD)
FLX+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 FLX+Olanzapine v FLX+Placebo
Shapira 2004 22 -5.10(4.90) 22 -3.80(3.80) -0.29 [-0.89, 0.30]
Subtotal (95% CI) 22 22 -0.29 [-0.89, 0.30]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
-1 -0.5 0 0.5 1
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 09 Pindolol vs placebo
Outcome: 01 Leaving the study early
Study or sub-category
Paroxetine+Pindolol n/N
Paroxetine+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 PAR+Pindolol v PAR+Placebo
Dannon 2000 0/8 2/8 0.20 [0.01, 3.61]
Subtotal (95% CI) 8 8 0.20 [0.01, 3.61]
Total events: 0 (Paroxetine+Pindolol), 2 (Paroxetine+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
0.01 0.1 1 10 100
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 09 Pindolol vs placebo
Outcome: 02 Leaving the study early due to adverse effects
Study or sub-category
Paroxetine+Pindolol n/N
Paroxetine+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 PAR+Pindolol v PAR+Placebo
Dannon 2000 0/8 2/8 0.20 [0.01, 3.61]
Subtotal (95% CI) 8 8 0.20 [0.01, 3.61]
Total events: 0 (Paroxetine+Pindolol), 2 (Paroxetine+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
0.01 0.1 1 10 100
Favours augmentation
Favours non-aug

Review: OCD: augmentation strategies
Comparison: 09 Pindolol vs placebo
Outcome: 03 Y-BOCS



Review: OCD: augmentation strategies
Comparison: 09 Pindolol vs placebo
Outcome: 04 MADRS



Review: OCD: augmentation strategies
Comparison: 09 Pindolol vs placebo
Outcome: 05 Hamilton Anxiety Scale



Review: OCD: augmentation strategies
Comparison: 10 Quetiapine vs placebo
Outcome: 01 Adverse effects



Review: OCD: augmentation strategies
Comparison: 10 Quetiapine vs placebo
Outcome: 02 Leaving the study early




Review: OCD: augmentation strategies
Comparison: 10 Quetiapine vs placebo
Outcome: 03 Non-responders (Y-BOCS 30%)
Study or sub-category
SRI+Quetiapine n/N
SRI+placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 SRI+Quetiapine v SRI+Placebo
Atmaca 2002 4/14 13/13 0.29 [0.12, 0.65]
Subtotal (95% CI) 14 13 0.29 [0.12, 0.65]
Total events: 4 (SRI+Quetiapine), 13 (SRI+placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.96 (P = 0.003)
0.1 0.2 0.5 1 2 5 10
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 10 Quetiapine vs placebo
Outcome: 04 Y-BOCS
Study or sub-category
SRI+Quetiapine N Mean (SD)
SRI+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 SRI+Quetiapine v SRI+Placebo
Atmaca 2002 14 13.40(3.20) 13 21.40(4.30) -2.06 [-3.02, -1.10]
Subtotal (95% CI) 14 13 -2.06 [-3.02, -1.10]
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.20 (P < 0.0001)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 10 Quetiapine vs placebo
Outcome: 05 CGI: severity of illness
Study or sub-category
SRI+Quetiapine N Mean (SD)
SRI+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 SRI+Quetiapine v SRI+Placebo
Atmaca 2002 14 2.42(0.80) 13 3.76(1.40) -1.15 [-1.98, -0.33]
Subtotal (95% CI) 14 13 -1.15 [-1.98, -0.33]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.74 (P = 0.006)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 01 Adverse effects
Study or sub-category
SRI+Risperidone n/N
SRI+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 SRI+Risperidone v SRI+Placebo
Hollander 2003e 4/10 2/6 1.20 [0.31, 4.69]
McDougle 2000a 18/20 15/16 0.96 [0.79, 1.16]
Subtotal (95% CI) 30 22 0.99 [0.77, 1.28]
Total events: 22 (SRI+Risperidone), 17 (SRI+Placebo)
Test for heterogeneity: Chi² = 0.18, df = 1 (P = 0.67), I² = 0%
Test for overall effect: Z = 0.07 (P = 0.95)
0.2 0.5 1 2 5
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 02 Leaving the study early
Study or sub-category
SRI+Risperidone n/N
SRI+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 SRI+Risperidone v SRI+Placebo
Hollander 2003e 1/10 2/6 0.30 [0.03, 2.65]
McDougle 2000a 2/20 1/16 1.60 [0.16, 16.10]
Subtotal (95% CI) 30 22 0.70 [0.16, 3.01]
Total events: 3 (SRI+Risperidone), 3 (SRI+Placebo)
Test for heterogeneity: Chi² = 1.07, df = 1 (P = 0.30), I² = 6.9%
Test for overall effect: Z = 0.48 (P = 0.63)
0.01 0.1 1 10 100
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 03 Leaving the study early due to adverse effects
Study or sub-category
SRI+Risperidone n/N
SRI+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 SRI+Risperidone v SRI+Placebo
McDougle 2000a 1/20 0/16 2.43 [0.11, 55.89]
Subtotal (95% CI) 20 16 2.43 [0.11, 55.89]
Total events: 1 (SRI+Risperidone), 0 (SRI+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
0.01 0.1 1 10 100
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 04 Non-responders
Study or sub-category
SRI+Risperidone n/N
SRI+Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 SRI+Risperidone v SRI+Placebo: CGI much or very much improved, Y-BOCS>=35% reduction
McDougle 2000a 16/20 16/16 0.80 [0.64, 1.00]
Subtotal (95% CI) 20 16 0.80 [0.64, 1.00]
Total events: 16 (SRI+Risperidone), 16 (SRI+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.05)
02 SRI+Risperidone v SRI+Placebo: CGI much or very much improved, Y-BOCS>=25% reduction
Hollander 2003e 6/10 6/6 0.60 [0.36, 1.00]
Subtotal (95% CI) 10 6 0.60 [0.36, 1.00]
Total events: 6 (SRI+Risperidone), 6 (SRI+Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.05)
Total (95% CI) 30 22 0.74 [0.60, 0.91]
Total events: 22 (SRI+Risperidone), 22 (SRI+Placebo)
Test for heterogeneity: Chi² = 1.14, df = 1 (P = 0.29), I² = 12.3%
Test for overall effect: Z = 2.81 (P = 0.005)
0.2 0.5 1 2 5
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 05 Y-BOCS change score
Study or sub-category
SRI+Risperidone N Mean (SD)
SRI+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 SRI+Risperidone v SRI+Placebo
Hollander 2003e 10 -6.10(8.18) 6 -1.33(3.14) -0.66 [-1.71, 0.38]
McDougle 2000a 20 -8.00(7.32) 16 -6.60(0.97) -0.25 [-0.91, 0.41]
Subtotal (95% CI) 30 22 -0.37 [-0.92, 0.19]
Test for heterogeneity: Chi² = 0.43, df = 1 (P = 0.51), I² = 0%
Test for overall effect: Z = 1.28 (P = 0.20)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 06 Hamilton Depression Scale
Study or sub-category
SRI+Risperidone N Mean (SD)
SRI+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 SRI+Risperidone v SRI+Placebo
McDougle 2000a 18 7.60(4.90) 15 15.20(8.70) -1.08 [-1.82, -0.34]
Subtotal (95% CI) 18 15 -1.08 [-1.82, -0.34]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.004)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 11 Risperidone vs placebo
Outcome: 07 Hamilton Anxiety Scale
Study or sub-category
SRI+Risperidone N Mean (SD)
SRI+Placebo N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 SRI+Risperidone v SRI+Placebo
McDougle 2000a 18 9.10(4.30) 15 15.40(6.90) -1.09 [-1.83, -0.35]
Subtotal (95% CI) 18 15 -1.09 [-1.83, -0.35]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.89 (P = 0.004)
-4 -2 0 2 4
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 01 Adverse effects
Study or sub-category
Augmentation n/N
non-augmentation n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 SRI+Quetiapine v SRI+Placebo
Atmaca 2002 9/14 4/13 2.09 [0.85, 5.16]
Subtotal (95% CI) 14 13 2.09 [0.85, 5.16]
Total events: 9 (Augmentation), 4 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
02 SRI+Risperidone v SRI+Placebo
Hollander 2003e 4/10 2/6 1.20 [0.31, 4.69]
McDougle 2000a 18/20 15/16 0.96 [0.79, 1.16]
Subtotal (95% CI) 30 22 0.99 [0.77, 1.28]
Total events: 22 (Augmentation), 17 (non-augmentation)
Test for heterogeneity: Chi² = 0.18, df = 1 (P = 0.67), I² = 0%
Test for overall effect: Z = 0.07 (P = 0.95)
Total (95% CI) 44 35 1.19 [0.89, 1.58]
Total events: 31 (Augmentation), 21 (non-augmentation)
Test for heterogeneity: Chi² = 6.13, df = 2 (P = 0.05), I² = 67.3%
Test for overall effect: Z = 1.17 (P = 0.24)
0.1 0.2 0.5 1 2 5 10
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 02 Leaving the study early
Study or sub-category
Augmentation n/N
non-augmentation n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLX+Olanzapine v FLX+Placebo
Shapira 2004 5/22 2/22 2.50 [0.54, 11.54]
Subtotal (95% CI) 22 22 2.50 [0.54, 11.54]
Total events: 5 (Augmentation), 2 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
02 SRI+Quetiapine v SRI+Placebo
Atmaca 2002 0/14 0/13 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Augmentation), 0 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 SRI+Risperidone v SRI+Placebo
Hollander 2003e 1/10 2/6 0.30 [0.03, 2.65]
McDougle 2000a 2/20 1/16 1.60 [0.16, 16.10]
Subtotal (95% CI) 30 22 0.70 [0.16, 3.01]
Total events: 3 (Augmentation), 3 (non-augmentation)
Test for heterogeneity: Chi² = 1.07, df = 1 (P = 0.30), I² = 6.9%
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 66 57 1.34 [0.49, 3.67]
Total events: 8 (Augmentation), 5 (non-augmentation)
Test for heterogeneity: Chi² = 2.48, df = 2 (P = 0.29), I² = 19.3%
Test for overall effect: Z = 0.57 (P = 0.57)
0.01 0.1 1 10 100
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 03 Leaving the study early due to adverse effects
Study or sub-category
Augmentation n/N
non-augmentation n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLX+Olanzapine v FLX+Placebo
Shapira 2004 2/22 2/22 1.00 [0.15, 6.48]
Subtotal (95% CI) 22 22 1.00 [0.15, 6.48]
Total events: 2 (Augmentation), 2 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
02 SRI+Risperidone v SRI+Placebo
McDougle 2000a 1/20 0/16 2.43 [0.11, 55.89]
Subtotal (95% CI) 20 16 2.43 [0.11, 55.89]
Total events: 1 (Augmentation), 0 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Total (95% CI) 42 38 1.31 [0.27, 6.35]
Total events: 3 (Augmentation), 2 (non-augmentation)
Test for heterogeneity: Chi² = 0.23, df = 1 (P = 0.63), I² = 0%
Test for overall effect: Z = 0.33 (P = 0.74)
0.01 0.1 1 10 100
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 04 Non-responders
Study or sub-category
Augmentation n/N
non-augmentation n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 FLV+Haloperidol v FLV+Placebo
McDougle 1994a 10/17 17/17 0.59 [0.40, 0.88]
Subtotal (95% CI) 17 17 0.59 [0.40, 0.88]
Total events: 10 (Augmentation), 17 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.009)
02 FLX+Olanzapine v FLX+Placebo
Shapira 2004 13/22 13/22 1.00 [0.61, 1.64]
Subtotal (95% CI) 22 22 1.00 [0.61, 1.64]
Total events: 13 (Augmentation), 13 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
03 SRI+Quetiapine v SRI+Placebo
Atmaca 2002 4/14 13/13 0.29 [0.12, 0.65]
Subtotal (95% CI) 14 13 0.29 [0.12, 0.65]
Total events: 4 (Augmentation), 13 (non-augmentation)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.96 (P = 0.003)
04 SRI+Risperidone v SRI+Placebo
Hollander 2003e 6/10 6/6 0.60 [0.36, 1.00]
McDougle 2000a 16/20 16/16 0.80 [0.64, 1.00]
Subtotal (95% CI) 30 22 0.74 [0.60, 0.91]
Total events: 22 (Augmentation), 22 (non-augmentation)
Test for heterogeneity: Chi² = 1.14, df = 1 (P = 0.29), I² = 12.3%
Test for overall effect: Z = 2.81 (P = 0.005)
Total (95% CI) 83 74 0.66 [0.54, 0.81]
Total events: 49 (Augmentation), 65 (non-augmentation)
Test for heterogeneity: Chi² = 9.98, df = 4 (P = 0.04), I² = 59.9%
Test for overall effect: Z = 4.05 (P < 0.0001)
0.1 0.2 0.5 1 2 5 10
Favours augmentation
Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 05 Y-BOCS
Study or sub-category | N | Augmentation Mean (SD) | N | non-augmentation Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 FLV+Haloperidol v FLV+Placebo
McDougle 1994a 17 18.53(2.71) 17 23.18(1.10) -2.20 [-3.07, -1.32]
Subtotal (95% CI) 17 17 -2.20 [-3.07, -1.32]
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.94 (P < 0.00001)
02 FLX+Olanzapine v FLX+Placebo
Shapira 2004 22 -5.10(4.90) 22 -3.80(3.80) -0.29 [-0.89, 0.30]
Subtotal (95% CI) 22 22 -0.29 [-0.89, 0.30]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
03 SRI+Quetiapine v SRI+Placebo
Atmaca 2002 14 13.40(3.20) 13 21.40(4.30) -2.06 [-3.02, -1.10]
Subtotal (95% CI) 14 13 -2.06 [-3.02, -1.10]
Test for heterogeneity: not applicable
Test for overall effect: Z = 4.20 (P < 0.0001)
04 SRI+Risperidone v SRI+Placebo
Hollander 2003e 10 -6.10(8.18) 6 -1.33(3.14) -0.66 [-1.71, 0.38]
McDougle 2000a 20 -8.00(7.32) 16 -6.60(0.97) -0.25 [-0.91, 0.41]
Subtotal (95% CI) 30 22 -0.37 [-0.92, 0.19]
Test for heterogeneity: Chi² = 0.43, df = 1 (P = 0.51), I² = 0%
Test for overall effect: Z = 1.28 (P = 0.20)
Total (95% CI) 83 74 -0.84 [-1.19, -0.50]
Test for heterogeneity: Chi² = 21.94, df = 4 (P = 0.0002), I² = 81.8%
Test for overall effect: Z = 4.80 (P < 0.00001)
-4 -2 0 2 4
Favours augmentation Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 06 Hamilton Depression Scale
Study or sub-category | N | Augmentation Mean (SD) | N | non-augmentation Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 SRI+Risperidone v SRI+Placebo
McDougle 2000a 18 7.60(4.90) 15 15.20(8.70) -1.08 [-1.82, -0.34]
Subtotal (95% CI) 18 15 -1.08 [-1.82, -0.34]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.004)
-4 -2 0 2 4
Favours augmentation Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 07 Hamilton Anxiety Scale
Study or sub-category | N | Augmentation Mean (SD) | N | non-augmentation Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 SRI+Risperidone v SRI+Placebo
McDougle 2000a 18 9.10(4.30) 15 15.40(6.90) -1.09 [-1.83, -0.35]
Subtotal (95% CI) 18 15 -1.09 [-1.83, -0.35]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.89 (P = 0.004)
-4 -2 0 2 4
Favours augmentation Favours non-aug


Review: OCD: augmentation strategies
Comparison: 12 All antipsychotics v placebo
Outcome: 08 CGI: severity of illness
Study or sub-category | N | Augmentation Mean (SD) | N | non-augmentation Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 SRI+Quetiapine v SRI+Placebo
Atmaca 2002 14 2.42(0.80) 13 3.76(1.40) -1.15 [-1.98, -0.33]
Subtotal (95% CI) 14 13 -1.15 [-1.98, -0.33]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.74 (P = 0.006)
-4 -2 0 2 4
Favours augmentation Favours non-aug

SSRIs (OCD, children)

Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 01 Adverse events



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 02 Serious adverse events




Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 03 Leaving the study early
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Geller 2001 22/71 12/32 0.83 [0.47, 1.46]
Liebowitz 2002 1/21 4/22 0.26 [0.03, 2.16]
Riddle 1992 2/7 1/7 2.00 [0.23, 17.34]
Subtotal (95% CI) 99 61 0.78 [0.46, 1.32]
Total events: 25 (SSRI), 17 (Placebo)
Test for heterogeneity: Chi² = 1.80, df = 2 (P = 0.41), I² = 0%
Test for overall effect: Z = 0.93 (P = 0.35)
02 Fluvoxamine
Riddle 2001 19/57 27/63 0.78 [0.49, 1.24]
Subtotal (95% CI) 57 63 0.78 [0.49, 1.24]
Total events: 19 (SSRI), 27 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
03 Sertraline
March 1998 20/94 13/95 1.55 [0.82, 2.94]
POTS 2004 2/28 7/28 0.29 [0.06, 1.26]
Subtotal (95% CI) 122 123 1.11 [0.64, 1.93]
Total events: 22 (SSRI), 20 (Placebo)
Test for heterogeneity: Chi² = 4.30, df = 1 (P = 0.04), I² = 76.7%
Test for overall effect: Z = 0.36 (P = 0.72)
04 Paroxetine
Geller 2004 35/100 27/107 1.39 [0.91, 2.11]
Subtotal (95% CI) 100 107 1.39 [0.91, 2.11]
Total events: 35 (SSRI), 27 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Total (95% CI) 378 354 1.02 [0.80, 1.30]
Total events: 101 (SSRI), 91 (Placebo)
Test for heterogeneity: Chi² = 10.37, df = 6 (P = 0.11), I² = 42.1%
Test for overall effect: Z = 0.16 (P = 0.88)
0.1 0.2 0.5 1 2 5 10
Favours SSRI
Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 04 Leaving the study early due to adverse events
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Geller 2001 6/71 2/32 1.35 [0.29, 6.34]
Liebowitz 2002 0/21 0/22 Not estimable
Riddle 1992 1/7 0/6 2.63 [0.13, 54.64]
Subtotal (95% CI) 99 60 1.56 [0.40, 6.10]
Total events: 7 (SSRI), 2 (Placebo)
Test for heterogeneity: Chi² = 0.15, df = 1 (P = 0.70), I² = 0%
Test for overall effect: Z = 0.64 (P = 0.52)
02 Fluvoxamine
Riddle 2001 3/57 1/63 3.32 [0.35, 30.98]
Subtotal (95% CI) 57 63 3.32 [0.35, 30.98]
Total events: 3 (SSRI), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
03 Sertraline
March 1998 12/92 3/95 4.13 [1.20, 14.16]
POTS 2004 1/28 0/28 3.00 [0.13, 70.64]
Subtotal (95% CI) 120 123 3.97 [1.26, 12.48]
Total events: 13 (SSRI), 3 (Placebo)
Test for heterogeneity: Chi² = 0.03, df = 1 (P = 0.85), I² = 0%
Test for overall effect: Z = 2.36 (P = 0.02)
04 Paroxetine
Geller 2004 10/98 3/105 3.57 [1.01, 12.60]
Subtotal (95% CI) 98 105 3.57 [1.01, 12.60]
Total events: 10 (SSRI), 3 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.05)
Total (95% CI) 374 351 3.05 [1.55, 6.00]
Total events: 33 (SSRI), 9 (Placebo)
Test for heterogeneity: Chi² = 1.37, df = 5 (P = 0.93), I² = 0%
Test for overall effect: Z = 3.24 (P = 0.001)
0.01 0.1 1 10 100
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 05 Non-responders (25% CY-BOCS)
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluvoxamine
Riddle 2001 33/57 46/63 0.79 [0.61, 1.04]
Subtotal (95% CI) 57 63 0.79 [0.61, 1.04]
Total events: 33 (SSRI), 46 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.09)
02 Paroxetine
Geller 2004 39/100 65/107 0.64 [0.48, 0.86]
Subtotal (95% CI) 100 107 0.64 [0.48, 0.86]
Total events: 39 (SSRI), 65 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.01 (P = 0.003)
Total (95% CI) 157 170 0.70 [0.58, 0.86]
Total events: 72 (SSRI), 111 (Placebo)
Test for heterogeneity: Chi² = 1.15, df = 1 (P = 0.28), I² = 13.2%
Test for overall effect: Z = 3.44 (P = 0.0006)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 06 Non-responders (40% CY-BOCS)
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Geller 2001 36/71 24/32 0.68 [0.50, 0.92]
Subtotal (95% CI) 71 32 0.68 [0.50, 0.92]
Total events: 36 (SSRI), 24 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.01)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 07 Non-responders (all)
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Geller 2001 36/71 24/32 0.68 [0.50, 0.92]
Subtotal (95% CI) 71 32 0.68 [0.50, 0.92]
Total events: 36 (SSRI), 24 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.01)
02 Fluvoxamine
Riddle 2001 33/57 46/63 0.79 [0.61, 1.04]
Subtotal (95% CI) 57 63 0.79 [0.61, 1.04]
Total events: 33 (SSRI), 46 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.09)
03 Paroxetine
Geller 2004 39/100 65/107 0.64 [0.48, 0.86]
Subtotal (95% CI) 100 107 0.64 [0.48, 0.86]
Total events: 39 (SSRI), 65 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.01 (P = 0.003)
Total (95% CI) 228 202 0.70 [0.59, 0.83]
Total events: 108 (SSRI), 135 (Placebo)
Test for heterogeneity: Chi² = 1.24, df = 2 (P = 0.54), I² = 0%
Test for overall effect: Z = 4.18 (P < 0.0001)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 08 Non-responders (CGI Global Improvement)
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Paroxetine
Geller 2004 55/100 72/107 0.82 [0.66, 1.02]
Subtotal (95% CI) 100 107 0.82 [0.66, 1.02]
Total events: 55 (SSRI), 72 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.07)
0.1 0.2 0.5 1 2 5 10
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 09 Remission (CY-BOCS < 11)
Study or sub-category
Sertraline n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Sertraline
POTS 2004 22/28 27/28 0.81 [0.66, 1.00]
Subtotal (95% CI) 28 28 0.81 [0.66, 1.00]
Total events: 22 (Sertraline), 27 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.05)
0.1 0.2 0.5 1 2 5 10
Favours Sertraline Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 10 CY-BOCS
Study or sub-category
N
SSRI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine
Geller 2001 71 -9.50(9.20) 32 -5.20(7.40) -0.49 [-0.91, -0.07]
Liebowitz 2002 21 14.71(8.73) 22 18.55(11.44) -0.37 [-0.97, 0.23]
Riddle 1992 7 13.60(5.70) 6 14.80(7.00) -0.18 [-1.27, 0.92]
Subtotal (95% CI) 99 60 -0.43 [-0.76, -0.10]
Test for heterogeneity: Chi² = 0.33, df = 2 (P = 0.85), I² = 0%
Test for overall effect: Z = 2.53 (P = 0.01)
02 Fluvoxamine
Riddle 2001 57 18.20(8.60) 63 20.90(8.50) -0.31 [-0.67, 0.05]
Subtotal (95% CI) 57 63 -0.31 [-0.67, 0.05]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.09)
03 Sertraline
March 1998 92 -6.80(8.35) 95 -3.40(8.00) -0.41 [-0.70, -0.12]
POTS 2004 28 16.50(9.10) 28 21.50(5.40) -0.66 [-1.20, -0.12]
Subtotal (95% CI) 120 123 -0.47 [-0.72, -0.21]
Test for heterogeneity: Chi² = 0.61, df = 1 (P = 0.43), I² = 0%
Test for overall effect: Z = 3.60 (P = 0.0003)
04 Paroxetine
Geller 2004 94 -8.78(7.65) 102 -5.34(7.78) -0.44 [-0.73, -0.16]
Subtotal (95% CI) 94 102 -0.44 [-0.73, -0.16]
Test for heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.002)
Total (95% CI) 370 348 -0.43 [-0.58, -0.28]
Test for heterogeneity: Chi² = 1.44, df = 6 (P = 0.96), I² = 0%
Test for overall effect: Z = 5.59 (P < 0.00001)
-1 -0.5 0 0.5 1
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 11 NIMH-OC
Study or sub-category
N
SSRI Mean (SD)
N
Placebo Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Fluoxetine
Geller 2001 71 -3.10(3.00) 32 -1.30(2.20) -0.64 [-1.07, -0.22]
Liebowitz 2002 21 6.24(2.45) 22 7.18(2.75) -0.35 [-0.96, 0.25]
Subtotal (95% CI) 92 54 -0.55 [-0.89, -0.20]
Test for heterogeneity: Chi² = 0.59, df = 1 (P = 0.44), I² = 0%
Test for overall effect: Z = 3.07 (P = 0.002)
02 Fluvoxamine
Riddle 2001 57 7.50(3.20) 63 8.30(2.60) -0.27 [-0.63, 0.09]
Subtotal (95% CI) 57 63 -0.27 [-0.63, 0.09]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
03 Sertraline
March 1998 92 -2.20(2.78) 95 -1.30(2.63) -0.33 [-0.62, -0.04]
Subtotal (95% CI) 92 95 -0.33 [-0.62, -0.04]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.02)
Total (95% CI) 241 212 -0.38 [-0.57, -0.19]
Test for heterogeneity: Chi² = 1.91, df = 3 (P = 0.59), I² = 0%
Test for overall effect: Z = 3.93 (P < 0.0001)
-1 -0.5 0 0.5 1
Favours SSRI Favours Placebo

Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 12 Child Obsessive Compulsive Impact Scale (Parent Version)



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 13 Leyton Obsessional Inventory (Child Version): interference



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 14 Leyton Obsessional Inventory (Child Version): resistance



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 15 Leyton Obsessional Inventory (Child Version): symptoms



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 16 Children's Depression Rating Scale (Revised Version)



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 17 Hamilton Rating Scale for Depression




Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 18 Depression (CDRS; HRSD)
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Liebowitz 2002 21 9.14(6.56) 22 7.09(7.39) 0.29 [-0.31, 0.89]
Subtotal (95% CI) 21 22 0.29 [-0.31, 0.89]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
02 Fluvoxamine
Riddle 2001 57 27.40(8.00) 63 27.10(8.00) 0.04 [-0.32, 0.40]
Subtotal (95% CI) 57 63 0.04 [-0.32, 0.40]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 78 85 0.10 [-0.20, 0.41]
Test for heterogeneity: Chi² = 0.49, df = 1 (P = 0.48), I² = 0%
Test for overall effect: Z = 0.65 (P = 0.51)
-1 -0.5 0 0.5 1
Favours SSRI Favours placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 19 Multidimensional Anxiety Scale for Children
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Geller 2001 71 -9.00(18.60) 32 -4.50(16.50) -0.25 [-0.67, 0.17]
Subtotal (95% CI) 71 32 -0.25 [-0.67, 0.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.24)
-1 -0.5 0 0.5 1
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 20 Revised Children's Manifest Anxiety Scale
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Riddle 1992 6 45.70(13.30) 5 40.20(16.90) 0.34 [-0.86, 1.53]
Subtotal (95% CI) 6 5 0.34 [-0.86, 1.53]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
-4 -2 0 2 4
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 21 Anxiety (MASC; RCMAS)
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Geller 2001 71 -9.00(18.60) 32 -4.50(16.50) -0.25 [-0.67, 0.17]
Riddle 1992 6 45.70(13.30) 5 40.20(16.90) 0.34 [-0.86, 1.53]
Subtotal (95% CI) 77 37 -0.19 [-0.58, 0.21]
Test for heterogeneity: Chi² = 0.81, df = 1 (P = 0.37), I² = 0%
Test for overall effect: Z = 0.92 (P = 0.36)
-4 -2 0 2 4
Favours SSRI Favours placebo


Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 22 Children's Global Assessment Scale
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Riddle 1992 7 70.40(13.20) 6 62.00(8.40) 0.69 [-0.44, 1.83]
Subtotal (95% CI) 7 6 0.69 [-0.44, 1.83]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
-4 -2 0 2 4
Favours SSRI Favours Placebo

Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 23 Systolic blood pressure - supine

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Sertraline v Placebo (at 1 week)						
March 1998	92	108.50(12.50)	95	107.60(10.60)		0.08 [-0.21, 0.36]
Subtotal (95% CI)	92		95			0.08 [-0.21, 0.36]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.53 (P = 0.60)						
02 Sertraline v Placebo (at 4 weeks)						
March 1998	92	108.10(12.10)	95	107.00(11.00)		0.09 [-0.19, 0.38]
Subtotal (95% CI)	92		95			0.09 [-0.19, 0.38]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.65 (P = 0.52)						
03 Sertraline v Placebo (at 12 weeks)						
March 1998	92	107.00(11.00)	95	107.40(10.60)		-0.04 [-0.32, 0.25]
Subtotal (95% CI)	92		95			-0.04 [-0.32, 0.25]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.25 (P = 0.80)						



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 24 Systolic blood pressure - standing

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Sertraline v Placebo (at 1 week)						
March 1998	92	108.40(11.00)	95	107.40(10.90)		0.09 [-0.20, 0.38]
Subtotal (95% CI)	92		95			0.09 [-0.20, 0.38]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.62 (P = 0.53)						
02 Sertraline v Placebo (at 4 weeks)						
March 1998	92	106.20(11.40)	95	107.20(11.70)		-0.09 [-0.37, 0.20]
Subtotal (95% CI)	92		95			-0.09 [-0.37, 0.20]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.59 (P = 0.56)						
03 Sertraline v Placebo (at 12 weeks)						
March 1998	92	105.80(10.80)	95	107.10(10.90)		-0.12 [-0.41, 0.17]
Subtotal (95% CI)	92		95			-0.12 [-0.41, 0.17]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.81 (P = 0.42)						



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 25 Diastolic blood pressure - supine

Study or sub-category	N	Sertraline Mean (SD)	N	Placebo Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Sertraline v Placebo (at 1 week)						
March 1998	92	64.80(8.50)	95	64.40(10.20)		0.04 [-0.24, 0.33]
Subtotal (95% CI)	92		95			0.04 [-0.24, 0.33]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.29 (P = 0.77)						
02 Sertraline v Placebo (at 4 weeks)						
March 1998	92	63.00(8.70)	95	63.80(9.40)		-0.09 [-0.37, 0.20]
Subtotal (95% CI)	92		95			-0.09 [-0.37, 0.20]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.60 (P = 0.55)						
03 Sertraline v Placebo (at 12 weeks)						
March 1998	92	63.70(10.90)	95	64.50(8.80)		-0.08 [-0.37, 0.21]
Subtotal (95% CI)	92		95			-0.08 [-0.37, 0.21]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 0.55 (P = 0.58)						



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 26 Diastolic blood pressure - standing



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 27 Heart rate - supine



Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 28 Heart rate - standing




Review: OCD children: SSRIs
Comparison: 01 SSRI vs placebo (acute phase)
Outcome: 29 Suicidality (Columbia reclassification - "Outcome 3: definitive suicidal behaviour/ ideation")
Study or sub-category
Treatment n/N
Control n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Geller 2001 1/71 0/32 1.38 [0.06, 32.87]
Subtotal (95% CI) 71 32 1.38 [0.06, 32.87]
Total events: 1 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
02 Fluvoxamine
Riddle 2001 2/57 0/63 5.52 [0.27, 112.55]
Subtotal (95% CI) 57 63 5.52 [0.27, 112.55]
Total events: 2 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
03 Paroxetine
Geller 2004 1/99 0/107 3.24 [0.13, 78.62]
Subtotal (95% CI) 99 107 3.24 [0.13, 78.62]
Total events: 1 (Treatment), 0 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
04 Sertraline
March 1998 0/92 1/95 0.34 [0.01, 8.34]
Subtotal (95% CI) 92 95 0.34 [0.01, 8.34]
Total events: 0 (Treatment), 1 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 319 297 1.81 [0.46, 7.13]
Total events: 4 (Treatment), 1 (Control)
Test for heterogeneity: Chi² = 1.72, df = 3 (P = 0.63), I² = 0%
Test for overall effect: Z = 0.84 (P = 0.40)
0.01 0.1 1 10 100
Favours treatment Favours control


Review: OCD children: SSRIs
Comparison: 02 SSRI vs placebo (continuation phase)
Outcome: 01 Adverse events
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Liebowitz 2002 3/11 0/7 4.67 [0.28, 78.68]
Subtotal (95% CI) 11 7 4.67 [0.28, 78.68]
Total events: 3 (SSRI), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
0.01 0.1 1 10 100
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 02 SSRI vs placebo (continuation phase)
Outcome: 02 Leaving study early
Study or sub-category
SSRI n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Fluoxetine
Liebowitz 2002 1/12 0/7 1.85 [0.09, 40.05]
Subtotal (95% CI) 1/12 0/7 1.85 [0.09, 40.05]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
0.01 0.1 1 10 100
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 02 SSRI vs placebo (continuation phase)
Outcome: 03 CY-BOCS
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Liebowitz 2002 11 5.64(5.41) 7 11.43(11.12) -0.69 [-1.67, 0.30]
Subtotal (95% CI) 11 7 -0.69 [-1.67, 0.30]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
-10 -5 0 5 10
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 02 SSRI vs placebo (continuation phase)
Outcome: 04 NIMH-OC
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Liebowitz 2002 11 3.73(1.74) 7 5.43(3.10) -0.69 [-1.67, 0.29]
Subtotal (95% CI) 11 7 -0.69 [-1.67, 0.29]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
-10 -5 0 5 10
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 02 SSRI vs placebo (continuation phase)
Outcome: 05 Child Obsessive Compulsive Impact Scale (Parent version)
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Liebowitz 2002 11 23.00(20.57) 7 49.29(32.70) -0.97 [-1.98, 0.04]
Subtotal (95% CI) 11 7 -0.97 [-1.98, 0.04]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.06)
-100 -50 0 50 100
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 02 SSRI vs placebo (continuation phase)
Outcome: 06 Hamilton Rating Scale for Depression
Study or sub-category | N | SSRI Mean (SD) | N | Placebo Mean (SD) | SMD (fixed) 95% CI | SMD (fixed) 95% CI
01 Fluoxetine
Liebowitz 2002 11 4.64(6.14) 7 7.14(5.24) -0.41 [-1.37, 0.55]
Subtotal (95% CI) 11 7 -0.41 [-1.37, 0.55]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
-10 -5 0 5 10
Favours SSRI Favours Placebo


Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 01 Adverse events
Study or sub-category | Paroxetine n/N | Placebo n/N | RR (fixed) 95% CI | RR (fixed) 95% CI
Carpenter 1999 73/95 80/98 0.94 [0.81, 1.09]
Total (95% CI) 95 98 0.94 [0.81, 1.09]
Total events: 73 (Paroxetine), 80 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
0.5 0.7 1 1.5 2
Favours Paroxetine Favours Placebo

Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 02 Serious adverse events



Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 03 Leaving the study early



Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 04 Leaving the study early due to adverse events



Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 05 Non-responders (25% CY-BOCS)



Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 06 Non-responders (CGI Global Improvement < "much improved")



Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 07 Relapse (CGI Global Improvement score increase)



Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 08 CY-BOCS



Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 09 Hamilton Rating Scale for Depression



Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 10 Hamilton Rating Scale for Anxiety



Review: OCD children: SSRIs
Comparison: 03 SSRIs vs placebo (discontinuation)
Outcome: 11 Global Assessment of Functioning



Clomipramine (OCD, children)











Review: OCD children: Clomipramine
Comparison: 02 Clomipramine continuation vs Desipramine substitution
Outcome: 02 Relapse (Physician's Relapse Scale)



Review: OCD children: Clomipramine
Comparison: 02 Clomipramine continuation vs Desipramine substitution
Outcome: 03 Comprehensive Psychopathological Rating Scale: obsessive-compulsive

Review: OCD children: Clomipramine
Comparison: 02 Clomipramine continuation vs Desipramine substitution
Outcome: 04 NIMH-OC



Pharmacological (BDD)











Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo
Outcome: 06 BDD-NIMH



Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo
Outcome: 07 Hamilton Rating Scale for Depression



Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo
Outcome: 08 Global Assessment of Functioning Scale



Review: BDD: pharmacological interventions
Comparison: 01 Fluoxetine vs placebo
Outcome: 09 Social & Occupational Functioning Scale



Review: BDD: pharmacological interventions
Comparison: 02 Clomipramine v Desipramine
Outcome: 01 BDD-YBOCS at 8 weeks



Review: BDD: pharmacological interventions
Comparison: 02 Clomipramine v Desipramine
Outcome: 02 NIMH-BDD at 8 weeks




Review: BDD: pharmacological interventions
Comparison: 02 Clomipramine v Desipramine
Outcome: 03 HAM-D at 8 weeks
Study or sub-category
Clomipramine N Mean (SD)
Desipramine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Hollander 1999 12 9.42(7.89) 11 14.64(5.61) -0.73 [-1.58, 0.12]
Total (95% CI) 12 11 -0.73 [-1.58, 0.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.09)
-4 -2 0 2 4
Favours CMI Favours DMI


Review: BDD: pharmacological interventions
Comparison: 03 Pimozide v Placebo
Outcome: 01 Non-responders (Y-BOCS 30%)
Study or sub-category
Pimozide n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Phillips_in press 9/11 14/17 0.99 [0.70, 1.42]
Total (95% CI) 9/11 14/17 0.99 [0.70, 1.42]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
0.2 0.5 1 2 5
Favours Pimozide Favours Placebo


Review: BDD: pharmacological interventions
Comparison: 03 Pimozide v Placebo
Outcome: 02 Leaving the study early
Study or sub-category
Pimozide n/N
Placebo n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Phillips_in press 6/11 13/17 0.71 [0.39, 1.30]
Total (95% CI) 6/11 13/17 0.71 [0.39, 1.30]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
0.2 0.5 1 2 5
Favours Pimozide Favours Placebo


Review: BDD: pharmacological interventions
Comparison: 03 Pimozide v Placebo
Outcome: 03 Y-BOCS
Study or sub-category
Pimozide N Mean (SD)
Placebo N Mean (SD)
WMD (random) 95% CI
WMD (random) 95% CI
Phillips_in press 11 23.90(6.60) 17 28.00(7.80) -4.10 [-9.48, 1.28]
Total (95% CI) 11 17 -4.10 [-9.48, 1.28]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
-10 -5 0 5 10
Favours Pimozide Favours Placebo


Review: BDD: pharmacological interventions
Comparison: 03 Pimozide v Placebo
Outcome: 04 Brown Assessment of Beliefs Scale
Study or sub-category
Pimozide N Mean (SD)
Placebo N Mean (SD)
WMD (random) 95% CI
WMD (random) 95% CI
Phillips_in press 11 13.50(7.30) 17 17.20(6.00) -3.70 [-8.87, 1.47]
Total (95% CI) 11 17 -3.70 [-8.87, 1.47]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
-10 -5 0 5 10
Favours Pimozide Favours Placebo

Review: BDD: pharmacological interventions
Comparison: 03 Pimozide v Placebo
Outcome: 05 Hamilton Depression Rating Scale



Review: BDD: pharmacological interventions
Comparison: 03 Pimozide v Placebo
Outcome: 06 Brief Psychiatric Rating Scale



Appendix 17c: Forest plots for clinical evidence reviews on psychological vs. pharmacological interventions, combination therapy and other medical interventions

Psychological vs. Pharmacological (OCD)
Combination therapy (OCD)
Other medical interventions

Psychological vs. Pharmacological (OCD)

Review: OCD: psychological v pharmacological
Comparison: 01 ERP vs Clomipramine
Outcome: 01 Y-BOCS or Compulsion checklist



Review: OCD: psychological v pharmacological
Comparison: 01 ERP vs Clomipramine
Outcome: 02 Leaving the study early



Review: OCD: psychological v pharmacological
Comparison: 01 ERP vs Clomipramine
Outcome: 03 Non-responders (CGI)



Review: OCD: psychological v pharmacological
Comparison: 02 Children: CBT v Clomipramine
Outcome: 01 Leaving the study early



Review: OCD: psychological v pharmacological
Comparison: 02 Children: CBT v Clomipramine
Outcome: 02 Non-responders (CY-BOCS 30%)



Review: OCD: psychological v pharmacological
Comparison: 02 Children: CBT v Clomipramine
Outcome: 03 CY-BOCS



Review: OCD: psychological v pharmacological
Comparison: 02 Children: CBT v Clomipramine
Outcome: 04 Leyton Inventory - child version



Review: OCD: psychological v pharmacological
Comparison: 02 Children: CBT v Clomipramine
Outcome: 05 Child Behaviour Checklist




Review: OCD: psychological v pharmacological
Comparison: 02 Children: CBT v Clomipramine
Outcome: 06 Children's Depression Inventory
Study or sub-category
N
CBT Mean (SD)
N
Clomipramine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
de Haan 1998 11 129.20(50.80) 9 143.20(37.90) -0.29 [-1.18, 0.59]
Total (95% CI) 11 9 -0.29 [-1.18, 0.59]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
-4 -2 0 2 4
Favours CBT
Favours Clomipramine


Review: OCD: psychological v pharmacological
Comparison: 03 Children: CBT v Sertraline
Outcome: 01 Leaving the study early
Study or sub-category
CBT n/N
Sertraline n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
POTS 2004 3/28 2/28 1.50 [0.27, 8.30]
Total (95% CI) 3/28 2/28 1.50 [0.27, 8.30]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
0.1 0.2 0.5 1 2 5 10
Favours CBT
Favours Sertraline


Review: OCD: psychological v pharmacological
Comparison: 03 Children: CBT v Sertraline
Outcome: 02 CY-BOCS
Study or sub-category
N
CBT Mean (SD)
N
Sertraline Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
POTS 2004 28 14.00(9.50) 28 16.50(9.10) -0.27 [-0.79, 0.26]
Total (95% CI) 28 28 -0.27 [-0.79, 0.26]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
-1 -0.5 0 0.5 1
Favours CBT
Favours Sertraline

Combination therapy (OCD)

Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 01 Leaving the study early



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 02 Leaving the study early due to adverse effects



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 03 Non-responders (Y-BOCS 35%)




Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 04 Non-responders (CGI)
Study or sub-category
ERP + SRI n/N
ERP n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 ERP + Clomipramine v ERP
Foa 2005 12/33 19/37 0.71 [0.41, 1.23]
Subtotal (95% CI) 33 37 0.71 [0.41, 1.23]
Total events: 12 (ERP + SRI), 19 (ERP)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
0.1 0.2 0.5 1 2 5 10
Favours ERP+SRI
Favours ERP


Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 06 Global criterion of non-improvement (duration of rituals)
Study or sub-category
ERP + SRI n/N
ERP n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 ERP + Fluvoxamine v ERP + placebo: post-treatment
Cottraux 1990 9/20 14/20 0.64 [0.37, 1.13]
Subtotal (95% CI) 9/20 14/20 0.64 [0.37, 1.13]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
02 ERP + Fluvoxamine v ERP + placebo: 6 months follow-up
Cottraux 1990 11/20 14/20 0.79 [0.48, 1.28]
Subtotal (95% CI) 11/20 14/20 0.79 [0.48, 1.28]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
03 ERP + Fluvoxamine v ERP + placebo: 1 year follow-up
Cottraux 1990 11/20 12/20 0.92 [0.54, 1.56]
Subtotal (95% CI) 11/20 12/20 0.92 [0.54, 1.56]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
0.1 0.2 0.5 1 2 5 10
Favours ERP+SRI
Favours ERP


Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 07 Y-BOCS
Study or sub-category
N
ERP + SRI Mean (SD)
N
ERP Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 ERP + Fluvoxamine v ERP
van Balkom 1998 18 12.60(6.60) 19 17.10(8.40) -0.58 [-1.24, 0.08]
Subtotal (95% CI) 18 19 -0.58 [-1.24, 0.08]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.08)
02 MBT + Fluvoxamine v MBT + placebo
Hohagen 1998 24 12.40(6.80) 25 15.90(7.90) -0.47 [-1.03, 0.10]
Subtotal (95% CI) 24 25 -0.47 [-1.03, 0.10]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
03 ERP + Clomipramine v ERP
Foa 2005 19 10.50(8.20) 21 11.00(7.90) -0.06 [-0.68, 0.56]
Subtotal (95% CI) 19 21 -0.06 [-0.68, 0.56]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI) 61 65 -0.37 [-0.72, -0.01]
Test for heterogeneity: Chi² = 1.46, df = 2 (P = 0.48), I² = 0%
Test for overall effect: Z = 2.04 (P = 0.04)
-4 -2 0 2 4
Favours ERP+SRI
Favours ERP

Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 08 Padua Inventory



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 09 Depression scales (post treatment)



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 10 Hamilton Depression Rating scale (follow-up)



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 11 Symptom Checklist-90



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 12 Anxiety Discomfort Scale: patient's ratings



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 13 Anxiety Discomfort Scale: therapist's ratings



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 14 Anxiety Discomfort Scale: assessor's ratings



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 15 Clinical Anxiety Scale



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 16 Global Assessment Scale



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 17 CGI - therapist rating



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 18 CGI - patient rating



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 19 Compulsive activity checklist (post treatment)



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 20 Compulsive activity checklist (follow-up)



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 21 Target rituals (assessor): time (post-treatment)



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 22 Target rituals (assessor): time (follow-up)



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 23 Target rituals (assessor): discomfort (post-treatment)



Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 24 Target rituals (assessor): discomfort (follow-up)




Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 25 Target rituals (assessor): duration per day
Study or sub-category
BT + SRI N Mean (SD)
BT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 ERP + Fluvoxamine v ERP + placebo (post treatment)
Cottraux 1990 16 3.93(2.26) 15 5.40(2.19) -0.64 [-1.37, 0.08]
Subtotal (95% CI) 16 15 -0.64 [-1.37, 0.08]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.08)
02 ERP + Fluvoxamine v ERP + placebo (6 months follow-up)
Cottraux 1990 14 4.00(2.80) 12 4.67(2.27) -0.25 [-1.03, 0.52]
Subtotal (95% CI) 14 12 -0.25 [-1.03, 0.52]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
03 ERP + Fluvoxamine v ERP + placebo (1 year follow-up)
Cottraux 1990 12 2.70(2.70) 11 3.30(2.70) -0.21 [-1.04, 0.61]
Subtotal (95% CI) 12 11 -0.21 [-1.04, 0.61]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
-4 -2 0 2 4
Favours BT+SRI
Favours BT


Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 26 Behavioural avoidance test: discomfort (post treatment)
Study or sub-category
BT + SRI N Mean (SD)
BT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 ERP + Fluvoxamine v ERP + placebo (post treatment)
Cottraux 1990 16 9.12(6.55) 15 15.61(7.61) -0.89 [-1.64, -0.15]
Subtotal (95% CI) 16 15 -0.89 [-1.64, -0.15]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.02)
02 Exposure + Clomipramine v Exposure + placebo (at 7 weeks)
Marks 1980 10 15.40(11.90) 10 16.90(10.00) -0.13 [-1.01, 0.75]
Subtotal (95% CI) 10 10 -0.13 [-1.01, 0.75]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 26 25 -0.57 [-1.14, -0.01]
Test for heterogeneity: Chi² = 1.69, df = 1 (P = 0.19), I² = 40.7%
Test for overall effect: Z = 1.98 (P = 0.05)
-4 -2 0 2 4
Favours BT+SRI
Favours BT


Review: OCD: combination therapy
Comparison: 01 ERP+ SRI v ERP
Outcome: 27 Behavioural avoidance test: discomfort (follow-up)
Study or sub-category
BT + SRI N Mean (SD)
BT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 ERP + Fluvoxamine v ERP + placebo (1 year follow-up)
Cottraux 1990 12 10.20(9.20) 11 11.50(9.20) -0.14 [-0.96, 0.68]
Subtotal (95% CI) 12 11 -0.14 [-0.96, 0.68]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
-4 -2 0 2 4
Favours BT+SRI
Favours BT


Review: OCD: combination therapy
Comparison: 02 ERP + Clomipramine v Clomipramine
Outcome: 01 Leaving the study early
Study or sub-category
BT + Clomipramine n/N
Clomipramine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Foa 2005 14/33 20/47 1.00 [0.59, 1.67]
Total (95% CI) 33 47 1.00 [0.59, 1.67]
Total events: 14 (BT + Clomipramine), 20 (Clomipramine)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
0.1 0.2 0.5 1 2 5 10
Favours BT+CMI
Favours CMI

Review: OCD: combination therapy
Comparison: 02 ERP + Clomipramine v Clomipramine
Outcome: 03 Non-responders (CGI)



Review: OCD: combination therapy
Comparison: 02 ERP + Clomipramine v Clomipramine
Outcome: 05 Y-BOCS



Review: OCD: combination therapy
Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine
Outcome: 01 Leaving the study early



Review: OCD: combination therapy
Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine
Outcome: 02 Leaving the study early due to adverse effects




Review: OCD: combination therapy
Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine
Outcome: 03 Global criterion of non-improvement (duration of rituals)
Study or sub-category
ERP+Fluvoxamine n/N
Anti-ERP+Fluvoxamine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Post-treatment
Cottraux 1990 9/20 13/20 0.69 [0.39, 1.24]
Subtotal (95% CI) 9/20 13/20 0.69 [0.39, 1.24]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
02 6 months follow-up
Cottraux 1990 11/20 15/20 0.73 [0.46, 1.17]
Subtotal (95% CI) 11/20 15/20 0.73 [0.46, 1.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
03 1 year follow-up
Cottraux 1990 11/20 14/20 0.79 [0.48, 1.28]
Subtotal (95% CI) 11/20 14/20 0.79 [0.48, 1.28]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
0.1 0.2 0.5 1 2 5 10
Favours ERP+FLV
Favours Anti-ERP+FLV


Review: OCD: combination therapy
Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine
Outcome: 04 Hamilton Depression Scale
Study or sub-category
ERP+Fluvoxamine N Mean (SD)
Anti-ERP+Fluvoxamine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Cottraux 1990 16 9.12(6.03) 13 10.46(6.98) -0.20 [-0.94, 0.53]
Subtotal (95% CI) 16 13 -0.20 [-0.94, 0.53]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
02 6 months follow-up
Cottraux 1990 14 10.71(6.27) 11 11.27(6.02) -0.09 [-0.88, 0.70]
Subtotal (95% CI) 14 11 -0.09 [-0.88, 0.70]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
03 1 year follow-up
Cottraux 1990 12 11.80(7.90) 10 8.50(3.80) 0.50 [-0.36, 1.35]
Subtotal (95% CI) 12 10 0.50 [-0.36, 1.35]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
-10 -5 0 5 10
Favours ERP + FLV
Favours Anti-ERP+FLV


Review: OCD: combination therapy
Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine
Outcome: 05 Target rituals (assessor): time
Study or sub-category
ERP+Fluvoxamine N Mean (SD)
Anti-ERP+Fluvoxamine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Cottraux 1990 16 8.50(7.30) 13 12.84(7.78) -0.56 [-1.31, 0.19]
Subtotal (95% CI) 16 13 -0.56 [-1.31, 0.19]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
02 6 months follow-up
Cottraux 1990 14 10.30(8.70) 11 13.50(3.11) -0.45 [-1.25, 0.35]
Subtotal (95% CI) 14 11 -0.45 [-1.25, 0.35]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
03 1 year follow-up
Cottraux 1990 12 9.70(9.90) 10 11.40(9.40) -0.17 [-1.01, 0.67]
Subtotal (95% CI) 12 10 -0.17 [-1.01, 0.67]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.69)
-4 -2 0 2 4
Favours ERP+FLV
Favours Anti-ERP+FLV

Review: OCD: combination therapy
Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine
Outcome: 06 Target rituals (assessor): discomfort



Review: OCD: combination therapy
Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine
Outcome: 07 Target rituals (assessor): duration per day



Review: OCD: combination therapy
Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine
Outcome: 08 Behavioural avoidance test: discomfort




Review: OCD: combination therapy
Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine
Outcome: 09 Compulsive activity checklist
Study or sub-category
ERP+Fluvoxamine N Mean (SD)
Anti-ERP+Fluvoxamine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Post treatment
Cottraux 1990 16 14.56(17.38) 13 21.53(12.56) -0.44 [-1.18, 0.30]
Subtotal (95% CI) 16 13 -0.44 [-1.18, 0.30]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
02 1 year follow-up
Cottraux 1990 12 15.50(17.60) 10 20.70(14.30) -0.31 [-1.15, 0.54]
Subtotal (95% CI) 12 10 -0.31 [-1.15, 0.54]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
-4 -2 0 2 4
Favours ERP+FLV
Favours Anti-ERP+FLV


Review: OCD: combination therapy
Comparison: 04 CT + Fluvoxamine v CT
Outcome: 01 Leaving the study early
Study or sub-category
CT + Fluvoxamine n/N
CT n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
van Balkom 1998 10/24 6/25 1.74 [0.75, 4.03]
Total (95% CI) 10/24 6/25 1.74 [0.75, 4.03]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
0.1 0.2 0.5 1 2 5 10
Favours CT+FLV
Favours CT


Review: OCD: combination therapy
Comparison: 04 CT + Fluvoxamine v CT
Outcome: 02 Y-BOCS
Study or sub-category
CT + Fluvoxamine N Mean (SD)
CT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
van Balkom 1998 14 15.60(5.40) 19 13.50(9.70) 0.25 [-0.44, 0.94]
Total (95% CI) 14 19 0.25 [-0.44, 0.94]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
-1 -0.5 0 0.5 1
Favours CT+FLV
Favours CT


Review: OCD: combination therapy
Comparison: 04 CT + Fluvoxamine v CT
Outcome: 03 Padua Inventory
Study or sub-category
CT + Fluvoxamine N Mean (SD)
CT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
van Balkom 1998 14 43.50(18.40) 19 49.10(23.60) -0.25 [-0.95, 0.44]
Total (95% CI) 14 19 -0.25 [-0.95, 0.44]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
-1 -0.5 0 0.5 1
Favours CT+FLV
Favours CT


Review: OCD: combination therapy
Comparison: 04 CT + Fluvoxamine v CT
Outcome: 04 Beck Depression Inventory
Study or sub-category
CT + Fluvoxamine N Mean (SD)
CT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
van Balkom 1998 14 10.80(6.60) 19 9.90(7.00) 0.13 [-0.56, 0.82]
Total (95% CI) 14 19 0.13 [-0.56, 0.82]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
-1 -0.5 0 0.5 1
Favours CT+FLV
Favours CT


Review: OCD: combination therapy
Comparison: 04 CT + Fluvoxamine v CT
Outcome: 05 Symptom Checklist-90
Study or sub-category
CT + Fluvoxamine N Mean (SD)
CT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
van Balkom 1998 14 162.00(42.70) 19 163.40(44.40) -0.03 [-0.72, 0.66]
Total (95% CI) 14 19 -0.03 [-0.72, 0.66]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
-1 -0.5 0 0.5 1
Favours CT+FLV Favours CT


Review: OCD: combination therapy
Comparison: 04 CT + Fluvoxamine v CT
Outcome: 06 Anxiety Discomfort Scale: patient's ratings
Study or sub-category
CT + Fluvoxamine N Mean (SD)
CT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
van Balkom 1998 14 13.00(4.90) 19 12.50(9.30) 0.06 [-0.63, 0.75]
Total (95% CI) 14 19 0.06 [-0.63, 0.75]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
-1 -0.5 0 0.5 1
Favours CT+FLV Favours CT


Review: OCD: combination therapy
Comparison: 04 CT + Fluvoxamine v CT
Outcome: 07 Anxiety Discomfort Scale: therapist's ratings
Study or sub-category
CT + Fluvoxamine N Mean (SD)
CT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
van Balkom 1998 14 13.60(7.50) 19 13.10(10.20) 0.05 [-0.64, 0.74]
Total (95% CI) 14 19 0.05 [-0.64, 0.74]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
-1 -0.5 0 0.5 1
Favours CT+FLV Favours CT


Review: OCD: combination therapy
Comparison: 04 CT + Fluvoxamine v CT
Outcome: 08 Anxiety Discomfort Scale: assessor's ratings
Study or sub-category
CT + Fluvoxamine N Mean (SD)
CT N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
van Balkom 1998 14 13.80(4.70) 19 12.50(9.50) 0.16 [-0.53, 0.85]
Total (95% CI) 14 19 0.16 [-0.53, 0.85]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
-1 -0.5 0 0.5 1
Favours CT+FLV Favours CT


Review: OCD: combination therapy
Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine
Outcome: 01 Leaving the study early
Study or sub-category
ERP + Fluvoxamine n/N
CT + Fluvoxamine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
van Balkom 1998 10/28 10/24 0.86 [0.43, 1.70]
Total (95% CI) 10/28 10/24 0.86 [0.43, 1.70]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
0.1 0.2 0.5 1 2 5 10
Favours ERP+FLV Favours CT+FLV


Review: OCD: combination therapy
Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine
Outcome: 02 Y-BOCS
Study or sub-category
ERP + Fluvoxamine N Mean (SD)
CT + Fluvoxamine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
van Balkom 1998 18 12.60(6.60) 14 15.60(5.40) -0.48 [-1.19, 0.23]
Total (95% CI) 18 14 -0.48 [-1.19, 0.23]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
-4 -2 0 2 4
Favours ERP+FLV Favours CT+FLV


Review: OCD: combination therapy
Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine
Outcome: 03 Padua Inventory
Study or sub-category
ERP + Fluvoxamine N Mean (SD)
CT + Fluvoxamine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
van Balkom 1998 18 43.20(23.50) 14 43.50(18.40) -0.01 [-0.71, 0.68]
Total (95% CI) 18 14 -0.01 [-0.71, 0.68]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
-1 -0.5 0 0.5 1
Favours ERP+FLV
Favours CT+FLV


Review: OCD: combination therapy
Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine
Outcome: 04 Beck Depression Inventory
Study or sub-category
ERP + Fluvoxamine N Mean (SD)
CT + Fluvoxamine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
van Balkom 1998 18 10.10(7.20) 14 10.80(6.60) -0.10 [-0.80, 0.60]
Total (95% CI) 18 14 -0.10 [-0.80, 0.60]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
-1 -0.5 0 0.5 1
Favours ERP+FLV
Favours CT+FLV


Review: OCD: combination therapy
Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine
Outcome: 05 Symptom Checklist-90
Study or sub-category
ERP + Fluvoxamine N Mean (SD)
CT + Fluvoxamine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
van Balkom 1998 18 154.50(51.40) 14 162.00(42.70) -0.15 [-0.85, 0.55]
Total (95% CI) 18 14 -0.15 [-0.85, 0.55]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
-1 -0.5 0 0.5 1
Favours ERP+FLV
Favours CT+FLV


Review: OCD: combination therapy
Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine
Outcome: 06 Anxiety Discomfort Scale: patient's ratings
Study or sub-category
ERP + Fluvoxamine N Mean (SD)
CT + Fluvoxamine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
van Balkom 1998 18 13.00(4.90) 14 13.00(4.90) 0.00 [-0.70, 0.70]
Total (95% CI) 18 14 0.00 [-0.70, 0.70]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
-1 -0.5 0 0.5 1
Favours ERP+FLV
Favours CT+FLV


Review: OCD: combination therapy
Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine
Outcome: 07 Anxiety Discomfort Scale: therapist's ratings
Study or sub-category
ERP + Fluvoxamine N Mean (SD)
CT + Fluvoxamine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
van Balkom 1998 18 14.20(10.30) 14 13.60(7.50) 0.06 [-0.64, 0.76]
Total (95% CI) 18 14 0.06 [-0.64, 0.76]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
-1 -0.5 0 0.5 1
Favours ERP+FLV
Favours CT+FLV


Review: OCD: combination therapy
Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine
Outcome: 08 Anxiety Discomfort Scale: assessor's ratings
Study or sub-category
ERP + Fluvoxamine N Mean (SD)
CT + Fluvoxamine N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
van Balkom 1998 18 14.20(8.70) 14 13.80(4.70) 0.05 [-0.64, 0.75]
Total (95% CI) 18 14 0.05 [-0.64, 0.75]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
-1 -0.5 0 0.5 1
Favours ERP+FLV
Favours CT+FLV


Review: OCD: combination therapy
Comparison: 06 Children: ERP + Fluvoxamine v Fluvoxamine alone
Outcome: 01 Non-responder (Y-BOCS reliable change)
Study or sub-category
ERP + Fluvoxamine n/N
Fluvoxamine n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 At 43 weeks
Neziroglu 2000 0/5 3/5 0.14 [0.01, 2.21]
Subtotal (95% CI) 0/5 3/5 0.14 [0.01, 2.21]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
02 At 52 weeks
Neziroglu 2000 0/5 2/5 0.20 [0.01, 3.35]
Subtotal (95% CI) 0/5 2/5 0.20 [0.01, 3.35]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
03 At 2 years
Neziroglu 2000 0/5 2/5 0.20 [0.01, 3.35]
Subtotal (95% CI) 0/5 2/5 0.20 [0.01, 3.35]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
0.001 0.01 0.1 1 10 100 1000
Favours ERP+FLV
Favours FLV


Review: OCD: combination therapy
Comparison: 06 Children: ERP + Fluvoxamine v Fluvoxamine alone
Outcome: 02 CY-BOCS
Study or sub-category
N
ERP + Fluvoxamine Mean (SD)
N
Fluvoxamine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 At 43 weeks
Neziroglu 2000 5 -11.60(5.64) 5 -3.60(4.28) -1.44 [-2.93, 0.04]
Subtotal (95% CI) 5 5 -1.44 [-2.93, 0.04]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.06)
02 At 52 weeks
Neziroglu 2000 5 -14.00(6.08) 5 -3.40(6.69) -1.50 [-3.00, 0.00]
Subtotal (95% CI) 5 5 -1.50 [-3.00, 0.00]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.05)
03 At 2 years
Neziroglu 2000 5 -20.20(2.17) 5 -9.00(11.42) -1.23 [-2.65, 0.19]
Subtotal (95% CI) 5 5 -1.23 [-2.65, 0.19]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.09)
-4 -2 0 2 4
Favours ERP+FLV
Favours FLV


Review: OCD: combination therapy
Comparison: 06 Children: ERP + Fluvoxamine v Fluvoxamine alone
Outcome: 03 NIMH-GOCS
Study or sub-category
N
ERP + Fluvoxamine Mean (SD)
N
Fluvoxamine Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 At 43 weeks
Neziroglu 2000 5 -4.00(1.58) 5 -2.80(2.39) -0.54 [-1.81, 0.74]
Subtotal (95% CI) 5 5 -0.54 [-1.81, 0.74]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
02 At 52 weeks
Neziroglu 2000 5 -3.80(2.17) 5 -2.20(2.39) -0.63 [-1.92, 0.66]
Subtotal (95% CI) 5 5 -0.63 [-1.92, 0.66]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
03 At 2 years
Neziroglu 2000 5 -7.40(2.88) 5 -4.00(4.53) -0.81 [-2.13, 0.51]
Subtotal (95% CI) 5 5 -0.81 [-2.13, 0.51]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
-10 -5 0 5 10
Favours ERP+FLV
Favours FLV

Review: OCD: combination therapy
Comparison: 07 Children: CBT + Sertraline v Sertraline
Outcome: 01 Leaving the study early



Review: OCD: combination therapy
Comparison: 07 Children: CBT + Sertraline v Sertraline
Outcome: 02 Leaving the study early due to adverse events



Review: OCD: combination therapy
Comparison: 07 Children: CBT + Sertraline v Sertraline
Outcome: 03 CY-BOCS



Review: OCD: combination therapy
Comparison: 08 Children: CBT + Sertraline v CBT
Outcome: 01 Leaving the study early



Review: OCD: combination therapy
Comparison: 08 Children: CBT + Sertraline v CBT
Outcome: 02 CY-BOCS



Other medical interventions

Review: OCD: other medical
Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy
Outcome: 01 CPRS @ 3 months: change score



Review: OCD: other medical
Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy
Outcome: 02 CPRS @ 6 months: change score



Review: OCD: other medical
Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy
Outcome: 03 CPRS @ 12 months: change score



Review: OCD: other medical
Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy
Outcome: 04 HAM-D @ 3 months: change score



Review: OCD: other medical
Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy
Outcome: 05 HAM-D @ 6 months: change score



Review: OCD: other medical
Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy
Outcome: 06 HAM-D @ 12 months: change score




Review: OCD: other medical
Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy
Outcome: 07 HAM-A @ 3 months: change score
Study or sub-category
Capsulotomy N Mean (SD)
Cingulotomy N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Fodstad 1982 2 -4.00(1.41) 2 -11.50(12.02) 0.50 [-2.94, 3.95]
Total (95% CI) 2 2 0.50 [-2.94, 3.95]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
-4 -2 0 2 4
Favours capsulotomy Favours cingulotomy


Review: OCD: other medical
Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy
Outcome: 08 HAM-A @ 6 months: change score
Study or sub-category
Capsulotomy N Mean (SD)
Cingulotomy N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Fodstad 1982 2 -3.00(2.83) 2 -6.00(5.66) 0.38 [-2.54, 3.31]
Total (95% CI) 2 2 0.38 [-2.54, 3.31]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
-4 -2 0 2 4
Favours capsulotomy Favours cingulotomy


Review: OCD: other medical
Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy
Outcome: 09 HAM-A @ 12 months: change score
Study or sub-category
Capsulotomy N Mean (SD)
Cingulotomy N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Fodstad 1982 2 -2.50(3.54) 2 -7.50(7.78) 0.47 [-2.84, 3.79]
Total (95% CI) 2 2 0.47 [-2.84, 3.79]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
-4 -2 0 2 4
Favours capsulotomy Favours cingulotomy


Review: OCD: other medical
Comparison: 02 Repetitive transcranial magnetic stimulation: active vs placebo
Outcome: 01 Adverse effects
Study or sub-category
Active RTMS n/N
Placebo RTMS n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Alonso 2001 1/10 0/8 2.45 [0.11, 53.25]
Total (95% CI) 10 8 2.45 [0.11, 53.25]
Total events: 1 (Active RTMS), 0 (Placebo RTMS)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
0.01 0.1 1 10 100
Favours active RTMS Favours placebo RTMS


Review: OCD: other medical
Comparison: 02 Repetitive transcranial magnetic stimulation: active vs placebo
Outcome: 02 Non-responders (Y-BOCS 40%)
Study or sub-category
Active RTMS n/N
Placebo RTMS n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Alonso 2001 8/10 7/8 0.91 [0.61, 1.37]
Total (95% CI) 10 8 0.91 [0.61, 1.37]
Total events: 8 (Active RTMS), 7 (Placebo RTMS)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
0.5 0.7 1 1.5 2
Favours active RTMS Favours placebo RTMS


Review: OCD: other medical
Comparison: 02 Repetitive transcranial magnetic stimulation: active vs placebo
Outcome: 03 Y-BOCS: change score
Study or sub-category
Active RTMS N Mean (SD)
Placebo RTMS N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Alonso 2001 10 -3.40(8.24) 8 -0.25(3.92) -0.45 [-1.39, 0.50]
Total (95% CI) 10 8 -0.45 [-1.39, 0.50]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
-4 -2 0 2 4
Favours active RTMS Favours placebo RTMS


Review: OCD: other medical
Comparison: 02 Repetitive transcranial magnetic stimulation: active vs placebo
Outcome: 04 HAM-D: change score
Study or sub-category
Active RTMS N Mean (SD)
Placebo RTMS N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Alonso 2001 10 -0.30(3.95) 8 0.25(1.16) -0.17 [-1.10, 0.76]
Total (95% CI) 10 8 -0.17 [-1.10, 0.76]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
-4 -2 0 2 4
Favours active RTMS Favours placebo RTMS


Review: OCD: other medical
Comparison: 03 Repetitive transcranial magnetic stimulation: right vs left
Outcome: 01 Y-BOCS @ post-treatment
Study or sub-category
Right N Mean (SD)
Left N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Right prefrontal v Left prefrontal
Sachdev 2001 6 17.00(4.86) 6 16.67(12.31) 0.03 [-1.10, 1.16]
Subtotal (95% CI) 6 6 0.03 [-1.10, 1.16]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
-4 -2 0 2 4
Favours right Favours left


Review: OCD: other medical
Comparison: 03 Repetitive transcranial magnetic stimulation: right vs left
Outcome: 02 BDI @ post-treatment
Study or sub-category
Right N Mean (SD)
Left N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Right prefrontal v Left prefrontal
Sachdev 2001 6 14.17(8.91) 6 9.67(8.26) 0.48 [-0.67, 1.64]
Subtotal (95% CI) 6 6 0.48 [-0.67, 1.64]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
-4 -2 0 2 4
Favours right Favours left


Review: OCD: other medical
Comparison: 03 Repetitive transcranial magnetic stimulation: right vs left
Outcome: 03 MADRS @ post-treatment
Study or sub-category
Right N Mean (SD)
Left N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Right prefrontal v Left prefrontal
Sachdev 2001 6 15.33(10.35) 6 6.00(7.51) 0.95 [-0.27, 2.18]
Subtotal (95% CI) 6 6 0.95 [-0.27, 2.18]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
-4 -2 0 2 4
Favours right Favours left


Review: OCD: other medical
Comparison: 03 Repetitive transcranial magnetic stimulation: right vs left
Outcome: 04 STAI-S @ post-treatment
Study or sub-category
Right N Mean (SD)
Left N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Right prefrontal v Left prefrontal
Sachdev 2001 6 45.50(9.67) 6 45.00(15.02) 0.04 [-1.10, 1.17]
Subtotal (95% CI) 6 6 0.04 [-1.10, 1.17]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
-4 -2 0 2 4
Favours right Favours left


Review: OCD: other medical
Comparison: 03 Repetitive transcranial magnetic stimulation: right vs left
Outcome: 05 Y-BOCS @ 1-month follow-up
Study or sub-category
Right N Mean (SD)
Left N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Right prefrontal v Left prefrontal
Sachdev 2001 6 12.00(3.94) 6 16.50(8.31) -0.64 [-1.81, 0.54]
Subtotal (95% CI) 6 6 -0.64 [-1.81, 0.54]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
-4 -2 0 2 4
Favours right Favours left


Review: OCD: other medical
Comparison: 03 Repetitive transcranial magnetic stimulation: right vs left
Outcome: 06 BDI @ 1-month follow-up
Study or sub-category
Right N Mean (SD)
Left N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Right prefrontal v Left prefrontal
Sachdev 2001 6 11.60(14.64) 6 10.83(7.78) 0.06 [-1.07, 1.19]
Subtotal (95% CI) 6 6 0.06 [-1.07, 1.19]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
-4 -2 0 2 4
Favours right Favours left


Review: OCD: other medical
Comparison: 03 Repetitive transcranial magnetic stimulation: right vs left
Outcome: 07 MADRS @ 1-month follow-up
Study or sub-category
Right N Mean (SD)
Left N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Right prefrontal v Left prefrontal
Sachdev 2001 6 12.20(8.81) 6 6.83(5.71) 0.67 [-0.51, 1.85]
Subtotal (95% CI) 6 6 0.67 [-0.51, 1.85]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
-4 -2 0 2 4
Favours right Favours left


Review: OCD: other medical
Comparison: 03 Repetitive transcranial magnetic stimulation: right vs left
Outcome: 08 STAI-S @ 1-month follow-up
Study or sub-category
Right N Mean (SD)
Left N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Right prefrontal v Left prefrontal
Sachdev 2001 6 44.50(18.96) 6 45.33(12.72) -0.05 [-1.18, 1.08]
Subtotal (95% CI) 6 6 -0.05 [-1.18, 1.08]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
-4 -2 0 2 4
Favours right Favours left


Review: OCD: other medical
Comparison: 03 Repetitive transcranial magnetic stimulation: right vs left
Outcome: 09 Non-responders (Y-BOCS 40%) @ 1-month follow-up
Study or sub-category
Right n/N
Left n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Right prefrontal v Left prefrontal
Sachdev 2001 2/6 2/6 1.00 [0.20, 4.95]
Subtotal (95% CI) 6 6 1.00 [0.20, 4.95]
Total events: 2 (Right), 2 (Left)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
0.2 0.5 1 2 5
Favours right Favours left


Review: OCD: other medical
Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)
Outcome: 01 Adverse effects
Study or sub-category
Treatment 1 n/N
Treatment 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Plasma exchange vs placebo
Perlmutter 1999 7/10 2/10 3.50 [0.95, 12.90]
Subtotal (95% CI) 10 10 3.50 [0.95, 12.90]
Total events: 7 (Treatment 1), 2 (Treatment 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.06)
02 IV immunoglobulin vs placebo
Perlmutter 1999 6/10 2/10 3.00 [0.79, 11.44]
Subtotal (95% CI) 10 10 3.00 [0.79, 11.44]
Total events: 6 (Treatment 1), 2 (Treatment 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
03 Plasma exchange vs IV immunoglobulin
Perlmutter 1999 7/10 6/10 1.17 [0.61, 2.23]
Subtotal (95% CI) 10 10 1.17 [0.61, 2.23]
Total events: 7 (Treatment 1), 6 (Treatment 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
0.01 0.1 1 10 100
Favours Treatment 1
Favours Treatment 2


Review: OCD: other medical
Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)
Outcome: 02 Leaving study early
Study or sub-category
Treatment 1 n/N
Treatment 2 n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
01 Plasma exchange vs placebo
Perlmutter 1999 0/10 0/10 Not estimable
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Treatment 1), 0 (Treatment 2)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 IV immunoglobulin vs placebo
Perlmutter 1999 1/10 0/10 3.00 [0.14, 65.90]
Subtotal (95% CI) 10 10 3.00 [0.14, 65.90]
Total events: 1 (Treatment 1), 0 (Treatment 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
03 Plasma exchange vs IV immunoglobulin
Perlmutter 1999 0/10 1/10 0.33 [0.02, 7.32]
Subtotal (95% CI) 10 10 0.33 [0.02, 7.32]
Total events: 0 (Treatment 1), 1 (Treatment 2)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
0.01 0.1 1 10 100
Favours Treatment 1
Favours Treatment 2


Review: OCD: other medical
Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)
Outcome: 03 Y-BOCS*
Study or sub-category
N
Treatment 1 Mean (SD)
N
Treatment 2 Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Plasma exchange vs placebo
Perlmutter 1999 5 18.20(6.10) 7 29.71(3.55) -2.24 [-3.83, -0.66]
Subtotal (95% CI) 5 7 -2.24 [-3.83, -0.66]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.77 (P = 0.006)
02 IV immunoglobulin vs placebo
Perlmutter 1999 6 17.83(9.68) 7 29.71(3.55) -1.57 [-2.88, -0.26]
Subtotal (95% CI) 6 7 -1.57 [-2.88, -0.26]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.02)
03 Plasma exchange vs IV immunoglobulin
Perlmutter 1999 5 18.20(6.10) 6 17.83(9.68) 0.04 [-1.15, 1.23]
Subtotal (95% CI) 5 6 0.04 [-1.15, 1.23]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
-4
-2
0
2
4
Favours Treatment 1
Favours Treatment 2


Review: OCD: other medical
Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)
Outcome: 04 NIMH-Global Severity*
Study or sub-category
N
Treatment 1 Mean (SD)
N
Treatment 2 Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Plasma exchange vs placebo
Perlmutter 1999 5 6.33(2.30) 7 8.29(0.76) -1.15 [-2.43, 0.13]
Subtotal (95% CI) 5 7 -1.15 [-2.43, 0.13]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.08)
02 IV immunoglobulin vs placebo
Perlmutter 1999 6 6.33(1.97) 7 8.29(0.76) -1.26 [-2.50, -0.03]
Subtotal (95% CI) 6 7 -1.26 [-2.50, -0.03]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.04)
03 Plasma exchange vs IV immunoglobulin
Perlmutter 1999 5 6.33(2.30) 6 6.33(1.97) 0.00 [-1.19, 1.19]
Subtotal (95% CI) 5 6 0.00 [-1.19, 1.19]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
-4
-2
0
2
4
Favours Treatment 1
Favours Treatment 2


Review: OCD: other medical
Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)
Outcome: 05 CGI-Symptom Severity*
Study or sub-category
N
Treatment 1 Mean (SD)
N
Treatment 2 Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Plasma exchange vs placebo
Perlmutter 1999 5 3.60(1.14) 7 4.86(0.48) -1.43 [-2.78, -0.09]
Subtotal (95% CI) 5 7 -1.43 [-2.78, -0.09]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.04)
02 IV immunoglobulin vs placebo
Perlmutter 1999 6 3.92(1.11) 7 4.86(0.48) -1.06 [-2.25, 0.14]
Subtotal (95% CI) 6 7 -1.06 [-2.25, 0.14]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.08)
03 Plasma exchange vs IV immunoglobulin
Perlmutter 1999 5 3.60(1.14) 6 3.92(1.11) -0.26 [-1.45, 0.93]
Subtotal (95% CI) 5 6 -0.26 [-1.45, 0.93]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
-4
-2
0
2
4
Favours Treatment 1
Favours Treatment 2


Review: OCD: other medical
Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)
Outcome: 06 Global Assessment Scale*
Study or sub-category
N
Treatment 1 Mean (SD)
N
Treatment 2 Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Plasma exchange vs placebo
Perlmutter 1999 5 -63.40(12.36) 7 -54.86(4.30) -0.93 [-2.16, 0.31]
Subtotal (95% CI) 5 7 -0.93 [-2.16, 0.31]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
02 IV immunoglobulin vs placebo
Perlmutter 1999 6 -62.83(10.69) 7 -54.86(4.30) -0.94 [-2.11, 0.23]
Subtotal (95% CI) 6 7 -0.94 [-2.11, 0.23]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
03 Plasma exchange vs IV immunoglobulin
Perlmutter 1999 5 -63.40(12.36) 6 -62.83(10.69) -0.05 [-1.23, 1.14]
Subtotal (95% CI) 5 6 -0.05 [-1.23, 1.14]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
-4
-2
0
2
4
Favours Treatment 1
Favours Treatment 2


Review: OCD: other medical
Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)
Outcome: 07 NIMH-Anxiety*
Study or sub-category
N
Treatment 1 Mean (SD)
N
Treatment 2 Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Plasma exchange vs placebo
Perlmutter 1999 5 4.20(2.28) 7 7.00(1.41) -1.43 [-2.77, -0.09]
Subtotal (95% CI) 5 7 -1.43 [-2.77, -0.09]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.04)
02 IV immunoglobulin vs placebo
Perlmutter 1999 6 5.33(1.37) 7 7.00(1.41) -1.12 [-2.32, 0.09]
Subtotal (95% CI) 6 7 -1.12 [-2.32, 0.09]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.07)
03 Plasma exchange vs IV immunoglobulin
Perlmutter 1999 5 4.20(2.28) 6 5.33(1.37) -0.56 [-1.79, 0.66]
Subtotal (95% CI) 5 6 -0.56 [-1.79, 0.66]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
-4
-2
0
2
4
Favours Treatment 1
Favours Treatment 2


Review: OCD: other medical
Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)
Outcome: 08 NIMH-Depression*
Study or sub-category
N
Treatment 1 Mean (SD)
N
Treatment 2 Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Plasma exchange vs placebo
Perlmutter 1999 5 3.60(2.19) 7 7.57(2.30) -1.62 [-3.02, -0.23]
Subtotal (95% CI) 5 7 -1.62 [-3.02, -0.23]
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.02)
02 IV immunoglobulin vs placebo
Perlmutter 1999 6 4.83(2.14) 7 7.57(2.30) -1.14 [-2.35, 0.07]
Subtotal (95% CI) 6 7 -1.14 [-2.35, 0.07]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.06)
03 Plasma exchange vs IV immunoglobulin
Perlmutter 1999 5 3.62(0.19) 6 4.83(2.14) -0.69 [-1.93, 0.55]
Subtotal (95% CI) 5 6 -0.69 [-1.93, 0.55]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
-4
-2
0
2
4
Favours Treatment 1
Favours Treatment 2


Review: OCD: other medical
Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)
Outcome: 09 NIMH-OC*
Study or sub-category
Treatment 1 N Mean (SD)
Treatment 2 N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
01 Plasma exchange vs placebo
Perlmutter 1999 5 7.20(2.78) 7 9.57(1.51) -1.04 [-2.29, 0.22]
Subtotal (95% CI) 5 7 -1.04 [-2.29, 0.22]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
02 IV immunoglobulin vs placebo
Perlmutter 1999 6 7.33(2.34) 7 9.57(1.51) -1.08 [-2.28, 0.12]
Subtotal (95% CI) 6 7 -1.08 [-2.28, 0.12]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.08)
03 Plasma exchange vs IV immunoglobulin
Perlmutter 1999 5 7.20(2.78) 6 7.33(2.34) -0.05 [-1.23, 1.14]
Subtotal (95% CI) 5 6 -0.05 [-1.23, 1.14]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
-4 -2 0 2 4
Favours Treatment 1
Favours Treatment 2


Review: OCD: other medical
Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)
Outcome: 01 Leaving study early
Study or sub-category
Plasma exchange n/N
IV immunoglobulin n/N
RR (fixed) 95% CI
RR (fixed) 95% CI
Perlmutter 1999 2/10 0/9 4.55 [0.25, 83.70]
Total (95% CI) 10 9 4.55 [0.25, 83.70]
Total events: 2 (Plasma exchange), 0 (IV immunoglobulin)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
0.01 0.1 1 10 100
Favours plasma exch.
Favours IV immu.


Review: OCD: other medical
Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)
Outcome: 02 Y-BOCS*
Study or sub-category
Plasma exchange N Mean (SD)
IV immunoglobulin N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Perlmutter 1999 5 10.50(8.27) 6 12.00(2.45) -0.24 [-1.43, 0.96]
Total (95% CI) 5 6 -0.24 [-1.43, 0.96]
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
-4 -2 0 2 4
Favours plasma exch.
Favours IV immu.


Review: OCD: other medical
Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)
Outcome: 03 Global Assessment Scale*
Study or sub-category
Plasma exchange N Mean (SD)
IV immunoglobulin N Mean (SD)
SMD (fixed) 95% CI
SMD (fixed) 95% CI
Perlmutter 1999 5 -81.75(15.88) 6 -70.00(5.48) -0.95 [-2.23, 0.34]
Total (95% CI) 5 6 -0.95 [-2.23, 0.34]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
-4 -2 0 2 4
Favours plasma exch.
Favours IV immu.